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Glucose-6-phosphatase - its structure, function and regulation in relation to blood
glucose homeostasis
Hepatic glucose-6-phosphatase (G6Pase) catalyses the final step in blood glucose
production by the liver. It is a multicomponent system:the catalytic subunit is on the
luminal surface of the endoplasmic reticulum membrane; and there are transport
proteins for glucose-6-phosphate, inorganic phosphate and glucose across the ER
membrane; and there is a calcium-binding stabilising protein associated to the
catalytic subunit. In fasted and diabetic humans (and rat models) kinetic analysis has
shown that the capacity of the glucose-6-phosphate transport protein is the rate-
limiting step in G6Pase activity, making this protein vital in controlling hepatic
glucose output. However, deficiency of any part of this system will lead to
hypoglycaemia and other possible metabolic upsets (type 1 glycogen storage
diseases). The structure and known regulation of the G6Pase system are reviewed in
the introduction to this thesis.
The aims of the work presented here are to investigate the human glucose-6-
phosphatase system by studying adult patients newly diagnosed with abnormalities
of the G6Pase system, and tissues not previously proven to contain G6Pase in
healthy adults thereby improving understanding of the enzyme, its regulation and
physiological role and to look for a tissue more accesible than liver in which to
study human G6Pase activity.
A unique series of eight adult patients each with an abnormality of hepatic G6Pase
(two with previously unrecorded defects) is presented and the features of these cases
are discussed with reference to the existing literature on type 1 glycogen storage
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diseases. The cases demonstrate how difficult it can be to prove hypoglycaemia in
adults; the diversity of presenting symptoms and signs; the use of a screening test
(blood glucose response to a lmg intramuscular dose of glucagon) for such patients;
and the benefits of developing reliable assays for the protein components of the
G6Pase system. This series of patients also give further clues to the physiological
role of glucose-6-phosphatase in extra-hepatic tissues and the regulation of the
hepatic G6Pase system.
The diagnosis and subsequent follow-up of the above patients would have been
eased by being able to study a more accessible tissue than liver. Intestinal mucosa
and neutrophils have been described as abnormal in G6Pase deficiencies. Therefore
G6Pase activity was sought in these tissues from normal adult humans.
Confirmation of the presence of the G6Pase catalytic subunit in intestinal mucosa is
presented; and data from neutrophils which is highly suggestive of catalytic subunit
being present, but little demonstrable activity due to proteolysis. The use of either
of these tissues to study human glucose-6-phosphatase activity is therefore still not
reliable. Possible physiological roles for glucose-6-phosphatase in both intestinal
mucosa and neutrophils is discussed.
I also set out to study the structure and regulation of the glucose-6-phosphate
transport protein with the (long-term) view of understanding and down-regulating
the increased hepatic glucose output seen in diabetes mellitus.
Studies of the G6P transport protein required the development of new techniques
(such as microsomal transport assays, sodium-free systems and affinity
chromatography).
Little has been known of the glucose-6-phosphate transport protein (Tl), despite its
obvious importance in the pathogenesis and possible site of pharmacological
manipulation in diabetes mellitus. I have demonstrated, for the first time, that
glucose-6-phosphate co-transports with sodium across the endoplasmic reticulum
membrane and that the normal transport of both requires a divalent metal ion
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(probably calcium). Following from this is the first evidence of in vitro
pharmacological manipulation of T1 with the sodium channel inhibitor amiloride.
Early work to isolate and purify T1 using affinity chromatography techniques is also
presented, and data using antibody raised to a protein isolated in this fashion is
shown. The protein isolated is compared to an earlier protein which was thought
originally to be Tl.




The liver plays a vital role in controlling glucose homeostasis in mammals (Nordlie
1985). In the post prandial state the liver takes up glucose for storage as glycogen
or metabolism. Under fasting conditions the liver produces glucose to maintain
blood glucose levels. In times of acute stress the liver rapidly releases glucose to
maintain blood glucose levels for use as a fuel by tissues which cannot produce
glucose - eg brain and muscle (Nordlie 1985). In the liver the final step in glucose
production via both the glycogenolytic and gluconeogenic pathways is the hydrolysis
of glucose-6-phosphate by a substrate specific phosphatase (Figure 1.1). This
phosphatase is glucose-6-phosphatase (EC 3.1.3.9). Any compound, deficiency or
disease state affecting glucose-6-phosphatase structure or function will, therefore,
affect glucose homeostasis by influencing the final step in both glycogenolysis and
gluconeogenesis.
The work in this thesis is concerned with this final step in glucose production within
the liver - the hydrolysis of glucose-6-phosphate by the enzyme glucose-6-
phosphatase.
In this opening Chapter I will summarise the knowledge and the theories concerning
glucose-6-phosphatase as they were when my work started.
Despite its crucial position in glucose homeostasis and many years of study, the
biochemistry of glucose-6-phosphatase is not well understood. This is mainly due to
the fact that the enzyme is intimately associated with intracellular membranes, and





A representation of the pathways of metabolism in hepatocytes showing the central
position of glucose-6-phosphate in a number of pathways, and the terminal step in
glucose production by glycogenolysis and gluconeogenesis being catalysed by
glucose-6-phosphatase. Also indicated is the substrate cycle between glucose-6-
phosphate and glucose which occurs continuously and which is a site of control of
hepatic glucose output and uptake.
6
1.1 HISTORICAL BACKGROUND
1.1.1 Multifunctional potential of glucose-6-phosphatase
In vivo the glucose-6-phosphatase enzyme is very substrate specific. In vitro
however glucose-6-phosphatase can catalyse many reactions. Some of these
reactions can be employed to study glucose-6-phosphatase activity in tissue samples.
Glucose-6-phosphate + H2O > Glucose + Pi (1)
Mannose-6-phosphate + H2O » Mannose + (2)
Glucose + Carbamyl-phosphate » Glucose-6-P + NH3 +CO2 (5)
* Many other phosphate salts (notably glucosamine-6-phosphate and carbamyl-
phosphate but not glucose-1-phosphate) can also be hydrolysed by glucose-6-
phosphatase.
The specificity of glucose-6-phosphatase for different phosphate salts was
recognised relatively early after the discovery of the enzyme (Beaufay & De Duve
1954a). Not until much later was this specificity satisfactorily interpreted along with
kinetic analyses to produce the models of glucose-6-phosphatase described below.
The physiological role of glucose-6-phosphatase has been subject to much
speculation. There is no doubt that reaction (1) above occurs in vivo. Reactions (2)
and, probably, (3) do not. The physiological role of the microsomal pyrophosphate
transport protein (T2) is unclear; it is possible that pyrophosphate is required for
another intraluminal process. It has been proposed that reactions (4) and (5) can
occur in hepatocytes (Nordlie 1985) in conditions of glucose excess. The Km of
glucose-6-phosphatase for glucose in the latter two reactions in vitro is 80-90mM
(Arion & Nordlie 1964) and in vitro 120mM glucose has been used to assess the
Pyrophosphate (PPi) + H2O
Glucose + PP,-
- 2Pi (3)
-* Glucose-6-phosphate + Pj (4)
( )
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phosphotransferase activity of glucose-6-phosphatase (Nordlie 1976). It seems
unlikely that this concentration of glucose will occur in vivo. However it can be
argued that as microsomes are artefacts, the conditions needed for reactions (4) &
(5) to proceed in vitro do not reflect those necessary in vivo.
Glucose-6-phosphatase in vivo also shows multifunctionality. The most convincing
evidence for this was the demonstration that microsomes prepared from the liver of
a patient with type la glycogen storage disease (complete absence of glucose-6-
phosphatase activity) could not perform any of the reactions attempted: glucose-6-
phosphate and sodium pyrophosphate hydrolysis; and pyrophosphate-glucose and
carbamyl phosphate-glucose phosphotransferase (Hefferan & Howell 1977).
The multifunctionality of the glucose-6-phosphatase enzyme has been exploited in
assaying microsomes prepared from patients (especially reactions 1-3 above) and is
important in understanding the biochemistry of glucose-6-phosphatase.
1.1.2. Biochemistry
Cori and Cori showed in 1938 that glucose was produced in the liver by the action
of a phosphatase (Cori & Cori 1938) and in 1945 Fantl and Rome demonstrated that
the final step in hepatic glucose production involved the specific hydrolysis of
glucose-6-phosphate. From this time on a lot of work was done trying to isolate and
characterise the glucose-6-phosphatase enzyme (for a detailed early review of this
work see Ashmore & Weber 1959). Much of this pioneering work has been
confirmed and used to formulate the present day ideas about glucose-6-phosphatase.
For instance the pH optimum of the enzyme was shown to be between 6 and 7 (eg
Ashmore et al 1954) and has subsequently been shown to be 6.5; the marked
sensitivity of the enzyme to temperature changes (Cori & Cori 1952 and Beaufay et
al 1954); and (very importantly) the inactivation of the glucose-6-phosphatase
enzyme by incubation at pH 5 (Beaufay & de Duve 1954a) became clear.
Unfortunately some of this data (especially the last work mentioned above) has
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subsequently been ignored by many workers. This has lead to numerous erroneous
claims in the literature of "glucose-6-phosphatase" activity where data have been
confused by the presence of non-specific phosphatase activity, which could easily
have been corrected for using careful experimental technique.
The intracellular distribution of glucose-6-phosphatase in the hepatocyte was first
recognised in 1951: using the then new technique of differential centrifugation Hers
et al (1951) demonstrated that glucose-6-phosphatase activity was in the microsomal
fraction. Another important piece of early work concerned the effects of detergents
on microsomal glucose-6-phosphatase activity (Beaufay & de Duve 1954b). This
data showed that at low concentrations of detergent there was activation of the
enzyme's activity but inhibition at higher concentrations. This was the first
demonstration of the "latency" of microsomal glucose-6-phosphatase activity. It is
the mechanism of this "latency" which has stimulated much of the investigation into
and caused much of the controversy surrounding microsomal glucose-6-
phosphatase.
1.1.3 The latency of microsomal glucose-6-phosphatase.
The latency (or "detergent sensitivity") of microsomal glucose-6-phosphatase is the
percentage of specific glucose-6-phosphatase activity which is not expressed in an
assay of untreated microsomal preparations, but which is expressed when the
integrity of the microsomal membrane is disrupted. Latency is caused by the
catalytic site of the enzyme being buried within the lipid component of the
endoplasmic reticulum membrane.
Latency is calculated from the following equation:




Where dm and im are the activity of glucose-6-phosphatase in disrupted and intact
microsomes respectively. "Disrupted" microsomes are those treated, for example,
with detergent, by sonication or with histone 2A and "intact" microsomes have had
their activity "corrected" for intactness (see below).
The latency of microsomal glucose-6-phosphatase is variable, and depends upon a
number of factors: the method of microsomal preparation; how old the preparation
is (the apparent latency falls as microsomes become older due to a decrease in the
glucose-6-phosphatase activity of disrupted microsomes because of temperature
inactivation of the enzyme); and how often the preparation has been frozen and
thawed (this reduces the latency of untreated microsomes by disrupting the
microsomal membrane). The latency of hepatic microsomal glucose-6-phosphatase
activity is also altered by the metabolic state of the animal from which the
microsomes are prepared: latency is increased in microsomes prepared from fasting
animals compared to fed ones (Nordlie et al 1968) and is increased again in diabetic
animals (Nordlie et al 1979b); in glucocorticoid-treated animals the latency is
decreased (Arion et al 1976b).
Microsomes are an artefact and comprise vesicular fragments of endoplasmic
reticulum surrounded by a single continuous membrane (Palade & Siekevitz 1956).
During the preparation of microsomes there is no guarantee that the endoplasmic
reticulum membrane vesicles will be intact. This would result in an apparent
decrease in latency of microsomal glucose-6-phosphatase activity as the apparent
activity of untreated microsomes will be higher. Knowing the percentage latency of
untreated microsomal preparations is important in correctly interpreting kinetic data
of hepatic microsomal glucose-6-phosphatase activity. This percentage of
"correctly" formed microsomes can be assessed by exploiting the substrate
specificity of glucose-6-phosphatase in untreated microsomes. It was recognised in
1955 that, for example, the hydrolysing ability of glucose-6-phosphatase for
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mannose-6-phosphate and glucosamine-6-phosphate was lower than for glucoses-
phosphate. It is likely that these data were obtained using microsomes not fully
"intact" as the mannose-6-phosphate hydrolysing activity he demonstrated was much
higher than was subsequently found in microsomes known to be "intact" (Arion et
al 1972). Using detergent treated microsomes, however, the hydrolytic activity of
glucose-6-phosphatase is identical for both glucose-6-phosphate and mannose-6-
phosphate substrates (Arion et al 1972). The hydrolysing activity of untreated
microsomes with mannose-6-phosphate substrate compared to this activity measured
in disrupted microsomes has been adopted as a reliable way of assessing the
intactness or otherwise of a microsomal preparation which should then be allowed
for in kinetic studies (Arion et al 1976a). As the Km of glucose-6-phosphatase in
intact microsomes is much higher than that in disrupted microsomes, therefore only
a small proportion of disrupted microsomes will markedly alter the apparent kinetics
of the hydrolysis of glucose-6-phosphate.
The calculation of "intactness" of a microsomal preparation (expressed as a
percentage of the total microsomal population) is calculated from the following
equation:
Mannose-6-phosphataseum
^im = Vum - V(jm x
Mannose-6-phosphatasedm
Where Vjm is the velocity of the reaction in microsomes with intact membranes,
Vum is the velocity of the reaction in untreated microsomes and V(jm the velocity
in fully disrupted microsomes.
Data using permeablised hepatocytes has shown differences in kinetic constants of
glucose-6-phosphatase to microsomes (Jorgenson & Nordlie 1980 and McEwen &
Arion 1985): the main difference is that the latency of the enzyme and the Vmax do
not increase as much as they do in microsomal preparations moving from fed to
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starved to diabetic animals. However there are some concerns about this data,
mainly that the methods used to permeabilise microsomes may have damaged the
ER too.
The explanation of the phenomena of latency and substrate specificity have occupied
many workers on glucose-6-phosphatase for many years and has given rise to one of
the most controversial aspects of the enzyme: its structure in, and relationship to,
the endoplasmic reticulum membrane.
1.1.4 Two theories on the structure of glucose-6-phosphatase.
Two theories have arisen - largely based upon the interpretations made by a number
of individuals on data available at the time - to explain the latency and substrate
specificity of microsomal glucose-6-phosphatase. These are the "Conformational"
and "Multicomponent Transporter System" models, and will be discussed
individually. Initially these two theories were seen by many as mutually exclusive,
but it may be that both are, to differing extents, correct.
The presence of latency of glucose-6-phosphatase activity which can be removed by
detergent treatment and the specificity of the hydrolysing capability of the enzyme
in untreated microsomes for glucose-6-phosphate suggests that the catalytic activity
is contained within a phospholipid membrane and that the presence of the membrane
in some way constrains the catalytic activity.
Once the microsomal model of glucose-6-phosphatase has been clarified (a difficult
enough task) the in vivo model of glucose-6-phosphatase will then have to be
defined.
a) The Conformational Model of glucose-6-phosphatase
The basic concept of this model is that glucose-6-phosphatase catalytic activity is
buried in the endoplasmic reticulum membrane and that changes in the local
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membrane microenvironment result in the interactions of the catalytic site with its
various substrates. Initially this model suggested that the catalytic site of the
glucose-6-phosphatase was on the outside of the endoplasmic reticulum in vivo (but
became buried within the membrane during the preparation of microsomes). The
binding of the substrate caused a conformational change whereby the enzyme-
substrate complex crossed the ER membrane and glucose was then produced inside
the lumen of the endoplasmic reticulum (Stetten & Burnett 1967) which was in
continuity with the extracellular space where the glucose was required. Therefore
there is no transport of glucose-6-phosphate or reaction products across the ER
membrane.
It had earlier been proposed that this conformation would favour the synthesis of
glucose-6-phosphate from extracellular glucose (Siekevitz 1958) - one of the
postulated roles of glucose-6-phosphatase (see above). However as pointed out
above, the synthesis of glucose-6-phosphate by glucose-6-phosphatase will only
occur (in vitro) at very high glucose concentrations which are very unlikely to occur
in vivo. Stetten and Burnett suggested that treating microsomes with detergent
restored the in vivo conformation of the enzyme in the endoplasmic reticulum
membrane. However this is difficult to believe as the activity of detergent treated
microsomal glucose-6-phosphatase is very high and (by this early model) relatively
uncontrolled and would presumably result in a huge out-pouring of glucose by the
liver. It is likely that glucose-6-phosphatase activity is under extra cellular control
as it catalyses one side of a substrate cycle (see Figure 1.1 and discussion below).
Subsequently the conformational model has been modified from that described by
Stetten and Burnett to that summarised by Schulze et al in 1986. The glucose-6-
phosphatase molecule now is interpreted as a water-filled tube through the
hydrophobic endoplasmic reticulum membrane. Much of the basis of this theory is
inferred from the interpretation of studies of inhibitors of glucose-6-phosphatase
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activity (sulfhydryl reagents and organic mercurials). The purification of this single
protein has not been achieved.
This model disregards most of the kinetic observations of glucose-6-phosphatase
activity and makes understanding the type 1 glycogen storage disease variants very
difficult.
b) The Multicomponent Transport Theory ofGlucose-6-phosphatase
The basis of this model is that the catalytic subunit of glucose-6-phosphatase lies on
the luminal surface of the endoplasmic reticulum and that there are individual
transport proteins to permit the passage of substrate and reaction products across the
endoplasmic membrane. This model of glucose-6-phosphatase was first suggested
after careful kinetic studies on microsomal glucose-6-phosphatase and the substrate
specificity conferred by the intact microsomal membrane (Arion et al 1972).
Arion's data showed clearly that in intact microsomes the hydrolysis of glucose-6-
phosphate was more rapid than the hydrolysis of mannose-6-phosphate. Further
work in Arion's laboratory using sulfhydryl poisons lead to the evolution of the
multicomponent model as it has become understood (Wallin & Arion 1973, Arion et
al 1975 and Arion et al 1980b).
There are now three postulated transport proteins across the ER membrane for
glucose-6-phosphate, phosphate and glucose (named Tl, T2 and T3 respectively).
In 1982 a 21kDA protein was isolated from microsomes, antibodies to which
immunoprecipitated >90% glucose-6-phosphatase activity from microsomes
(Burchell & Burchell 1982) but which was subsequently shown to be a regulatory
protein closely associated with the glucose-6-phosphatase catalytic subunit (Burchell
et al 1985). Ann Burchell has called this protein "stabilising protein" as (in vitro) it
stabilised glucose-6-phosphatase activity (Burchell et al 1985).
Figure 1.2 shows the structure of the glucose-6-phosphatase multicomponent model
as it was visualised when my work started. The catalytic subunit is associated to the















Diagrammatic representation of the multicomponent transporter model of hepatic
microsomal glucose-6-phosphatase as it was visualised when this thesis started. The
catalytic subunit (enzyme) is associated to the luminal surface of the ER membrane
and a calcium-binding stabilising protein. There are three transport proteins to allow
the influx of substrate glucose-6-phosphate and the efflux of reaction products
phosphate (which counter-transports with pyrophosphate) and glucose from the
lumen of the ER; named Tl, T2 and T3 respectively.
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The model suggests three transport proteins to allow substrate (glucose-6-phosphate)
to cross into the lumen of the ER, and the reaction products inorganic phosphate
(Pj) and glucose to pass back into the cytoplasm. These transport proteins have been
called Tl, T2 and T3 respectively. The inorganic phosphate transport protein (T2)
was also postulated to counter-transport pyrophosphate.
The ultimate proof of existence of the multicomponent model of glucose-6-
phosphatase will be the isolation of the proteins involved.
In the rest of this thesis the Multicomponent Transport Model of glucose-6-
phosphatase activity is assumed
1.1.5 Purification of the proteins of the glucose-6-phosphatase system
Purification of the active microsomal glucose-6-phosphatase protein has proved
difficult. The protein has proved very difficult to dissociate from the microsomal
membrane and all the detergents used to achieve the dissociation also inhibit
glucose-6-phosphatase activity. Once dissociated from the ER membrane the
glucose-6-phosphatase activity is very unstable in a time and temperature dependent
manner. This instability may reflect dissociation of the enzyme activity from the
stabilising protein as much as from the membrane environment.
Several claims of the purification of the glucose-6-phosphatase protein have been
made from a variety of tissues and involve a variety of differing sizes of peptide:
Anchors and Karnovsky isolated a 28kDa protein from rat brain which reportedly
retained glucose-6-phosphatase activity and similar kinetic characteristics to the
microsomal enzyme (Anchors & Karnovsky 1975); Reczek and Villee claimed that
a 58-64kDa protein they isolated from human liver and placenta was the glucose-6-
phosphatase enzyme, but it only displayed a small increase in glucose-6-phosphatase
activity (Reczek & Villee 1982). No further data has been forthcoming about these
proteins: such as structures, sequences or studies with specific antibodies. Therefore
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it seems unlikely that they do in fact represent the glucose-6-phosphatase catalytic
protein. Furthermore, subsequent work has shown clearly that specific glucose-6-
phosphatase activity is not present in placenta, but that high levels of non-specific
phosphatases are (Chen & Kato 1985 and Barash et al 1991).
Ann Burchell has tried over a number of years to purify a single glucose-6-
phosphatase catalytic protein without success. The best attempt resulted in the
isolation of 5 peptides identified by SDS-PAGE. Studies on these five peptides
(which together retained glucose-6-phosphatase activity) revealed the presence of
the 21kDa stabilising protein (Burchell et al 1985) and studies on microsomes
identified the catalytic subunit as part of a 36.5kDa doublet (Countaway et al 1988).
Polyclonal antibodies raised to this doublet used to immunostain liver microsomes
from a patient with type la glycogen storage disease (complete absence of glucose-
6-phosphatase activity) showed this 36.5kDa protein to be absent, thus confirming
that this doublet did indeed represent the glucose-6-phosphatase catalytic protein
(Burchell et al 1988b).
Progress on the purification of the transport proteins has been slow. In 1982 Zoccoli
et al published work regarding a 54kDa protein that they had identified and which
they considered to be the microsomal glucose-6-phosphate transport protein T1
(Zoccoli et al 1982). In 1986 (Countaway & Arion) this protein was shown not to
be T1 and the original group reported nothing more on this protein. No other
reports regarding the structure of the T1 transporter have been published. The T1
transport protein is the subject of Chapter 5 where it is discussed in greater detail.
In contrast the pyrophosphate/phosphate antiporter T2 has been shown to be a
37kDa peptide (Waddell et al 1988). No data was forthcoming regarding the
microsomal glucose transport protein T3 when my work started.
Studies of the genetic deficiencies of glucose-6-phosphatase have resulted in major
advances in the understanding of the structure of the enzyme and its associated
proteins.
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1.1.6 Genetic Deficiencies of Hepatic Glucose-6-phosphatase
The first description of a human condition involving an apparent abnormality of
hepatic glucose production was made in 1929 by von Gierke when he described the
autopsy findings on two children with clinical histories compatible with a glycogen
storage disease. In 1952 Cori and Cori demonstrated for the first time the absence
of glucose-6-phosphatase activity in the liver of a patient with hypoglycaemia and
hepatomegaly (Cori & Cori 1952). The Cori's called this disease "von Gierke's"
disease in deference to the 1929 report. However it seems likely in retrospect that
the cases described in 1929 had a deficiency of the debranching enzyme rather than
of glucose-6-phosphatase. The use of eponymous names for the glycogen storage
diseases is confusing, and throughout this thesis the numerical classification as
described in Hers et al 1989 will be used. Thus the deficiencies of glucose-6-
phosphatase are the type 1 glycogen storage diseases (GSDs).
Several clinical pictures have been recognised in patients with type 1 glycogen
storage disease and these will be discussed in more detail in Chapter 3. Briefly there
are patients who have severe hypoglycaemia, huge livers and kidneys (which are
full of glycogen), hyperuricaemia, hyperlipidaemia, a bleeding tendency and high
plasma lactate levels (especially on fasting) and who tend to die young of
hypoglycaemic coma, renal failure or hepatocellular carcinoma. There is no
demonstrable glucose-6-phosphatase activity in either intact or disrupted
microsomes made from the livers of these patients. This pattern is called type la
glycogen storage disease. This was thought to be a severe condition which was
diagnosed in early life, but more recently partial forms of the disease have been
demonstrated in adults (Burchell et al 1987).
Other patients have all the above signs and a tendency to bacterial sepsis. These
subjects often have demonstrable abnormalities of neutrophil function (eg Anderson
1981). Study of hepatic microsomal glucose-6-phosphatase activity in these subjects
was initially confusing as low levels of activity are found in intact microsomes but
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in disrupted microsomes the glucose-6-phosphatase activity is normal or high.
However careful kinetic studies by Lange et al explained these findings as
representing deficiency of the microsomal glucose-6-phosphate transport protein T1
- ie type lb glycogen storage disease (Lange et al 1980). Types la and lb glycogen
storage disease are diagnosed by assaying intact and disrupted microsomes with both
glucose-6-phosphate and mannose-6-phosphate as substrates. Type la glycogen
storage disease may be confirmed in some cases (but not all) by immunoblot
analysis of microsomes using the polyclonal antibody to the catalytic protein. If the
microsomal hydrolytic activity for glucose-6-phosphate is present but the patient has
excess glycogen stores and recurrent hypoglycaemia then the microsomes (intact and
disrupted) must be assayed for hydrolysing activity of pyrophosphate - absent
activity in intact microsomes which is present in disrupted microsomes is indicative
of type lc glycogen storage disease: absence of a functional
phosphate/pyrophosphate transport protein, T2. This can also be confirmed by
immunoblot analysis using the antibody raised against T2 and described by Waddell
et al (1988). However some type la and lc glycogen storage disease patients do
have the relevant immunoreactive protein in hepatic microsomal preparations.
There have been (at the time of writing) no descriptions of type Id glycogen storage
disease (absence/deficiency of the microsomal glucose transporter T3). This may be
because the existence of T3 is still unproven and/or because there is no clear assay
for the capacity of such a protein.
A review of the kinetic methods for diagnosing type 1 glycogen storage disease
variants is given in Burchell et al 1988a.
The study of these genetic deficiencies of glucose-6-phosphatase is some of the
strongest proof for the multicomponent model of glucose-6-phosphatase as described
above. It is difficult to conceive how the conformational model of glucose-6-
phosphatase can accommodate these data. Unfortunately the diagnosis of all these
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abnormalities has to be made on liver tissue as there is no more accessible tissue
with definite glucose-6-phosphatase activity to use.
1.1.7 Other observations on glucose-6-phosphatase
In other conditions of abnormal glucose output (such as diabetes mellitus and high
circulating corticosteroid levels) glucose-6-phosphatase activity is abnormal. In
untreated diabetes mellitus there is increased enzyme activity in disrupted
microsomes and increased latency for glucose-6-phosphate and mannose-6-
phosphate in intact microsomes (Arion et al 1976a and 1980b). Associated with this
increase in catalytic activity there is an increase in the amount of catalytic subunit
protein (Burchell & Cain 1985). Treatment with insulin in streptozotocin induced
diabetes decreases glucose-6-phosphatase activity (Nordlie & Arion 1965, Nordlie
1971 and Burchell and Leakey 1988).
In conditions of glucocorticoid excess, there is increased catalytic activity due
largely to a decrease in measured latency for glucose-6-phosphate (Arion et al
1976b).
As Figure 1.1 shows, glucose-6-phosphatase catalyses one side of a substrate cycle
involving the interconversion of glucose and glucose-6-phosphate. The opposite
reaction is catalysed by glucokinase, the activity of which is inhibited by glucose-6-
phosphate, but is markedly increased by glucose concentrations in the physiological
range 5-10mM. Both glucokinase and glucose-6-phosphatase have been suggested as
being continuously but variably active in hepatocytes (Hue 1982). The regulation of
glucokinase has been extensively investigated and is complex, as would be expected
from the theory that the substrate cycles can respond rapidly to a number of
different stimuli (van Schaftingen & Vandercammen 1989, Davies et al 1990,
Detheux et al 1991 and Vandercammen & van Schaftingen 1991). The balance
between the activity of the two enzymes therefore determines if there is net uptake
by or release of glucose from the liver. As the cycle continuously operates it means
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that the response to extra-hepatocyte conditions (such as hormonal stimulation) is
very rapid.
1.1.8 Tissue Distribution of Glucose-6-phosphatase
The type 1 glycogen storage diseases are associated with enlargement of the liver
and kidney due to increased glycogen stores. Glucose-6-phosphatase activity can be
measured in the kidney and the presence of the catalytic subunit has been shown by
immunoblotting with the antibody to the 36.5kDa protein described above (Waddell
& Burchell 1988). Many other tissues have been reported as containing glucose-6-
phosphatase (see Nordlie 1971, Colilla et al 1975 and Nordlie & Sukalski 1985 for
review) however some of the reviewed data is suspect as the assay techniques
employed have often identified non-specific phosphatase activity at such high levels
that any specific glucose-6-phosphatase activity is masked. To establish specific
glucose-6-phosphatase activity in a tissue it is necessary to demonstrate glucose-6-
phosphate hydrolysis in the microsomal fraction of that tissue with the same kinetic
and specificity profile as in liver microsomes; incubation of the microsomes at pH 5
and 37°C for 10 minutes should destroy the activity; and there should be a reaction
on immunoblot analysis with the antibody to the 36.5kDa catalytic subunit. Using
these strict criteria glucose-6-phosphatase activity has been confirmed in the liver
and kidney and demonstrated in pancreatic islet cells (Waddell & Burchell 1988)
and gall bladder mucosa (Hill et al 1989).
The physiological role for the enzyme in all these tissues is still to be clarified and
is discussed in more detail in Chapters 3 and 4 below.
The aims of the work described in this thesis were to further investigate
abnormalities of glucose-6-phosphatase activity in adult humans; to try and extend
knowledge regarding the tissue distribution of the enzyme, at the same time looking
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for a more accessible tissue on which to study glucose-6-phosphatase activity in
vivo; and to study the microsomal glucose-6-phosphate transport protein.
The study of human glucose-6-phosphatase abnormalities is described in Chapter 3
where as well as two new abnormalities, six unusual cases are presented. The
importance of correctly assaying microsomal preparations with up to three
substrates is clearly demonstrated. In an attempt to further understand the
physiology of glucose-6-phosphatase and to find a more accessible tissue than liver
in which to study the enzyme in vitro I wanted to look at the activity of the enzyme
in intestinal mucosa and neutrophils. This work is described in Chapter 4.
The key rate-limiting step to glucose-6-phosphatase activity is the capacity of the
glucose-6-phosphate transport protein, Tl. Nothing was known of this protein at the
start of this thesis, but its presence was inferred from kinetic analysis of glucose-6-
phosphatase activity and by its absence in type lb glycogen storage disease. I
wanted to isolate the protein, study its biochemistry and attempt to
pharmacologically manipulate its capacity for glucose-6-phosphate transport with






The cases described in Chapter Three were referred to Ninewells Hospital, Dundee
and were investigated under the direct supervision of Dr.Roland Jung, Consultant
Physician.
The studies of glucose-6-phosphatase activity in human intestinal mucosa described
in Chapter Three were performed on individuals undergoing routine gastrointestinal
endoscopy by the endoscopy service at Ninewells Hospital, Dundee.
The studies of glucose-6-phosphatase activity in human blood were performed on
venous blood samples drawn from normal volunteers.
Permission for both of these studies had been given by the Tayside Health Board
Committee on Medical Ethics.
2.1.1 Biopsies
a) Liver biopsies. These biopsies were performed under local anaesthesia (unless
otherwise specified) on conscious patients through the eighth right intercostal space
in the mid-axillary line. Biopsies were taken with 'Surecut' (modified Menghini)
needles (TSK Laboratories, Japan). Before biopsy all patients gave informed, signed
consent. Tests of in vitro blood clotting (prothrombin time and kaolin cephalin
clotting time unless otherwise specified) and a full blood count (for haemoglobin
concentration and platelet count) were routinely carried out before the biopsy.
Serum was also cross-matched for use in the case of emergency haemorrhage.
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After the biopsy patients rested flat in bed for at least four hours, and were not
allowed out of bed for at least twelve hours. During this period of rest regular
measurements of pulse and blood pressure were made and assessment of need for
analgesia was carried out. A number of the patients experienced mild right upper
abdominal/right shoulder-tip discomfort requiring simple oral analgesia
(paracetamol). One particularly anxious patient required a single dose of parenteral
analgesia (pethidine). No episodes of haemorrhage, peritonism or pleurisy were
observed. All patients were fit for discharge from hospital (with instruction to avoid
strenuous exercise and heavy lifting for seven days) twenty-four hours after the
biopsy.
Samples of liver for histology were transported in phosphate-buffered
formaldehyde/phenol-formaldehyde solution (Hopwood et al 1990). Paraffin
sections were stained with haematoxylin and eosin and PAS. Samples for electron
microscopy were fixed in 0.2M cacodylate buffered 3% glutaraldehyde and
embedded in Epon. Thin sections were stained with uranyl acetate and lead citrate
and examined with a JEOL 100 CX electron microscope at 60 kV.
Liver pathology for all patients described was examined by Dr. David Hopwood,
Consultant Pathologist, Ninewells Hospital, Dundee.
Samples of liver for biochemical analysis were placed immediately in ice-cold 0.25
M sucrose/5 mM HEPES buffered to pH 7.4 (SH pH 7.4). All assays for glucose-6-
phosphatase, mannose-6-phosphatase and pyrophosphatase activity were performed
on fresh unfrozen tissue within 1 hour of biopsying (see 2.6 below for methods).
Estimations of protein and glycogen content were performed on samples which had
been frozen at -70°C for a maximum of 48 hours (for assay methods see 2.6 below
and Chapter 3 for further details of the patients studied).
b) Gastrointestinal mucosa biopsies. Patients attending the Department of Clinical
Measurement, Ninewells Hospital, Dundee for routine out-patient endoscopic
examination of the gastrointestinal tract were approached and asked to give
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informed consent to biopsying of normal-looking areas of gut mucosa. Each patient
was biopsied from only one area of the gastrointestinal tract. No patient had
biopsies taken on more than one occasion. All patients were observed by the staff of
The Department of Clinical Measurement, Ninewells Hospital after the sample for
signs of significant haemorrhage. None were observed.
Samples of mucosa were taken from macroscopically normal areas of gut using
standard pinch biopsy forceps through an Olympus endoscope by experienced
endoscopists. Five or six biopsies were taken from a single area of gut in each
patient giving a total wet weight of 30-50 mg mucosa. The biopsies were collected
immediately into ice cold 0.25 M sucrose/5 mM HEPES pH 7.4 containing a
cocktail of protease inhibitors (see Table 2.1) or wrapped in aluminium foil and
frozen immediately in liquid nitrogen (see 2.5.1). The biopsies were assayed
immediately - the processing was started within 15 minutes of the biopsy being
taken. See Chapter 4.1 for details of results.
Protease inhibitor cocktail used to collect samples of intestinal mucosa used for
activity measurements.
Table 2,1






Phenylmethylsulphonyl fluoride (PMSF) 0.02 % (w/v)
0.1 mM
PMSF in 10% ethanol
c) Venous blood. Ten ml of peripheral venous blood was drawn (without stasis
whenever possible) from healthy volunteers into either tubes containing lithium
heparin or into tubes containing 1ml trisodium citrate. The blood cell types were
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then separated out immediately as described below (see Chapter 4.2 for details of
results). All blood samples were processed within 30 minutes of collection.
2.1.2 Endocrine Testing
Prior to all of these tests an indwelling intravenous cannula was placed into an
antecubital fossa vein. The cannula was kept patent with 1ml flushes of saline
containing heparin 10 U/ml. The first 1 ml of each blood sample was discarded.
a) Glucagon test One mg of glucagon (Novo Laboratories, UK) was given by
intramuscular injection (the deltoid in the non-dominant upper limb was used) at
time '0'. The subjects had been fasted overnight. Blood samples were taken at set
times (predose, 30, 60, 90 and 120 minutes post injection) for measurement of
blood glucose levels. Subjects were then fed and, if out-patients, allowed home.
Blood glucose levels were assayed in duplicate using a Beckman Glucose Analyser.
Serum insulin levels were measured by radio-immuno assay (kits from Amersham
Ltd and Serono were used).
Interpretation A rise in blood glucose of > 4mmol/l was taken as normal (see
Discussion in Chapter 3).
b) Oral glucose tolerance test After an overnight fast 75g of glucose dissolved in
200ml water was given as a drink (all drinks were completed within 3 minutes).
Samples of blood were taken at set times for glucose and (in case 8) insulin levels
(predose, 30, 60, 90, 120, [150 & 180] minutes after the drink - the 150 & 180
minute samples were not routine). The first 1ml of each sample was discarded.
After the last sample was drawn the subject was fed and, where appropriate,
allowed home.
Interpretation Standard World Health Organisation criteria (Report of the WHO
Study Group on Diabetes Mellitus 1985) were used to interpret the blood sugar
changes of diabetes/impaired glucose tolerance. The interpretation of the blood
glucose levels in terms of hypoglycaemia were made for individual cases. The
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serum insulin levels (when measured) were interpreted, likewise, in the context of
each case.
c) Intravenous glucose tolerance test This was performed only on case 8 (see
Chapter 3) and was unusual in that the subject needed resuscitation from profound
hypoglycaemia during the test.
After an overnight fast, at time 0, a bolus of glucose (0.5g/kg body weight) was
given. Blood for glucose, insulin, glucagon, Cortisol and growth hormone levels
was drawn at set times relative to the glucose bolus (predose, 15, 30, 45, 60, 90 &
120 minutes post dose). For further details of the test see case 8 in Chapter 3.
c) Short Synacthen test A single intramuscular injection of synthetic ACTH
analogue (Synacthen, Ciba Laboratories, UK) was given at time 0. Blood for serum
Cortisol measurement (Framos RIA, Pharmacia, UK) was drawn predose and at 30
and 60 minutes post dose.
Interpretation A rise in serum Cortisol of > 220nmol/l above the predose level with
a peak level of at least 500nmol/l was taken as normal.
All samples were assayed in the laboratories of the Department of Biochemical
Medicine, Ninewells Hospital and Medical School, Dundee.
2.2 ANIMALS
All animal experiments were carried out under the auspices of a Home Office
Project Licence to carry out a Programme of Scientific Procedures on Living
Animals granted to Dr. Ann Burchell, Lister Institute Research Fellow, Ninewells
Hospital and Medical School, Dundee and a Personal Licence to carry out
Regulated Procedures on living animals granted to me. At all times the terms of the
1986 Animals (Scientific Procedures) Act were diligently adhered to.
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The rats used to study the hepatic glucose-6-phosphatase system and to purify the
postulated microsomal glucose-6-phosphate transport protein were adult male Wistar
rats from the colony inbred and cared for in the University Animal Unit, Ninewells
Hospital and Medical School, Dundee. An adult female Cheviot sheep was used to
raise antibodies to the postulated hepatic microsomal glucose-6-phosphate transport
protein (Tl).
All the laboratory animals were maintained under standard conditions of
temperature and relative humidity with a 12 hour light/dark cycle. They had free
access to laboratory animal chow (unless specifically fasted for 16 hours prior to
death) and tap water.
2.2.1 Treatment of laboratory animals.
The hepatic microsomal glucose-6-phosphatase system was studied under different
metabolic conditions in the rats. These metabolic conditions were achieved as
follows.
a) Fed animals These animals had free access to food and water up until death.
b) Starved animals These animals were denied access to food for 16 hours prior to
death. They had free access to water at all times.
c) Diabetic animals To induce diabetes the animals were sedated with ether and
then given a single tail vein injection of 75 mg/kg body weight streptozotocin in
citrate buffered to pH 4.5. Control animals were injected with buffer only. The
animals then had free access to food and water for 72 hours at which time they were
killed. The development of diabetes was confirmed in the test animals by the
measurement of a blood glucose >13 mmol/1 using commercially available blood
glucose testing strips (BM 1-44 glycaemie sticks, Boehringer, UK).
After death whole livers were removed immediately by dissection and placed into
ice-cold 0.25M sucrose/5mM HEPES buffer, pH 7.4. Microsomes were prepared
from the livers immediately (see Microsomal preparation 2.5).
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2.3 CHEMICALS
Most reagents were of analytical grade or better, depending on availability. Several
reagents were especially used, either for their composition or purity, and these are
listed below.
The monosodium salt of glucose-6-phosphate, acrylamide, N'N'-BIS
methyleneacrylamide, unstained molecular mass markers for SDS-PAGE, Cocktail
T (scintillant) and Folin Ciocalteau's Reagent were from BDH Chemicals, Poole,
UK.
The monopotassium salt of glucose-6-phosphate, mannose-6-phosphate (disodium
salt), amiloride hydrochloride (3,5-diamino-6-chloro-N-(diaminomethylene)pyrazine
carboxamide), histone 2A, cacodylic acid (recrystallised from 95% ethanol after
Arion & Wallin 1973), streptozotocin (mixed isomers), prestained molecular mass
standards for SDS/polyacrylamide gel electrophoresis, 4-Chloro-l-naphthol and
Lymphoprep (ficoll + sodium diatrizoate, density 1.077) were all from Sigma
Chemicals, Poole, UK.
The protease inhibitor cocktail used to thaw the fast frozen gut mucosa specimens in
(see 2.5.1) was from Boehringer Mannheim Biochemica, Germany. Other protease
inhibitors were from Sigma Chemicals, UK. The nitrocellulose used for
immunoblotting and transport assays (0.45/zm pore size) was from Schleicher and
Schuell, Germany. Lubrol 12A-9 was from ICI Organics Division, Manchester,
UK. All Sepharose used to prepare affinity columns was from Pharmacia, Uppsala,
Sweden as were pre-poured Sephadex G-25 M columns.
[U-^C] Glucose-6-phosphate (monosodium salt), ^NaCl, biotin-linked anti-sheep
IgG and streptavidin linked horseradish peroxidase were all from Amersham
International, Amersham, UK.
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1-naphthol and UDPGA were a kind gift from Professor Brian Burchell,
Department of Biochemical Medicine, University of Dundee.
2.4. EQUIPMENT
Pipettes and glassware were standard laboratory items. MSD high speed centrifuges,
Kontron Ultracentrifuge and Eppendorf benchtop centrifuges were used. SDS-
PAGE was carried out using Hoeffer gel electrophoresis equipment. Dot blots and
transport assays were performed using Bio-Rad dot blot apparatus. Electrophoretic
transfer of proteins onto nitrocellulose from gels was carried out using an LKB
Multiphore II semi-dry blotting system. Scintillation counting was performed on
Packard 2200 CA C) and LKB (^^Na) machines. A Philips PU 8620
spectrophotometer containing an autocell and remote sampler was used for all
measures of absorbance.
Fast Pressurised Liquid Chromatography (FPLC) was carried out using a system
from Pharmacia, Uppsala, Sweden.
2.5 MICROSOMAL PREPARATION
Microsomes were isolated from all animal and human samples wherever possible for
study of the glucose-6-phosphatase system. With small tissue samples this was not
always possible, and these are stated in the relevant parts of the text: in these
instances studies were carried out on the 12,000 xg supernatant from the first
centrifugation step described below.
Stock solution: 0.25M sucrose/ 5mM HEPES (SH) pH 7.4
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Procedure Samples were homogenised fresh and unfrozen by hand or (for larger
samples such as whole rat livers) using a Griffin powered homogeniser in Jencons
teflon/glass homogenisers at 4°C in 9 parts (w/v) ice-cold SH pH 7.4. The
homogenate was centrifuged at 12,000 xg for 6 minutes at 4°C. The resulting
supernatant was then centrifuged at 105,000 xg for 1 hour at 4°C. The microsomal
pellet was resuspended in 1.0 ml per gram wet tissue weight SH pH 7.4 by hand in
a teflon/glass homogeniser. All samples were assayed fresh, any which were kept
were stored at -70°C and used within 3 months of preparation.
2.5.1 Intestinal mucosa samples
Strict conditions were imposed on these samples to prevent proteolysis by intestinal
enzyme systems. A different technique was used to handle the samples for
phosphatase activity measurement where it was necessary to preserve enzyme
activity from that used to handle the samples for immunoblotting where enzyme
activity is unnecessary.
Samples for determination of glucose-6-phosphatase and non-specific phosphatase
activity were placed immediately into ice-cold SH buffer containing the protease
inhibitor cocktail described in Table 2.1 above. The mucosal samples were
homogenised immediately by hand in a teflon/glass, ice-cold homogeniser. The
homogenate was made to a volume equal to 10 times the original wet weight and
centrifuged for 1 minute at 4,000 xg. The supernatant was assayed fresh for both
glucose-6-phosphatase and non-specific phosphatase activities as described
elsewhere (2.6.1 (a) & (e) and 4.1).
Samples of intestinal mucosa for immunoblotting and staining were frozen
immediately after taking in liquid nitrogen. The frozen samples were stored at -
70°C and all processed together. The samples were thawed in SH buffer pH 7.4
containing the protease inhibitor cocktail shown in Table 2.2 and homogenised by
hand to a final volume 10 times the wet weight of tissue.
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Table 2.2
Protease inhibitor cocktail used to thaw and homogenise intestinal mucosa samples.
These inhibitors form a commercially available kit (Boehringer-Mannheim, London,
UK).
Protease inhibitor Concentration Diluent











APMSF = (4-amidinophenyl)-methanesulphonyl fluoride
The homogenate was centrifuged for 1 minute at 4,000 xg and the supernatant
mixed immediately into a boiling mixture of 200/d sample buffer (see 2.9.2) and
100/u.l of mercaptoethanol. The whole was boiled for 10 minutes and then frozen at -
20°C before being separated by polyacrylamide gel electrophoresis.
2.5.2 Separation of neutrophil polymorphonuclear cells from blood. Boyum
1968 and Ferrante and Thong 1980.
Blood samples were collected as described above. The cell components were
separated from the blood immediately.
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Stock solutions: 5.7g/dl ficoll + 9g/dl sodium diatrizoate SG 1077
(Lymphoprep, Sigma Chemicals)
Hank's buffered saline pH 7.4 :
0.8% NaCl, 0.04% KC1, 0.005% NaH2P04
0.006% KH2P04, 0.01% MgS04.7H20
0.014% CaCl2, 0.1% glucose
0.01% MgCl2, 0.035% sodium bicarbonate
6% Dextran 70
1.8% sodium chloride
Protease inhibitors-several combinations were tried.
(See 4.2)
a) lmg/ml 1,10-phenanthroline+lmg/ml PMSF
b) 0.02% PMSF + 0.1mM pepstatin A
+ lOMm 1,10-phenanthroline-t-0.0 lmg/ml
Trypsin-chymotrypsin inhibitor
± 400KIU/ml aprotonin
c) 0.02% sodium azide + 2mM PMSF
Procedure The 10ml blood/anticoagulant was mixed with 5ml Dextran 70 by
inversion and then left at room temperature for 90 minutes to allow the red cells to
separate out under gravity. The leucocyte-rich top layer was pipetted off and layered
onto 5ml Lymphoprep in a conical plastic tube. After centrifuging at 200 xg at
room temperature the supernatant was discarded. 5ml distilled water was added to
lyse remaining red cells in the pellet followed by 5ml 1.8% sodium chloride 20
seconds later. This was respun at 100 xg for 5 minutes and the resulting pellet
washed in Hank's buffered saline containing protease inhibitors. After a final spin at
100 xg for 5 minutes the pellet, comprising neutrophil polymorphonuclear
lymphocytes, was resuspended in 0.5ml Hank's containing protease inhibitors. The
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number and composition of cells in the suspension was evaluated using a Coulter
T540 cell counter.
2.5.3 Disruption of neutrophils
Several methods were tried to disrupt the neutrophils (PMNs) which were isolated
as in 2.5.2 at the same time trying to prevent proteolysis of the organelles prior to
testing for the presence of glucose-6-phosphatase.
a) Detergent The separated cells were mixed with 0.01 % lubrol and frozen at -
70°C. The treated cells were thawed in Hank's + protease inhibitors before being
dropped into boiling sample buffer and mercaptoethanol (2.9.2).
b) Freeze-thawing Aliquots of isolated PMNs were frozen at -70 °C ± protease
inhibitors and thawed at 30°C before use
c) Homogenisation Aliquots of separated cells were homogenised with a
mechanical homogeniser.
The effects of these treatments is described in Chapter 4.2
2.6 ASSAYS
2.6.1 Colourimetric assays
The assays of glucose-6-phosphatase, mannose-6-phosphatase and pyrophosphatase
activity were performed after the methods described by Burchell et al 1988a with
the addition of histone 2A as described by Blair and Burchell 1988. All three assays
depend upon measuring the amount of inorganic phosphate (P^) produced by
incubating microsomes with appropriate substrates (modified from Ames 1966). The
Pj released during the incubation reacts with the stopping reagent to produce a blue
reduced phosphomolybdate complex the absorbance of which measured at 820 nm is
directly proportional to the concentration of Pj (/xmol/1) in the solution.
34
In all the above assays 0.1 M HEPES was used in place of cacodylate (as originally
used by Burchell et al 1988a) as the buffer, and substrate concentrations were as
indicated below.
Stock solutions: 0.3M glucose-6-phosphate (G6P) pH 6.5
12.5mM mannose-6-phosphate(M6P) pH 6.5
0.3M sodium pyrophosphate (PP) pH 6.0
0.1M HEPES pH 6.5




a) Glucose-6-phosphate substrates: all contained 2 ml stock HEPES pH 6.5 and
0.25 ml stock EDTA pH 6.5.







b) Mannose-6-phosphate substrates: all contained 1ml mannose-6-phosphate
(M6P), 2ml HEPES pH 6.5 and 0.25ml EDTA pH 6.5.
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c) Pyrophosphate substrates: all contained 2ml stock HEPES pH 6.0 and 0.25ml
stock EDTA pH 6.0







Substrates with the same G6P, M6P and PP concentrations were made containing 1
ml stock histone 2A, and correspondingly, 1ml less water.
All substrates were stored at -20°C and when thawed were kept on ice. Substrates
were discarded if the blank replicate in the assay showed increased absorbance at
820nm as this implied non-enzymatic degradation of the glucose-6-phosphate
substrate.
Stopping reagent: 6 parts 0.42% ammonium molybdate in
0.5N H2S04
2 parts 10% sodium dodecyl sulphate
1 part 10% ascorbic acid (made fresh
daily)
Procedure The basic assay was identical for all three substrates. 80/xl substrate at
each concentration was incubated in triplicate (two active and one blank). 20pi of
sample (diluted to approximately 2 mg/ml protein in 0.25M sucrose/ 5mM HEPES
pH 7.4) was added to the two 'active' tubes and incubated for exactly 10 minutes.
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900/xl of stopping reagent was then added to all tubes. 20|ul of diluted sample was
then added to the 'blank ' tubes. All tubes were then incubated to allow colour
production before absorbance at 820 nm (ODg2o) was measured. The mean of the
two replicates was taken and the blank value at the relevant substrate concentration
subtracted from this mean to calculate the kinetic constants.
Glucose-6-phosphatase and mannose-6-phosphatase assays were performed at 30 °C
and the colour production at 46°C for 20 minutes (the conditions which allow
maximum colour production).
Pyrophosphatase assays were performed at 30°C and the colour production at 30°C
for exactly 10 minutes (at 46°C pyrophosphate is acid labile and this significantly
increases the ODg20 blank values). These conditions allowed half-maximal colour
development but this was offset by the fact that two Pj molecules were produced,
but did mean that a new standard curve had to be performed with each assay to
allow for small variations in time or temperature.
After calculation of specific activity (see "d) Phosphate standard curve" below)
kinetic constants for glucose-6-phosphatase and pyrophosphatase activity in both
intact and disrupted microsomes were calculated from slopes and intercepts of
Lineweaver-Burk plots using a BBC computer programme of non-linear regression
analysis based upon Colquhon 1971.
From the mannose-6-phosphatase activity it is possible to calculate the "intactness"
of a microsomal preparation using the equation:
s.a.(+h) - s.a(-h)
Intactness = x 100
(%) s.a.(+h)
Where s.a. is specific activity and h is histone 2A.
(For explanation of intactness please see Chapter 1).
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d) Phosphate standard curve
In order to convert ODg20 readings into specific phosphatase activity a factor based
upon a phosphate standard curve had to be derived.
Stock solution: l.OmM soluble phosphate (eg NaH2P04)
Stopping reagent: See above.
Procedure Volumes of stock phosphate (1-100/u.l) were made up to 100/xl with water
in triplicate. 900/d stopping reagent was added at 10 second intervals and incubated
at 30°C for 10 minutes. The standards for glucose-6-phosphatase activity were then
incubated at 42°C for 20 minutes and those for pyrophosphatase at 30°C for 10
minutes before the ODg20 was measured. The standard curve plot was ODg20
against volume (/il) of stock phosphate added. The correction factor was calculated
as follows:
Factor"^ = (^mol of phosphate to give ODg20 = 1.0) x 5
For glucose-6-phosphatase the factor was approximately 4.8; for pyrophosphatase it
was 2.3 - the difference between the two reflecting the fact that the pyrophosphatase
reaction only took the colour reaction to approximately half completion.
Once the factor had been determined the specific activity (in ^mol Pj
produced/minute/mg microsomal protein added) of the components of the enzyme
system could be calculated from the equation:
(mean ODg20 - blank) x Dilution of sample
Specific activity =
Factor x protein concentration in assay
e) Non-specific phosphatase activity: Burchell and Burchell 1980.
The measurement of non-specific phosphatase activity in samples is vital to the
correct assessment of glucose-6-phosphatase, pyrophosphatase and mannose-6-
phosphatase activity. The method used relies on the fact that the hydrolytic
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component of the glucose-6-phosphatase system is inactivated by incubation at pH 5
and 37°C.
The assay method was exactly as described for glucose-6-phosphatase above,
however the samples were preincubated with 2.5% sodium acetate pH 5 (1 part
sodium acetate, 20 parts sample) and incubated at 37°C for 15 minutes. 400 times
the sample volume of 0.1 M HEPES pH 6.5 was then added and the treated sample
assayed as described above. The calculation of non-specific phosphatase activity was
also as described above, the correction factor being calculated in the same fashion
(Factor = 2 approximately).
In all rat liver microsomal preparations the proportion of non-specific phosphatase
activity was <3% of the total phosphatase activity and is not commented upon
again.
J) Protein concentrations: Peterson 1977
Stock solutions: 0.8N sodium hydroxide (NaOH)
10% sodium dodecylsulphate (SDS)
20% sodium carbonate, 0.1% copper
sulphate & 0.2% potassium tartrate
Folin-Ciocalteau's phenol reagent
Working solutions: 0.15% deoxycholic acid (DOC)
72% trichloroacetic acid (TCA)
0.1% bovine serum albumin (BSA)
Reagent A: equal parts of copper-
tartrate-carbonate, NaOH, SDS
and water (made fresh daily)
Reagent B: 1 part Folin-Ciocalteau and
four parts water (made fresh
daily)
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Procedure The sample (approximately 20/ig protein) was diluted to 1ml with water.
Each sample was assayed in duplicate and a blank was performed with each assay.
0.1ml DOC was added and the tubes incubated at room temperature for 10 minutes
before 0.1ml TCA was added. The samples were centrifuged at 3,000 xg for 10
minutes and the supernatant discarded. Each pellet was mixed into 0.4 ml reagent A
and 0.4 ml water. After standing for 10 minutes at room temperature 0.2 ml reagent
B was added. The OD 750nm was read after a further 30 minutes at room
temperature.
A standard curve was prepared using BSA (5-50^1 of the stock solution) each time
an assay was performed to allow for slight differences in solutions and reagents.
Standard curves were linear to a concentration of approximately 60^g BSA. The
OD 750nm for the sample assays were averaged and the blank subtracted before the
protein concentration in mg/ml was read from the standard curve.
g) Protein estimation: Bradford 1976
This rapid method was used to detect the presence of protein in fractions collected
from affinity columns. It was not used to quantify protein concentrations.
Stock solution: Brilliant blue G in 125ml methanol
4- 158ml orthophosphoric acid
made up to 500ml with water.
Procedure Equal volumes (50-100/il) of Bradford reagent and sample were mixed in
a clear plastic test-tube. If the sample turned blue instantly then this indicated the
presence of protein in the sample. All buffers were also tested to ensure they did not
give a false-positive reaction.
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h) Glycogen concentration: van Handel 1965
Working solutions: 95% ethanol
Anthrone/H2S04 -(150mg anthrone +
38ml conc.H2SC>4 + 15ml water)
0.04% glucose standard.
Procedure 25yu.l sample (approximately 20mg/ml protein) was mixed with 25/d
water and 60/xl ethanol along with a blank (50/d water and no sample) and then
centrifuged at 3,000 xg for 8 minutes. The pellet was mixed into 50/d water and
60/d ethanol and re-centrifuged at 3,000 xg for 8 minutes. The pellet was suspended
in 200/d of water and assayed immediately. 10/0 of this solution was diluted with
40/il water in triplicate in glass tubes and mixed well with 950/cl of ice cold
anthrone/H2SC>4 before being incubated at 90°C for 20 minutes. The OD 620nm
was then measured.
A standard curve was prepared using volumes of glucose standard (0-50/d,
equivalent to 0-20/ig glucose) diluted to 50/0 with water before the ethanol
extraction step described above. The glucose content of the sample was then read
off the standard curve using the mean of the three OD 620nm measurements and the
glycogen content of the sample calculated from the following equation:




a) Microsomal glucose-6-phosphate transport: Waddell & Burchell 1987a
At first I used the assay described by Waddell and Burchell, but soon modified this
to the method described here which was more flexible and, in my hands, more
reproducible.
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Incubation buffer: 40mM cacodylate pH 6.5
ImM sodium glucose-6-phosphate pH 6.5
5^Ci/ml [U^C] glucose-6-phosphate
Procedure Microsomal protein was diluted 100 times in 40mM cacodylate pH 6.5
and 900^1 was added to 1.35ml of the incubation mix in a test tube at room
temperature, to result in the final concentrations shown above. At the addition of
the protein to the incubation mix the clock was started. At the required times (from
15 seconds to 5 minutes) 250iA of the reaction mixture was pipetted into a different
well of a Bio-Rad dot blot and sucked rapidly (within 6 seconds) through a sheet of
nitrocellulose which had been well wetted with 40mM cacodylate pH 6.5. At the
end of the assay the nitrocellulose was dried under an infra-red lamp and then cut
into 0.5 x 0.5 cm squares with the (visible) microsomal protein at the centre. Each
square was counted in sequence thus allowing the time points to be identified. All
assays were performed in triplicate.
A blank assay was performed using microsomes which had been disrupted by pre¬
incubation with lubrol (5 parts microsomal protein : 4 parts 40mM cacodylate pH
6.5 : 1 part 2% lubrol mixed and incubated on ice for 30 minutes). All microsomes
treated with lubrol were assayed with low Km mannose-6-phosphate to confirm the
lack of integrity of the microsomal membrane.
250/xl of incubation mix containing no microsomal protein was also passed through
the nitrocellulose filter - the level of this buffer blank was always < 2 % of the
minimum value in the reaction mix, and was therefore ignored.
The squares of nitrocellulose were placed into vials with 4.5ml scintillant (Cocktail
T) and the trapped on the filter was counted (for 10 minutes and averaged). As
well as squares of nitrocellulose, 25^1 of incubation mix + microsomes was also
counted - the value obtained was multiplied by 10 to give a value for "total counts".
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The capacity for microsomal glucose-6-phosphate transport was calculated from the
formula:
Retained counts - Blank counts
Capacity for G6P transport = x F
(nmolesG6P/mg protein) Total counts
nmol G6P in incubation mix
Where F —
mg microsomal protein on each piece of filter
b) Microsomal sodium transport
Influx: The assay for glucose-6-phosphate transport was modified so that the
incubation mixtures contained 1/iCi/ml ^NaCl in place of the G6P. The assay
procedure was identical to that described for glucose-6-phosphate transport. The
pieces of nitrocellulose filter were counted on an LKB gamma counter.
99
Efflux: This assay required that NaCl be incorporated into microsomes and the
99efflux of the Na be followed. Previously prepared low metal ion microsomes (see
Chapter 5 for details) were centrifuged at 105,000 xg for 1 hour. The pellet was
resuspended in low-sodium SF1 pH 7.4 containing lOmM NaCl plus 12.5/nCi/ml
99NaCl and frozen at -70°C. The treated microsomes were thawed slowly on ice,
diluted in 9 parts low sodium cacodylate and added to an incubation mix containing
40mM low sodium cacodylate ± ImM potassium glucose-6-phosphate. At the
indicated time points (15 seconds - 10 minutes) 250/xl was pipetted into a well of the
dot blot apparatus and sucked through a presoaked nitrocellulose filter which was
then processed as already described.
c) 1-Naphtliol assay: Otani et al 1976
This assay was used as an alternative method of measuring microsomal membrane
integrity (Burchell & Coughtrie 1989). The assay measures the rate of
glucuronidation of 1-naphthol with its co-substrate UDPGA. The enzymatic
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glucuronidation of 1-naphthol is carried out in the lumen of the endoplasmic
reticulum, and is, therefore only expressed in disrupted microsomes.
Stock solutions: lOOmM Tris/maleate 5mM MgCl2 pH 7.4
5mM 1-naphthol dissolved in 3% DMSO
4pCi/ml 1-[1- Cjnaphthol, dissolved in methanol
20mM UDPGA dissolved in AIK (Alkaline Isotonic
KC1 - 154mM KC1,brought to pH 7.4 with solid
KHC03)
600mM TCA/400mM glycine, pH 2.2 with solid
NaOH
Procedure 30^1 of protein (50-150/xg) was mixed with lOpl lubrol and incubated on
ice for 30 minutes. 90pl Tris/maleate buffer, 20^il 1-naphthol, 10^1 1-[1-
^Cjnaphthol were added and preincubated at 30°C for 2 minutes before the
reaction was started by the addition of 40/xl UDPGA. Each assay was performed in
duplicate and with a blank in which AIK was substituted for UDPGA. After exactly
10 minutes at 30°C the reaction was stopped by the addition of 200pl ice-cold
TCA/glycine. Unconjugated 1-naphthol was extracted into chloroform (3ml) by
mixing for 4 minutes and then centrifugation for 4 minutes at 2,000 xg. 200pl of
the aqueous phase was added to 2.5ml Cocktail T (scintillant). The 1-[1-
^Cjnaphthyl glucuronide was counted for 1 minute. An aliquot of the incubation
mix was also counted to provide "total counts".





Specific activity 1-naphtol GT =
(nmol 1-napthol/min/mg protein) Incubation time(mins) x protein (mg)
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2.7 PROTEIN PURIFICATION
Affinity chromatography was the method used to attempt the purification of the rat
hepatic microsomal glucose-6-phosphate transport protein. In affinity
chromatography a ligand which is known to bind with the protein being sought is
linked covalently to a matrix - in all cases Sepharose (Pharmacia, Sweden) was
used. Once the ligand has bound, any sites on the matrix which have not bound
ligand have to be inactivated (by washing at high/low pH) or blocked (using
ethanolamine) to reduce non-specific protein binding to the matrix. The prepared
column then has to be protected from chemical and microbial attack (the
antimicrobial sodium azide was loaded onto the columns which were kept at 4°C)
and from light-induced damage.
A membrane-bound protein (such as the microsomal glucose-6-phosphate
transporter) has to be, as far as possible, separated from its membrane, while at the
same time trying to maintain enough of the structural integrity of the protein to
allow it to be recognised by the ligand. This process here has been called
solubilisation. The solubilised protein is run onto the column and left to incubate for
sufficient time to allow binding of ligand and protein. Excess/unwanted protein is
then washed of with buffer before an eluent is run through the column. An eluent is
usually a compound which has more affinity for the isolated protein than the ligand,
or which can break the bonding between ligand and protein.
Fractions from the column are collected (from when the eluent was first loaded onto
the column) and stored.
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Stock solutions Tris-buffered saline (TBS):10mM Tris/HCl
pH 7.4, 0.9% saline
TBS + 0.002% sodium azide
0.1M sodium bicarbonate pH 8.3
0.1M sodium acetate pH 4
1M ethanolamine pH 9
2% lubrol 12A-9
2.7.1 Glucose-6-phosphate.
The binding of the physiological ligand glucose-6-phosphate to the transport protein
is unlikely to be strong enough to make affinity chromatography possible, but was
tried in case the binding was stronger than expected.
Preparation of the column. Epoxysepharose 6B was swollen in a large excess of
water at 46°C before being incubated and shaken constantly at room temperature
overnight with 40mM glucose-6-phosphate pH 8.3.
The Sepharose was washed on sintered glass with a large excess of water, 0.1M
sodium bicarbonate pH 8 and 0.1M sodium acetate pH 4 in rotation, each wash
being used twice. The Sepharose was then incubated with 1M ethanolamine at 46°C
for 4 hours before being washed with water and loaded into the barrel of a 5ml
syringe (with glass wool in the tip).
The completed column (approximately 3ml) was washed through with 20ml Tris-
buffered-saline (TBS) and stored at 4°C in the dark in TBS containing 0.002%
sodium azide.
Solubilisation ofmicrosomes. 5ml of microsomes prepared from the livers of
streptozotocin-induced diabetic rats were mixed with 0.5ml agarose Concanavalin A
at 4°C for 10 minutes and then centrifuged at 2,500 xg for 10 minutes. The pellet
(remnant cell membrane) was discarded and the supernatant mixed with 0.5%
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Triton X in the ratio 8 Triton X : 5 supernatant (v/v). This mixture was centrifuged
at 105,000 xg for 1 hour at -4°C and the resulting pellet resuspended in 8% Triton
X to a final volume of 5ml using a hand-held glass homogeniser. This homogenate
was frozen and stored overnight at -70°C; the next day it was thawed and
centrifuged at 105,000 xg for 1 hour at 4°C. The supernatant was aliquoted and
kept at -70°C.
An alternative method for pretreating microsomes was also used - microsomes from
livers of streptozotocin-induced diabetic rats were mixed with SH pH 7.4 and 2%
lubrol 12A-9 (ratio v/v 5:4:1 respectively) and incubated on ice for 1 hour before
diluting in 19 parts SH pH 7.4 to load onto the column.
2.7.2 Phlorizin
Phlorizin has been shown to be an inhibitor of microsomal glucose-6-phosphate
transport (Arion et al 1980, Waddell & Burchell 1987a). Although the mechanism
of phlorizin binding to T1 is unknown, much is known of its binding to other
proteins. However it seemed suitable as a ligand to attempt to isolate the glucose-6-
phosphate transport protein.
Preparation of the column. l.Og Epoxysepharose 6B was swollen in distilled water
at 46°C and then washed on scintered glass with a large excess of water. lOOmg
phlorizin was dissolved in 1ml dimethylformamide - the solution was blue, but
turned yellow when the pH was adjusted to the working pH (approximately pH 8) -
3 drops of 10M sodium hydroxide were required. The solution was made to 10ml
with 1M sodium chloride in 0.1M sodium bicarbonate pH 8.3.
The swollen, washed Sepharose was incubated at room temperature overnight being
continuously shaken. Next morning the solution was brown. The Sepharose was
washed with a large excess of, in rotation twice, water containing 10%
dimethylformamide, water, 0.1M sodium bicarbonate pH 8.3 and 0.1M sodium
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acetate pH 4 then incubated with 1M ethanolamine at 40 °C overnight- again being
shaken continuously.
The Sepharose was washed with large excesses of water, sodium bicarbonate pH 8.3
and sodium acetate pH 4 in rotation, each one twice, and loaded into the barrel of a
5ml syringe with glass wool in the tip, washed with 50ml TBS and stored at 4°C in
the dark loaded with TBS containing 0.002% sodium azide. The final volume of
column was approximately 3ml.
2.7.3 4,4'-Diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS)
DIDS is a reversible inhibitor of microsomal glucose-6-phosphate transport (Zoccoli
& Karnovsky 1980 and Arion et al 1980b) and was therefore an obvious choice to
try and isolate the microsomal glucose-6-phosphate transport protein.
Preparation of the column. Epoxysepharose 6B was swollen in water at 46 °C before
being washed on scintered glass with a large excess of fresh water. The Sepharose
was then incubated with 5mg/ml DIDS at 40°C overnight while being continuously
shaken (the sepharose turned pale yellow), washed with excess water and incubated
over the next night with 1M ethanolamine at 42°C. After another wash with excess
water the sepharose was loaded into a 5ml syringe with a small glass wool plug in,
or into an XK 16/20 column for use on a fast, pressurised liquid chromatography
(FPLC) system. The columns were then washed with TBS (volume lOx that of the
column) before being stored at 4°C in the dark (DIDS is light-sensitive) containing
TBS and 0.002% sodium azide.
Running the columns. All the columns described above were run in the same way.
The column was brought to room temperature and washed with 50ml TBS + 0.2%
lubrol before detergent-treated microsomes from streptozotocin-induced diabetic rats
(see above), diluted in 19 parts TBS, were loaded. The column + microsomes were
incubated at room temperature for 1 hour and then washed with 20ml TBS + 0.2%
48
lubrol. The bound protein was eluted with 6ml 1M sodium chloride pH 9 and the
column then washed with 50ml TBS + 0.2% lubrol. 0.25ml fractions were
collected, tested for the presence of protein with the Bradford reagent and then
stored at -20°C.
The DIDS/sepharose column for the FPLC system was run under exactly the same
conditions, except all the washes were automatic, the column was much larger
(volume 20ml compared to 3ml) so the amount of protein loaded was greater, and
the presence of protein in the fractions was shown by a peak of infra-red absorption
on a chart recording.
2.7.4. Anti-Tl antibody
Once a protein (the putative glucose-6-phosphate transport protein) had been
isolated from the DIDS/Sepharose column and an antibody raised to it in a sheep
(see below) one step in trying to characterise the protein using the antibody was to
use the latter to try and isolate more of the former by affinity chromatography.
Preparation of the column. CNBr-activated Sepharose 4B was washed and swollen
in 1M hydrochloric acid (200ml/g Sepharose). One part anti-Tl IgG from
ammonium sulphate treated serum was diluted in 2 parts 0.1M sodium bicarbonate
pH 8.3 containing 0.5M sodium chloride and incubated with the CNBr-Sepharose
overnight on a rotary mixer at 4°C. The Sepharose was then washed with excess
sodium bicarbonate pH 8.3 containing 0.5M sodium chloride and then incubated at
4°C for 16 hours with 1M ethanolamine pH 9. Three washing cycles were then
performed, each cycle comprised 0.1M sodium acetate pH 4 and 0.1M Tris pH 8,
both containing 0.5M sodium chloride. The Sepharose was then loaded into the
barrel of a 5ml syringe, the tip of which contained a small glass wool plug.
The column was stored in the dark at 4°C having been washed with TBS and
0.002% sodium azide.
49
Solubilization ofmicrosomes. Microsomes prepared from the livers of
streptozotocin-induced diabetic rats were treated as described above. After
incubation on ice the microsomal mixture was diluted to 30x its original volume
with TBS and the whole volume run through a Sephadex G-25M column
(Pharmacia, Sweden). The early fractions from this column contained little lubrol
(it runs slower through Sephadex G-25M than protein) and were loaded onto the
anti-Tl antibody column.
Running the column. The antibody column was brought to room temperature and
washed with 30ml TBS before the microsomal preparation was loaded on and
incubated at room temperature for 1 hour. 20ml TBS was then washed through the
column followed by elution with fresh 0.1M glycine pH 3. 1ml fractions were
collected. The Bradford reagent was of no use as glycine alone turned it blue. The
fractions were stored at -20°C. The column was washed with 50ml TBS before
storage at 4°C.
All columns were used on several occasions. Between uses they had TBS containing
0.002% sodium azide (apart from the anti-Tl column which had TBS alone on it)
loaded onto them and were stored in the dark at 4°C.
The fractions collected from all columns were stored at -20°C before being
separated by SDS-polyacrylamide gel electrophoresis (see below). The samples
from the DIDS column which were injected into the sheep to produce antibody were
concentrated and pooled 4 times using a Speedivac vacuum system. By this method
injections of approximately 3mg protein/ml were given to the sheep.
2.8 PREPARATION OF ANTI-T1 IcrG
A Cheviot sheep was injected 3 times with a total of approximately lOOmg of
protein, molecular weight about 66 kDaltons which was isolated by affinity for
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DIDS/Sepharose. A month after the final injection a test sample of serum was taken
from the sheep and was shown to cross-react with a protein of rat hepatic
microsomes by immunostaining (see below). A 200ml sample of serum was then
prepared from the sheep.
IgG was purified by ammonium sulphate fractionation (Fahey & Terry 1978
modified by Burchell and Cain 1985).
Procedure Equal volumes of serum and 90% saturated ammonium sulphate were
mixed on ice for 15 mins. The mixture was then centrifuged at 5,000 xg for 20
minutes and the pellet resuspended in the minimum possible volume of TBS.
(Typical final volume was 190ml from 200ml serum). The resuspended pellet was
then dialysed against TBS at 4°C overnight with several changes of dialysate. The
resulting semi-purified antibody was aliquoted and stored at -20°C until required.
For immunostaining of nitrocellulose-bound proteins a dilution of the anti-Tl IgG
of 1:250 was used.
2.9. SDS POLYACRYLAMIDE GEL ELECTROPHORESIS
2.9.1. Preparation of gels.
The method of Laemmli 1970 was used to run 7-16% or 7-20% gradient or 10%
polyacrylamide gels. The gels were poured between vertical glass plates and
electrophoresis was carried out using a Hoeffer gel electrophoresis tank with a Bio-
Rad power pack.
Stock solutions : A: 29.2% acrylamide +
0.8% N'N'BIS methylene
acrylamide
B: 18.15% TRIS base pH 8.8
C: 3.0% TRIS base pH 6.8
51
D: 1.5% ammonium persulphate
(fresh daily)
E: 2% sodium dodecyl sulphate
F: N,N,N',N'-Tetramethylethyl-
-enediamine (TEMED)
Electrode buffer: 3.0g TRIS base
14.9g glycine
lg sodium dodecylsulphate
Made up to 1 litre.
Gels were prepared according to the following recipe:
% Acrylamide 7 10 16 20 4(stack)
Water (ml) 7.7 6.26 3.38 1.45 10
A (ml) 3.38 4.81 7.7 9.65 2.0
B (ml) 1.8 1.8 1.8 1.8 —
C (ml) — — — — 5.0
D (ml) 0.25 0.25 0.25 0.25 2.0
E (ml) 0.86 0.86 0.86 0.86 0.86
E(/xl) 5.0 5.0 5.0 5.0 10.0
Gel solution preparation and pouring of gels was carried out in accordance with the
precautions in the Bio-Rad Technical Bulletin No. 1156 (1984).
The solutions A - E were mixed in a beaker. The TEMED was added immediately
prior to adding the solutions to a gradient maker (LKB 110ml) for pouring of the
gradient gels. Non-gradient gels were poured from a pipette. The glass plates were
mounted vertically in a Hoeffer gel system. 0.5 cm of water was layered onto each
gel after pouring to prevent inhibition of polymerisation by atmospheric 02- The
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resolving gels were left to set at room temperature overnight before the stacking gel
was poured onto the top. The stacking gel was left 20 minutes at room temperature
to set. Once set the comb was removed and the wells were filled with electrode
buffer.
2.9.2 Preparation of samples
Protein samples for gel electrophoresis were homogenised, denatured and given a
negative charge by mixing them thoroughly with mercaptoethanol and sodium
dodecylsulphate contained in a solution of TRIS pH 6.8 and glycerol including the
dye bromophenol blue (Sample buffer). The mixture was then boiled for 10 minutes
before being loaded into the wells of the stacking gel using a gas-tight small volume
syringe.
10 - 150 fjLg of protein were loaded onto gels in volumes from 10 - 200pi. 20p\ of
both sample buffer and mercaptoethanol were used for all samples unless otherwise
stated in the text. Wells which did not contain protein samples were loaded with
sample buffer to prevent protein spreading from adjacent lanes.
Standard molecular weight markers were used - either unstained for gels to be
directly stained, or prestained for gels which were to be blotted. The unstained
molecular weight markers were treated as samples by mixing and boiling with
mercaptoethanol and sample buffer. The prestained molecular weight markers were
mixed with 8M urea, sample buffer and mercaptoethanol before boiling for 5
minutes. The markers were then aliquoted and stored at -20°C. Before use the
aliquot was boiled again for 10 minutes.
The contents of the unstained and prestained molecular weight standards are shown
in Table 2.3 (a+b) respectively.
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Table 2.3 (a) Unstained molecular weight markers
Protein Approx. molecular weight
Ovotransferrin 76-78,000





(b) Prestained molecular weight markers








2.9.3 Running of gels
Gels were run using a vertical Hoeffer gel tank, the electrode buffer in top and
bottom tanks was as described above. A Bio-Rad power pack was used to give a
constant current of 10mA per gel through the stack (about 45 minutes) and 30mA
per gel through the main gel. The current was switched off when the dye front was
l-2cm from the bottom of the gel. At all times the system was cooled by running
water and the bottom tank was stirred using a magnetic stirrer.
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2.10 STAINING AND BLOTTING OF GELS
2.10.1 Protein staining
a) Coomassie blue staining Gels were placed directly into a solution of 14% acetic
acid and 10% methanol containing sufficient Coomassie blue dye to make the
solution royal blue. The gel was left in the stain overnight and then put into
"destain" (14% acetic acid, 10% methanol). The non protein bound blue stain
leached out into the destain which needed changed frequently. Eventually the
protein bands appeared as blue against a clear background. This method of staining
will detect down to lOjug of protein.
b) Silver staining Oakley et al 1980 as modified by Morrissey 1981.
This method of staining gels is more sensitive and will detect lOng of protein. The
proteins show up as brown through to black bands depending upon the amount
present (darker band means more protein). The gel is washed several times in the
following sequence. The volumes of washes are 100ml unless otherwise stated. The
times are also minimum times - for all except the developing steps the longer the
time of the wash, the better. All solutions were made and used fresh.
Procedure:
1) 14% acetic acid +10% methanol for 1 hour
2) 10% glutaraldehyde for 30 minutes
3) Water: several large volume washes for a minimum 2 hours, best overnight
4) 5^g/ml dithiothreitol for 30 minutes
5) 0.1 % silver nitrate for 30 minutes
6) Water: 250ml for 30 minutes x2
7) Developer (3% sodium carbonate containing 50/d/ 100ml formaldehyde) - two
rapid washes in small volumes.
8) Developer until the desired staining is achieved.
9) 3% citric acid to stop the developing reaction.
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10) Store the gel in 0.03% sodium carbonate in the dark to prevent fading.
2.10.2 Blotting of proteins from gels onto nitrocellulose (Western blotting)
Towbin et al 1979 as modified by Burnette 1981 and Lin & Kasamatsu 1983.
Stock solution: Blotting buffer = 0.04M glycine,
0.05M Tris,1.3 mM sodium dodecyl
sulphate + 200ml 20% methanol
Made up to 1 litre
A sheet of nitrocellulose and 8 pieces of blotting paper were cut to be slightly larger
than the gel and soaked in blotting buffer for 30 minutes. The gel, nitrocellulose
and blotting paper were arranged as in Figure 2.1 (a). If two gels were blotted
simultaneously then the set up of the blotting apparatus was as in Figure 2.1 (b). No
more than 2 gels were blotted at the same time. Care was taken not to touch the gel
and nitrocellulose with skin or any other source of protein.
2.10.3 Immunostaining of blotted proteins.
The streptavidin-horseradish peroxidase system was used with 4-chloro-l naphthol
as substrate (Domin et al 1984). The principals of this method are shown
diagrammatically in Figure 2.2.
Stock solutions: 3 % bovine serum albumin in TBS
5 % skimmed milk solution (Marvel) in TBS
2% Tween 20 (polyoxyethylenesorbitan
monolaureate)
TBS ±2% Tween
Primary antibody - 1:1000 in TBS unless otherwise
stated. (Concentration varies with protein being
stained).
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Anti-IgG - Biotin-linked anti sheep IgG (as primary
antibodies raised in sheep). 1:300 in TBS.
Streptavidin - complexed with horseradish
peroxidase. 1:1000 in TBS.
TRIS/HC1 - 50mM TRIS to pH 7.6 with HC1
Substrate -100ml contains (made fresh):
40mg 4-chloro-l-naphthol in 10ml methanol,
90mM Tris/HCl, 100yu.l hydrogen peroxide
Procedure (all washes are 100ml at room temperature unless otherwise stated: times
given are all minimums):
(1) The blot was blocked with successive washes of 3% bovine serum albumin in
TBS (37°C, 30 minutes, usually overnight); 5% skimmed milk solution (37°C, 30
minutes) and 2% Tween. The purpose of the block is to bind protein to the
nitrocellulose so that the antibodies do not bind non-specifically to all of the
membrane.
(2) Wash with TBS +2% Tween x4 followed by TBS alone xl (10 minutes each).
(3) Incubate with primary antibody (1 hour).
(4) Wash with TBS +2% Tween x4 followed by TBS alone xl (10 minutes each).
(5) Incubate with anti-IgG (15 minutes).
(6) Wash with TBS +2% Tween x4 followed by TBS alone xl (10 minutes each).
(7) Incubate with Streptavidin (20 minutes)
(8) Wash with TBS +2% Tween xl followed by TBS alone xl (10 minutes each).
(9) Wash with Tris/HCl (6 minutes).
(10) Incubate with substrate solution (until desired staining produced).
(11) Wash with TRIS/HC1 x3 (10-20 minutes each).
(12) Nitrocellulose was then dried under an infra-red light source and stored in the













_ _ Dialysis membrane
ms SDS-Polyacrylamide gel
Figure 2.1
Diagrammatic representation of the semi-dry electrophoretic apparatus used to
transfer proteins from SDS-polyacrylamide gels to nitrocellulose. Figure (a) shows
the technique for transfer from one gel; the simultaneous transfer from 2 gels is
shown in (b).




Diagrammatic representation of the immunoblot developing technique employed
during the work in this thesis. At each step there is an amplification of the signal. 4-
Chloro-l-naphthol and hydrogen peroxide were the substrates for the horseradish
peroxidase.
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This method of immunostaining proteins on membranes was also used for proteins
which were directly blotted onto nitrocellulose.
All descriptions given above were the routine methods used. Any variation in assay
technique is described in the relevant place in the text.
At all times safety standards and guidelines were closely observed. Before handling
radioisotopes I attended a Radioisotopes User course organised by the Department
of Medical Physics, Ninewells Hospital and Medical School, Dundee.
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CHAPTER THREE
GLUCOSE-6-PHOSPHATASE ABNORMALITIES DIAGNOSED IN ADULTS
One of the major aims of my thesis was to try and link the increase in understanding
of the biochemistry of the glucose-6-phosphatase system over the last 10 years or so
with clinical problems in adults. The initial idea was to study diabetes mellitus, but
as I started my work data was just becoming available on the first adult patients
newly diagnosed as having underactivity of hepatic glucose-6-phosphatase and this
is where my work started.
Deficiencies in glucose-6-phosphatase activity - the Type 1 glycogen storage
diseases (GSDs) - have become increasingly well recognised since the first
description of a case in 1952 by Cori & Cori. The recognition of these
abnormalities has been made easier over the last few years by improved
understanding of the glucose-6-phosphatase system (Arion et al 1980b, Burchell et
al 1988b and Waddell et al 1988), improved microassays for components of this
system (Waddell et al 1987, Burchell et al 1988b and Blair & Burchell 1988) and
the production of antibodies to specific parts of the glucose-6-phosphatase system
(Countaway et al 1988 and Waddell et al 1988b).
Type 1 GSDs are usually recognised as diseases of infants, and less severely
affected children can survive to adulthood (see Moses 1990 and Burchell & Waddell
1991 for recent reviews). There are reports of Type 1 GSD cases being diagnosed in
adulthood (Stamm & Webb 1975 and Kuzuya et al 1983) but these are noteworthy.
In 1987 members of our group presented preliminary data on some of the cases
described here (Burchell et al 1987) and which I have included here as there are
further data to include on these individuals. During my period in Dr. Burchell's
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laboratory I was responsible for taking liver biopsies to increase the pool of normal
data to include samples from 60 livers from patients who did not have abnormal
carbohydrate metabolism. At the time of case l's terminal admission I was the
medical registrar responsible for his care and the first liver biopsy.
The laboratory assays on the biopsy samples taken from these patients were mostly
performed by a technician in Dr. Burchell's laboratory (Mrs. Lesley Gibb) who was
very experienced at performing these assays on small tissue samples, usually from
infants.
Using the new techniques outlined above and with local understanding of glucose-6-
phosphatase a total of 8 adult cases of type 1 GSD variants have been recognised in
Tayside (plus another 2 cases of partial phosphorylase kinase deficiency described in
Appendix C) - six of whom were variants of previously identified type 1 GSDs, and
two who showed unrecognised abnormalities of the hepatic glucose-6-phosphatase
system.
These cases have all been the subjects of papers in the medical literature, and copies
of the published papers can be found in Appendix A. Cases 1, 2, 3, 5 and 6 make
up the report by Burchell et al 1987, all the cases (plus the two in Appendix C) are
the subject of Pears et al 1992 (which also includes immunoblot analysis performed




Male, born 19.11.32, normal birth at term and breast fed. Mother had five other
pregnancies all producing live infants (no still births or miscarriages), one of which
died aged 12 months of 'pneumonia' and another died aged 18 months of 'gastritis'.
The other siblings were described as normal. The patient had always been
'backward' mentally, his parents said. There is no subsequent information regarding
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his schooling. He was a life-long bachelor who worked for Remploy (a firm who
give work-experience to retarded people) until 1971 from when he became
unemployed, largely it appears because of chronic ill-health (especially recurrent
arthritis).
In July 1940 at age 8 years he was admitted first to hospital dehydrated from
vomiting induced by an ear infection. At the time of his admission his parents said
that as an infant he had had recurrent spontaneous epistaxes and was regularly
constipated. While in hospital he became jaundiced and hepatomegaly was noted
(the liver edge was recorded at the umbilicus). The jaundice fluctuated (monitored
clinically and by urinalysis) and was associated with periodic delirium. At the onset
of jaundice, peripheral blood agranulocytosis was seen but subsequent blood films
during this illness were normal. He had been seen playing in open drains before the
illness. A diagnosis of leptospirosis was excluded by a normal lumbar puncture with
no direct evidence of leptospira in blood or urine and negative serum agglutination
tests. The final diagnosis given for the jaundice was 'subacute yellow atrophy'
although a liver biopsy was not performed.
In 1965 aged 33 years he was investigated for mild rectal bleeding thought to be due
to a small anal fissure. Hepatomegaly (described as 3-4 finger breadth) was again
noted. No bilirubin was detected in his serum, total serum protein and albumin were
measured as 83 and 50 g/1 respectively and serum protein electrophoresis is
described as being within normal limits. Detailed coagulation studies were
performed - Lee and White whole blood clotting times were 6, 6.5 and 6.5 minutes;
Duke bleeding time was 2.5 minutes; one-stage prothrombin time was 14 seconds
(control 15 seconds); thromboplastin generation test and peripheral blood films were
normal. The only abnormality was a slightly positive Hess test. He was clinically
hypogonadal - small testes, female distribution of body hair, poor beard growth (he
shaved three times a week) and was noted to be of short height (his adult height was
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5ft 3in, extended arm span 5ft 5in). Buccal smears were examined and showed no
sex chromatin.
That same year he developed chronic paronychia of the left great toe due to an
ingrowing nail which was excised. The infection and ingrowing nail recurred
requiring nail bed ablation.
In 1966 at age 34 years he was seen with a 6 week history of painful swelling of his
right elbow which had followed minor trauma. He also gave a two week history of
mildly painful swelling of his right foot. Clinical examination showed arthritis of
the right elbow and right first metatarsophalangeal joints. Routine serum urea,
electrolytes and liver biochemistry were normal. Blood film showed mild iron-
deficient picture - serum iron was low at 7.2 jumol/1. The erythrocyte sedimentation
rate in the first hour was 'elevated' (figures are not recorded). RA latex test was
initially strongly positive, but was negative two weeks later. Serum uric acid was
raised at 0.7 mmol/1 falling with colchicine therapy to 0.15 mmol/1. A glucose
tolerance test (as a test for malabsorption) was performed - Table 3.1. The arthritis
settled with rest and analgesia (regular paracetamol) and he was given oral iron
replacement therapy.
In 1967 he was seen by at a psychiatric out-patient clinic suffering from depression.
No drug therapy was given.
In 1970, aged 38 years, he had a further episode of polyarthritis affecting the
metatarsophalangeal joints of both great toes and the tarsal joints of the right foot.
There was no clinical or radiological evidence of rheumatoid disease. Hepatomegaly
almost to the umbilicus and small testes were again noted along with a left
hydrocoele. Other examination was unremarkable. ESR was raised at 83mm in the
first hour. Serum iron was again slightly low, but haemoglobin was 11.7g/dl and
the peripheral blood film was normal. Serum uric acid, on salicylate therapy, was
0.89 mmol/1. Other serum biochemistry including liver function tests (bilirubin
undetectable, total protein and albumin 75 and 43 g/1 respectively) were normal as
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was a bromsulphthalein test (levels at 4, 10, 25 & 45 minutes were 100, 48, 6.5 &
3% respectively). Antinuclear factor, antimitochondrial and antismooth muscle
antibodies were not detected in the serum. Radiology of the affected joints showed
soft tissue swelling only. Treatment with salicylates was not tolerated because of
vomiting (a barium meal at this time showed a little gastro-oesophageal reflux only
and no cause for the iron deficiency). The arthritis settled with rest and
phenylbutazone. Allopurinol was added once the acute phase was over, the
presumptive diagnosis being one of gout. The hydrocoele was aspirated and the
aspirate contained epithelial cells only.
In July 1971, aged 38 years, he collapsed unconscious after feeling light-headed, his
legs turn to jelly and noticing his vision blur. Physical examination at the time of
collapse was unhelpful in determining the cause and the lack of sweating is
particularly mentioned. His liver was noted to be one hand's breadth enlarged.
Blood glucose shortly after the collapse was 3.9mmol/l. He had painful swelling of
his left elbow and the hydrocoele had re-collected (further aspiration again revealed
epithelial cells only). He gave a history of further rectal bleeding for which no
cause could be found on sigmoidoscopy. He claimed to have recently lost a job due
to recurrent nose-bleeds. Further blood clotting studies were performed -
prothrombin time, kaolin cephalin clotting time, fibrinogen times with saline and
protamine, fibrinogen titres, factor VIII levels, bleeding and whole blood clotting
times were all normal. Bone marrow examination was normal. He gave a history of
episodic breathlessness on exercise (on occasion he could not climb a flight of
stairs) but no exertional chest pain, orthopnoea or PND. His chest was clear to
auscultation and chest X-ray and ECG were both normal. This symptom is not
mentioned again, nor were any further investigations performed.
A needle liver biopsy was taken in view of the hepatomegaly. Histology was
reported as showing marked swelling and widespread fatty change with collagen laid
down between hepatocytes and small foci of inflammation. Staining for proamyloid
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was negative and for glycogen was normal, although comment is specifically made
that the biopsy could represent a glycogen storage disorder and that the high fat
levels in the sample could make high glycogen stores appear normal. Overall,
however, it was thought that the biopsy was from a large nodule of a macrocirrhotic
liver.
A psoriatic-like dermatitis was noted over the extensor surfaces of the elbows and
on his hands. No clear history is recorded but a skin biopsy showed patchy peri¬
vascular infiltration with mononuclear cells and slight hydropic degeneration of the
basal cells of the epidermis. The condition appears to have resolved with
emulsifying ointment.
Some endocrine investigations were also performed: urinary excretion of 17-OHCS
and testosterone were low at 18.4mmol/ and 26.5nmol/l respectively. Urine
excretion of HCG was normal at < 1.6 U/24 hours. Serum Cortisol was 441.6
mmol/1 at 0800 and 184.9mmol/l at 2200 and a short synacthen test was normal
(baseline 463.7mmol/l to peak 1162.0 mmol/1). No cause for the collapse was
found and he was discharged.
In 1976 aged 44 years he was readmitted with recurrent blackouts. History and
examination were unhelpful and investigations showed a normal random blood
glucose (3.9mmol/l). No cause for the blackouts was found.
He was followed in out-patients until 1984, during which time he had several
episodes of polyarthritis affecting mainly his elbows, knees and first
metatarsophalangeal joints associated with marginally raised serum uric acid levels
and an ESR of between 20 and 40mm in the first hour. On only one occasion was
synovial fluid examined for crystals and it was negative. In 1984 (aged 52 years)
the serum gamma glutamyl transferase level was found to be elevated at 55 U/l
(upper limit normal = 42 U/l) with a slight increase in serum alkaline phosphatase
of 188 u/l (upper limit normal = 120 U/l). These abnormalities persisted.
In 1986 aged 53 years he was admitted to hospital with a six month history of cough
productive of white sputum and 3 months of increasing dyspnoea, initially on
exertion but latterly at rest. He described episodes of vomiting associated with right
upper quadrant abdominal pain. On examination he had air hunger, a tachycardia
and normal blood pressure but was pyrexial at 38°C. He had 8-finger breadth,
smooth, non-tender hepatomegaly and his chest was clear to auscultation. There was
no jaundice but he showed spider naevi, xanthelasmata and gouty tophi.
Initial blood glucose estimation on stick testing (BM 1-44 glycaemie stick,
Boehringer, Germany) was lmmol/1. The rest of his blood biochemistry at
presentation showed a metabolic acidosis with a degree of respiratory compensation
(an arterial sample showed pH 7.38, pCC>2 15.6mmHg, pC>2 45.1mmHg,
bicarbonate 9.3mmol/l, and base excess of-12.1). No salicylate or ethanol was
detected in his blood but blood lactate level was very high at 12.5mmol/l (normal
< 1.8mmol/l). ESR was 125mm in the first hour, haemoglobin was 10.5g/dl and
peripheral total white count was 11.9 x 10^/1. Blood film showed anisocytotic red
cells with some large polychromatic macrocytes and a neutrophil leucocytosis.
Prothrombin and kaolin cephalin clotting times were identical to controls. Blood
urea was 10. lmmol/1, creatinine 143jumol/l, bilirubin 27/*mol/l, serum alkaline
phosphatase 2124U/1 and aspartate aminotransferase 767IU. Culture of sputum,
urine and blood were initially and subsequently negative. Hepatitis B surface
antigen was not detected in serum. Chest and plain abdominal radiographs were
normal.
Treatment of the hypoglycaemia and dehydration was started with intravenous
dextrose and he subsequently required a continuous infusion of 1.5 litres of 10%
dextrose per day (2.5g dextrose/kg body weight/day) to maintain a blood glucose
level above 4mmol/l. 1.5 litres of 1.4% sodium bicarbonate was infused
intravenously per 24 hours for 48 hours by which time the acidosis had corrected.
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Broad spectrum antibiotic therapy was started and continued despite negative culture
results.
Thirty-six hours after admission, he developed oliguric renal failure (despite being
normotensive at all times) and gastrointestinal haemorrhage, requiring blood
transfusion. He continued to show air hunger despite correction of the metabolic
acidosis, and he became drowsy and pyrexial. The haemorrhage stopped and the
oliguria improved with infusion of low dose dopamine. Cerebral CT scan was
normal and lumbar puncture revealed crystal-clear CSF at an opening pressure of
130mm water, glucose 5.6mmol/l (blood glucose 6.7mmol/l) and protein
concentration 370mg/ml. Three white and 5 red blood cells per ml CSF were seen
and no organisms were seen or subsequently cultured.
Abdominal ultrasound suggested that the whole right lobe of the liver was taken
over by tumour and an echo-lucent area was seen in the left lobe. Serum
alphafetoprotein was undetectable. Needle liver biopsy of the right lobe showed
hepatocellular carcinoma (Table 3.2.a). Subsequent biopsies of liver less involved
with tumour were examined - Table 3.2b. The glucose-6-phosphatase analysis
suggested a diagnosis of type la glycogen storage disease.
Despite intensive supportive therapy, he died six days after admission.
At post-mortem, the liver filled most of the abdominal cavity and weighed 6.0kg -
10% of his body weight. A 140mm diameter tumour was visible in the right lobe
and the rest of the liver had a variegated appearance with numerous yellow nodules
scattered through the parenchyma. The liver histology is as in Table 3.2a and
Figures 3.1 & 3.2. The lungs were very congested and contained many tumour
emboli. The kidneys were enlarged and showed ischaemic damage with increased
glycogen in the cytoplasm and nuclei of the tubular cells. The brain, intestine and
pancreas were reported as normal. Skeletal muscle was macroscopically and




Case 1. H&E stain of section of liver biopsy, (a) x50 (b) x500.A nodule of
hepatocellular carcinoma is seen amongst liver parenchyma. Details of histology are
given in the P.M report (page 211).
Figure 3.2
Case 1. H & E stain of liver xl25 not involved with hepatocellular carcinoma
obtained at post mortem.
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Case 2
Female born 20.12.64. Presented in 1984 at the age of 19 with iron-deficiency
anaemia. Extensive investigations were normal (including biopsies of rectal and
duodenal mucosa and a small bowel barium meal) - the iron deficiency was
attributed to menstrual loss and responded well to three months of iron replacement
therapy and did not recur. She had mild post-exertional asthma requiring no regular
therapy, had a nasal currettage at age 12 years for persistent rhinitis and benign
familial tremor. The patient has one older sister who has had recurrent miscarriages.
The patient's mother's obstetric history is unremarkable and there is no family
history of neonatal deaths.
In 1986 at the age of 22, she presented with symptoms of loss of temper, light¬
headedness and hunger occurring between meals, especially if she ever missed a
meal which she was doing at this time as she had left home to become a student of
Town Planning. She had been born prematurely and her mother had had to feed her
frequently up to the age of 15 years, after which time the patient's symptoms had
worsened.
Examination apart from the tremor was unremarkable. There was no abdominal
organomegaly. An oral glucose tolerance test was normal (Table 3.1). All routine
serum biochemistry and haematology were normal. The prothrombin time was
slightly prolonged (14.5 seconds, control 13 seconds) as was the kaolin cephalin
clotting time (51 seconds, control 44 seconds). Fasting glucagon test showed a
blunted blood glucose response - Table 3.3.
Liver biopsy was performed - the liver was hard at the time of biopsy. The
histology of the liver is shown in Figure 3.3 and reported in Table 3.2a. Table 3.2b
shows the biochemical analysis showing the patient to have a partial type la
glycogen storage disorder. Her symptoms responded well to dietary advice.
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Figure 3.3
Case 2. H & E stain of a section of liver biopsy, x 660.




Female born 11.05.34. As a child she had diphtheria and chorea secondary to
scarlet fever. In 1955 when she was 21 years old she had her only pregnancy which
was uncomplicated and delivered a normal female infant at term. In 1965 at the age
of 31 she developed low back and knee pains. Orthopaedic examination and X-rays
were normal and the symptoms responded well to strengthening exercises. In 1980
at the age of 46 fibrocystic breast disease was diagnosed.
In 1986 aged 51 she presented with a two month history of 9kg weight loss. There
were no specific symptoms other than pain in the left medial epicondyle which was
relieved by a local steroid injection. She had smoked on average 15 cigarettes per
day for many years and took little alcohol at weekends only. Family history was
unremarkable.
Clinical examination was normal - in particular there was no hepatomegaly and she
was euthyroid. Glycosuria was not detected and random blood glucose was
4.4mmol/l. All other routine serum biochemical testing (including liver enzymes)
was normal. ESR was 7mm in the first hour; full blood count and film were
normal. Plain X-ray of the chest was normal. Upper abdominal ultrasound showed
no focal liver defects and normal liver and kidneys.
At the next outpatient visit she had gained 2kg in weight and she gave a history of
attacks of sudden tiredness occurring mid-afternoon which were worse if she was
very active. Her lunch usually comprised a cup of coffee. These attacks had been
occurring for many years and had worsened after the menopause. They were always
relieved within ten minutes by eating a bar of chocolate.
A short synacthen test was normal. After 48 hours fasting and exercise, blood
glucose was 3.1mmol/l and serum insulin < lOmU/ml. Fasting glucagon test was
performed and showed a blunted glucose response - Table 3.3.
Tests of in vitro blood clotting prior to liver biopsy showed prothrombin time equal
to control, but a kaolin cephalin clotting time prolonged at 62 seconds (control 45
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seconds). Further haematological investigation indicated a partial deficiency of
Factor XI as the cause of the prolonged kaolin cephalin clotting time. Despite the
lack of a clinical bleeding tendency, the liver biopsy was performed under cover of
infused fresh frozen plasma without difficulty.
The histology of the liver biopsy is shown in Figure 3.4 and in Table 3.2a.
Biochemical analysis (Table 3.2b) showed increased glycogen stores and diagnosis
of a partial type la glycogen storage disease.
During these investigations she developed post-menopausal bleeding. Cervical
smear was class 1 and subsequent cervical dilatation and uterine curettage were
normal.
She was given dietary advice and oral hormone replacement therapy and the attacks
lessened in severity and frequency. Seven months after diagnosis she defaulted from
follow-up.
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Figure 3.4
Case 3. H & E stain of sections of liver biopsy. xl25. Normal liver.
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Case 4
Female born 03.04.45. At the age of 25 in 1970 after a normal pregnancy a normal
female infant was delivered spontaneously at term. This was her only pregnancy. At
the age of 33 she had a course of radiotherapy for Stage Ilb/III cervical carcinoma.
Subsequent cervical smears up to 1989 were class 2 showing mild dyskaryosis only.
Her other medical history was unremarkable. Unfortunately the patient is a poor
historian with a dull affect and it was not possible to obtain detailed personal and
family history.
In 1984, aged 39, she had a bout of non-specific abdominal pain - upper
gastrointestinal endoscopy, barium follow-through and oral cholecystography were
all normal. Her history included weight gain and flushing episodes worsened by
exercise. Thyroid function was normal - total serum T4 (90 nmol/1) and TRH test
(baseline 2.7mU/l, peak 5.3mU/l at 20 minutes).
In 1987 (age 42) she was seen with attacks of sweating followed by syncope. No
temporal relationship to food was noted. An EEG was normal and no firm diagnosis
was made. Her general practitioner prescribed a course of anti-depressant and
sedative drugs.
In 1989 (age 44) she was seen with persisting, daily sweating attacks. The sweat
started on her face and spread to the scalp. The episodes lasted longer in warm
weather and were clearly induced by exercise. Occasionally the attacks progressed
to palpitations and even loss of consciousness. There had been no witnessed
convulsions. The episodes were not clearly terminated by ingestion of carbohydrate.
There was no diarrhoea or wheeze during the flushing/sweating episodes although
she was a heavy smoker and her chest was always a little wheezy.
Clinical examination showed her to be obese, have a dull affect and pigmentation of
the skin under the eyes and of the buccal mucosa. There was mild proximal muscle
weakness. A lmg overnight dexamethasone suppression test excluded Cushing's
syndrome (morning Cortisol 43nmol/). Two outpatient urine collections showed high
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excretion rates of 5HIAA (117 and 170/xmol per day - normal < 40/xmol/24 hours)
but were noted to be of small volume. Six subsequent (in-patient) collections
showed normal 24 hour urinary 5HIAA excretion. Thyroid function testing was
again normal. Short synacthen test showed baseline serum Cortisol 752nmol/l rising
to 1242nmol/l. Serum oestradiol (< 70pmol/l), LH (47 U/l) and FSH (>25 U/l)
confirmed that she was post-menopausal. Serum liver enzymes were mildly raised -
aspartate aminotransferase 87 U/l (normal < 30 U/l) and gamma glutamyl
transferase 77 U/l (normal < 40 U/l). Serum levels of alkaline phosphatase,
bilirubin and alpha alphafetoprotein were all normal. Full blood count was normal
except for an MCV of 102 fl (no macrocytes were seen on the blood film). In vitro
blood clotting studies were normal. Hepatitis B surface antigen, antinuclear factor,
antimitochondrial antibodies and RA latex factor were not detected in the serum.
An isotope liver scan showed a large liver with uniform uptake of isotope; upper
abdominal ultrasound examination confirmed the homogenous texture of the liver
parenchyma.
The fasting glucagon test showed a blunted glucose response (Table 3.3). Figures
3.5 and 3.6 and Tables 3.2a and 3.2b contain the results of the liver biopsy.
Biochemical analysis (of a small piece of liver) showed no glucose-6-phosphatase
activity and absent protein by immunoblotting suggesting type la glycogen storage
disease.




Case 4. H & E stain of sections of liver biopsy. xl25. There is an excess of fibrous
tissue extending from the portal tracts which disturbs the hepatic architecture.,
suggestive of micronodular cirrhosis (the specimen is too small to show any nodular
collections). Within the fibrous tissue and extending into the parenchyma there is a
moderate chronic active inflammatory infiltrate. No Mallory's hyaline is seen. The
features are of a moderately severe steatohepatitis with possible cirrhosis.
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Case 4. (a) and (b) Electron micrographs from liver biopsy.
(a) x3,200. Generalised fatty change (lipid droplets arrowed). Generalised increase
in glycogen (seen as black stippling) throughout hepatocytes.
(b) x32,000. Glycogen stores seen more clearly (black rosette pattern) and
mitochondrial paracystalline arrays are seen (arrowed).
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Case 5
Female born 03.03.35. In 1976 at the age of 41 years she was seen at another
hospital complaining of episodic weakness mainly after exercise which improved
within ten minutes of ingesting glucose tablets. Clinical examination was
unremarkable. After a 60 hour fast blood glucose was 2.4mmol/l (serum insulin was
not measured) and the patient was asymptomatic during the fast. A 75g oral glucose
tolerance test was performed (Table 3.1). An abnormality of hepatic glucose output
was considered and a fasting glucagon test was performed (Table 3.3); the absent
blood glucose response was not commented upon. Advice was given to cover
exercise with glucose and no further investigations performed.
In 1986 aged 51 years she presented first to this hospital giving a 20 year history of
episodic weakness, especially of the lower legs, associated with exercise and
associated with incoordination, light headedness and tremulousness. These episodes
were often, but not invariably associated with exercise and were always relieved
within ten minutes by ingestion of glucose tablets. The menarche is not known, but
her periods were always regular. She had had one pregnancy which produced a
normal female infant (who went on to become a medical practitioner). Her last
menstrual period had been in 1985 and her symptoms had worsened since then. She
owned a part share in a book shop which she helped run. Her only past history was
of a myomectomy at the age of 39 years. Physical examination was normal.
Fasting glucagon test was repeated (see Table 3.3) and this time a (subnormal) rise
in blood glucose was measured. A short synacthen test was normal (rise in serum
Cortisol 294nmol/l). Haematological, clotting and serum biochemical investigations
were normal. Fasting total cholesterol was 6.8mmol/l and triglycerides 0.91mmol/l.
Liver biopsy was performed and the biochemical analyses are shown in Tables 3.2a
and b. The biochemical analysis shows her to have a partial type la glycogen
storage disease. Photographs of histology and electron microscopy of the biopsy are
shown in Figures 3.7 and 3.8.
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Figure 3.7
Case 5. Section of liver from biopsy stained for glycogen. xl25. Excess of
glycogen uniformly distributed across all zones. (H & E showed some increased
lipofuscin in the perivenular hepatocytes, but was otherwise normal).
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Case 5. Electron micrographs of liver biopsy, (a) x2,600 and (b) x26,000. There is
an excess of glycogen with the organelles distributed uniformly (a). The sinusoidal
borders are normal as are the bile cannaliculi although these contain particulate
material. Some mitochondria are enlarged and contain paracrystalline arrays (not
shown). There is some dilatation of the rough and smooth endoplasmic reticulum.
The Golgi apparatus and nuclei show no significant abnormality. There are a few fat
droplets, some of which are incorporated in the residual bodies (b). The littoral cells
are within normal limits.
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Her symptoms improved with dietary advice.
Her mother and sister had similar symptoms; her sister subsequently had a normal
glucagon test; as her mother was over 80 years of age it was not felt appropriate to
investigate her.
Twelve months later she presented with flushing unrelated to exercise or meals.
This was successfully treated with hormone replacement therapy (Loestrin 20, later
changed to Prempak). A short time later, after a viral illness, she developed marked
tiredness of her lower limbs. There was no objective muscle weakness or clinical
neurological deficit. Electromyographical studies and muscle biopsy of affected
muscles were normal. Despite lack of serum viral antibodies, this illness was
attributed to post viral fatigue syndrome and the symptoms improved over the
subsequent three months.
More recently she has developed a thyroid nodule which has been aspirated and
shown to be cystic with benign histology. She has remained clinically and
biochemically euthyroid.
Case 6
Male born 05.05.33. In 1986 at the age of 53 he presented with polydipsia, polyuria
and nocturia, but no weight loss. He was a heavy smoker (40 cigarettes per day for
most of his adult life) and had drunk at least 30 units of alcohol per week until 1984
since when he stopped after his General Practitioner found mildly elevated serum
liver enzyme levels.
He worked as a labourer with the council Parks Department and was married with a
son born in 1964. On examination he was overweight (105.5kg, 1.79m tall),
hypertensive (186/100mm Hg, phase V) and had 2% glycosuria. He had palmar
erythema and several spider naevi. The liver was easily palpable, but not clinically
enlarged.
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Random blood glucose was 9.9mmol/l; an oral glucose tolerance test showed a
diabetic pattern (see Table 3.1). Random serum cholesterol was 5.93mmol/l. Serum
biochemistry was normal except for alkaline phosphatase 175 U/l (normal < 120
U/l). Haematology and blood film were normal. Hepatitis B surface antigen,
antinuclear factor, antimitochondrial and anti smooth muscle antibodies were not
detected in serum. Isotope liver scan showed a moderately enlarged liver with
uniform uptake. Chest X-ray was normal.
Liver biopsy was performed in view of the large liver. Only a very small piece of
tissue was received for biochemical analysis which showed normal disrupted
glucose-6-phosphatase activity but the activity in intact structures was too low to be
properly assessed (Table 3.2b). The glycogen content of the fragment was high. As
this abnormality was unexpected but potentially clinically important a wedge liver
biopsy was performed at laparotomy. The glucose-6-phosphatase analysis (Table
3.2b) and pyrophosphatase assay data (Table 3.2c) are characteristic of type lc
glycogen storage disease.
A fasting glucagon test was subsequently performed (Table 3.3) and was normal.
Follow-up random blood glucose levels at diabetic clinics were normal. At no time,
on a diabetic weight-reducing diet did he develop symptoms of hypoglycaemia.
The possibility of a Fanconi-type syndrome of proximal renal tubular damage was
considered if the renal tubular cell phosphate transporters were abnormal too.
However he had a normal renal phosphate threshold at 1.16mmol/l (normal 0.8 -
1.35mmol/l) with < 0. lg/1 proteinuria and no amino aciduria.
In 1989 he developed a painful lytic lesion in the left acromion process - biopsy
revealed anaplastic small cell carcinoma, probably metaplastic from a bronchogenic
primary. Chest X-ray showed slight mediastinal widening but bronchoscopy was
normal. Isotope bone scan revealed widespread bony metastases. Palliative
radiotherapy to the painful bony lesions and pulsed chemotherapy were started, but
he died in July 1989. Permission for post-mortem examination was not given.
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Case 7
Female born 24.04.69. Presented as a University student in 1989 at the age of 20
years with two or three episodes per day of blurring of vision, shakiness, illegible
handwriting and slurred speech. These episodes occurred usually before meals and
were relieved by eating. The symptoms had worsened since leaving home (and
eating less regularly) to come to University. Her general practitioner had given her
blood glucose testing sticks and with these she had demonstrated a blood glucose
less than 2mmol/l during one of these attacks. She had been vegetarian for 4 years,
did not smoke and took no alcohol. Her past medical history was unremarkable. She
had been born three weeks premature, but had developed normally. Her mother's
other obstetric history was unremarkable. There are no siblings. Her menses were
regular with a 21 day cycle. Later she complained of painful, heavy periods.
Clinical examination showed her to be overweight but was otherwise unremarkable.
During a 48 hour fast she often complained of symptoms of light headedness and
blurring of vision but at no time was her blood glucose less than 3.5mmol/l. She
was exercised at the end of 48 hours fasting and subsequent blood glucose was
3.2mmol/l, serum insulin 10mU/l. Blood glucose response to glucagon in the
fasting state was impaired (Table 3.3). Oral glucose tolerance test showed impaired
glucose tolerance (Table 3.1). Fasting lipids were normal (total cholesterol
5.38mmol/l, triglyceride 1.3mmol/l). Haematological testing (including in vitro
clotting studies) was normal.
The histology of the liver biopsy is shown in Figure 3.9.
The biochemical results of the liver biopsy are presented in Tables 3.2a,b and c.
The kinetic data indicate that all components of the glucose-6-phosphatase system
are present in the correct proportions, but the activity of each part and of the system
as a whole is low. The glucose-6-phosphatase data is very unusual and had never




Case 7. H & E stain of section of liver biopsy. xl25. Portal tracts expanded by
infiltrate of lymphocytes (some with a centrocytic appearance), PMNs and
eosinophils. In the sinusoids are some collections of lymphocytes arranged indian
file (arrowed).
Electron microscopy (blocks no longer available) shows some fatty droplets in
hepatocytes and lipid-containing residual bodies. Mitochondria contain
paracrystalline arrays. In some cells the organelles are pushed to the periphery (by
glycogen). Some bile cannaliculi contain particulate debris as does a bile duct.
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The liver histology was suggestive of a viral illness with lymphocytic infiltration but
there was no serological evidence of an acute viral illness - hepatitis A and B
serology were negative, but there was circulating IgG to the Epstein-Barr virus.
The patient always appeared very anxious, but eventually responded very well to
dietary manipulation.
At the age of 21 she presented with a 3 month history of colicky abdominal pain
and frequent looser-than-usual bowel motions. Examination and investigations
suggested a diagnosis of irritable bowel syndrome. These symptoms resolved
spontaneously some months later.
Case 8
Male born 1940. Led a very active working (farmer) and sporting life, playing
rugby and cricket into his thirties. He presented aged 42 years with symptoms
suggestive of reactive hypoglycaemia, worst between 1000 and 1030 h after an early
rise (0500 h) and heavy breakfast (0900 h). These symptoms were precipitated by
physical activity and were relieved by the ingestion of food. There was no past
history or family history of note. He did not smoke and alcohol consumption was
less than 1 unit per day. Physical examination was unremarkable.
A prolonged fast showed at 48 hours an insulin:glucose ratio of 0.12mU/mmol
(normal < 0.3mU/mmol). A prolonged 75 g oral glucose tolerance test (OGTT)
(Figure 3.10) produced symptomatic hypoglycaemia. A diagnosis of reactive
hypoglycaemia was made and dietary advice given.
At age 47 years, he was re-referred with worsening hypoglycaemic symptoms in the
same pattern as before. Other history and clinical examination were unremarkable.
OGTT demonstrated a large rise in total serum insulin (peak 720mU/l) with a small






Oral glucose tolerance test performed on case 8 then aged 42 years. (* -








Results of a series of oral glucose tolerance tests performed on case 8 now aged 47
years. Plate (a) shows the blood glucose levels and plate (b) the serum insulin
levels.
(i) At presentation, pretreatment; (ii) taking 900mg diazoxide per day; (iii) taking
lOOmg diazoxide x2 per day; (iv) taking 200mg diazoxide x2 per day; and (v) after
a single dose of octreotide lOO^g still taking 200mg diazoxide twice per day.
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An intravenous glucose tolerance test was performed. This produced severe,
profound hypoglycaemia after 90 minutes, following hyperinsulinaemia, and a
virtually absent glucagon counter-response (Table 3.5). Other counter-regulatory
hormone responses to hypoglycaemia were normal (including adrenaline and
noradrenaline, peak levels of both 3nmol/l at 120 mins). The test had to aborted to
revive the patient from his profound hypoglycaemia. He became drowsy and had to
be given small IV boluses of glucose and IV hydrocortisone and adrenaline until
such time as he was able to eat.
A short synacthen test was normal (baseline serum Cortisol 355nmol/l, peak
1000nmol/l).
A fasting glucagon test showed a blunted rise in blood glucose levels followed by
hypoglycaemia (Table 3.3). This test suggested abnormal hepatic glucose production
so a needle liver biopsy was performed after an overnight fast. Liver histology was
normal (except for lymphocytic infiltration of the liver initially taken to represent a
lymphoma - see Figure 3.12 and Discussion below) as was the measured glycogen
content of 27.2mg glycogen/g wet liver weight (normal <40mg/g). Hepatic
glucose-6-phosphatase kinetics were measured on a microsomal subfraction (Table
3.2b).
The high Km in intact microsomes, restored to normal by pre-incubating the
microsomes with lg/1 bovine serum albumin (BSA), implies that there is a
reversible inhibitor of T1 binding to the transport protein in this patient's liver
preparation. BSA is a non-specific binder of many ions and peptides and thus the
nature of this inhibitor is not clear. The activity of the catalytic subunit (as indicated
by the disrupted assays) was normal.
CT scan of the pancreas before and during rapid infusion of contrast medium did
not reveal any abnormality.
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Case 8. H & E stain of sections of liver biopsy, (a) xl25, (b) x660. (a) Sections
show extensive infiltration of the portal tracts by a mixed lymphocytic histiocytic
lymphoma. Portal tract magnified in plate (b) to show close up of infiltrate.
Sinusoids show some lymphocytes arranged indian file (arrowed).
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In view of the marked hyperinsulinaemic response to glucose, treatment with oral
diazoxide was commenced at 900mg/day. This gave good relief of hypoglycaemic
symptoms within 14 days.
Repeat OGTT performed after 14 days of 900mg/day diazoxide showed raised
fasting and peak plasma glucose levels but a reduced rise in serum insulin
concentration (peak 485mU/l) (Figure 3.1 lii).
The dose of diazoxide was reduced to 50 mg twice a day to alleviate the side effects
of fluid retention and hypertension and then gradually increased to 200 mg twice a
day with clinical improvement. OGTT was repeated 8 weeks after starting 400
mg/day diazoxide and although fasting and peak plasma glucose levels were
elevated compared with prior to therapy the peak rise in insulin was reduced (Figure
3.1 liii).
While on 400 mg/day diazoxide the patient was given a single dose of 100 fig
octreotide (Sandoz Pharmaceuticals, Camberley, UK) by IM injection and the
OGTT repeated. The insulin response to oral glucose was abolished (Figure
3.11 iv), but the patient suffered abdominal discomfort of such severity he was
reluctant to use the drug regularly.
Five years later the patient remains symptomatically well on diazoxide 200 mg
twice a day and has octreotide at home for emergency use (as yet unused).
Table3.1
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The existence of these cases is not surprising - all metabolic defects involving
enzyme abnormalities have a spectrum of severity of presentations. The ability to
diagnose such cases is new: using refined assay techniques and the confidence of a
large pool of "normal" data (Dr. Ann Burchell's laboratory has assayed over 600
normal and abnormal adult and children liver samples with the sensitive assays
described above). The literature on type 1 GSD contains reports of patients with no
measurable glucose-6-phosphatase activity in liver biopsies, but varying severity of
symptoms and measurable hepatic glucose production using stable isotope flux
measurements (Farber et al 1976, Kalhan et al 1982, Tsalikian et al 1984 and
Collins et al 1990). Other patients diagnosed as having "pseudotype 1 GSD or type
1 ^glycogenoses" (Nordlie & Sukalski 1986): patients with symptoms of type 1
GSD and "normal" assayed glucose-6-phosphatase activity (Rosenfeld et al 1978)
and the heterogeneity of type lb GSD patients based upon their clinical features
(Tada et al 1983) and how they handle ^H/^C labelled glucose infusions (Schaub
& Heyne 1983) may all represent partial deficiency states of proteins of the glucose-
6-phosphatase system. The assay data on the liver samples in these reports have not
been performed with sufficient substrates, have not been sensitive enough nor
interpreted in the light of sufficient normal data to allow such a refined diagnosis to
be made.
The clinical features of case 1 are very unusual. He was described as mentally
backward - it is possible that this was due to recurrent hypoglycaemia and it is
disappointing in retrospect that his brain was not more carefully examined at post
mortem. All the other cases above appeared to have achieved full mental, physical
and sexual maturation. The woman case 4 was not a good verbal communicator and
had a very flat affect which again may be secondary to chronic hypoglycaemic brain
damage. Case 1 was short in stature and there were repeated suggestions of poor
sexual maturation which again may be related to hypoglycaemia during
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development. He had long-standing hepatomegaly as would be expected with type 1
GSD - only 1 other of the patients (case 6) had a palpable liver (which may have
been caused by the fatty liver of diabetes or his heavy alcohol intake), although case
4 had a large liver as judged by isotope scanning. Case 1 alone had a long-standing
arthropathy which was probably gout which is a recognised long-term effect of type
1 GSD, and is the only similarity of case 1 with another case of type 1 GSD
diagnosed in an adult woman with chronic tophaceous gout (Stamm & Webb 1975).
This woman was a school-teacher who had had three children: in this respect she is
more like cases 2-5 above.
Cases 1 to 5 above represent different point mutations or deletions in or differing
expression of the gene(s) encoding the glucose-6-phosphatase catalytic subunit
protein. Only cases 1 and 4 did not have a microsomal protein which cross-reacted
to the polyclonal antibody against the rat hepatic microsomal catalytic subunit (see
Pears et al 1992).
Case 1 above showed complete absence of cross-reactivity with antibody raised to
the glucose-6-phosphatase catalytic subunit on immunoblot analysis, indicating
complete absence of that protein. Immunostaining is a very sensitive technique and
would have identified even very small amounts of the catalytic subunit in the liver
of case 1. There is good cross-reactivity of this antibody between the rat hepatic
microsomal glucose-6-phosphatase catalytic subunit and the catalytic subunit in
normal human liver preparations (Burchell et al 1988b). Case 1 must have had some
hepatic glucose production to have lived as long as he did: the only other way that
the liver can produce glucose is via substrate cycles and debranching enzyme
activity; no other phosphatase in hepatocytes has been identified which can
hydrolyse glucose-6-phosphate.
Case 4 is similar to case 1 in that the catalytic subunit protein was not identified by
immunoblotting. The reason why the woman in Case 4 did not have hyperuricaemia
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or any of the other recognised metabolic features of type 1 GSD (see Hers et al
1989 & Moses 1990 for recent review) is not clear.
Cases 2-8 inclusive had, by immunoblot analysis, normal levels of normal
molecular weight glucose-6-phosphatase catalytic subunit protein (Pears et al 1992).
The defect in these cases was therefore functional. The molecular level at which the
defect occurred is unclear; the chromosome(s) which contain the genes for the
proteins of the glucose-6-phosphatase system have not yet been identified and
cDNA probes do not exist for the glucose-6-phosphatase catalytic subunit and the
sequence of the human catalytic subunit protein is unknown.
None of the subjects other than case 1 had clinical evidence of hyperlipidaemia and
in retrospect it would have been interesting to classify in detail the lipid profiles in
these subjects. The evidence from children with type la GSD is that although the
lipid abnormalities (especially the hypertriglyceridaemia) improve to some extent
with dietary manipulation aimed at reducing hypoglycaemia, later there will be an
"escape" resulting in a marked rise in plasma triglycerides and cholesterol
(Fernandes et al 1979). Therefore it may still be possible (and important) to
demonstrate lipid abnormalities in the plasma of these patients some years after
commencing dietary therapy.
Another abnormality commonly noted in severe type 1 GSD patients is a bleeding
tendency, manifest often as epistaxes and excessive haemorrhage after surgery
(Moses 1990). Type 1 GSD patients can be shown to have prolonged bleeding times
and impaired platelet function (Gilchrist et al 1968, Czapek et al 1973, Green &
Ratnoff 1974, Corby et al 1974 and Ambruso et al 1985). This defect is probably
acquired as it improves markedly with dietary treatment (Czapek et al 1973 and
Moses 1990). Only case 1 above had clinical episodes of bleeding, but on 2
occasions detailed coagulation studies were normal. Case 3 was found to have a
deficiency of factor XI but only on the routine coagulation tests performed before a
liver biopsy. She gave no clinical history of bleeding tendency. The likelihood of
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the same individual having two protein defects are very small, but it is difficult to
perceive a link between glucose-6-phosphatase and factor XI levels. The only
abnormality of coagulation factors described before in type 1 GSD is an elevation of
factor VIII levels in a single patient (Green & Ratnoff 1974).
The development of hepatomas (Poe & Snover 1988) and hepatocellular carcinoma
first described in 1955 (Mason & Anderson, Limmer et al 1988 & Moses 1990) are
amongst the most sinister complications of type 1 GSD. Screening using circulating
aalphafetoprotein levels is unreliable (Limmer et al 1988 and case 1 above) so
patients should have regular ultrasound or CT visualisation of their liver. Any
increase in risk treating our patients with ovarian hormone replacement therapy on
the development of hepatic adenomata must be awaited (oral contraceptive usage is
associated with increased risk of developing hepatic adenomata). The likelihood is
that the adenomata in type 1 GSD (which are usually multifocal) undergo malignant
transformation to develop hepatocellular carcinoma. There has been a single report
of decrease in size of hepatic adenomata in type 1 GSD with intensive dietary
therapy (Parker et al 1981) but not of a reduced likelihood of malignant
transformation. As yet none of the cases other than case 1 above have been shown
to have liver tumours. The patients above are being followed wherever possible by
Dr. Roland Jung.
It is possible that other tumours could be more common in type 1 GSD - two of the
patients described here had carcinomas (cervix case 4 and bronchus case 6).
However, these are relatively common cancers and their development in these
patients may be co-incidental. There is no evidence of a defect in immuno-
surveillance in type la GSD (unlike in type lb where there is abnormal neutrophil
function). However it is interesting to note the lymphocytic infiltration seen in three
of the cases' liver biopsies (numbers 6,7 & 8) and to wonder whether this reflects
abnormal lymphocyte function. The initial liver biopsy appearances of cases 7 and 8
was taken to represent lymphomatous infiltrate, but this opinion was later revised.
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Only one case of a haematological malignancy has been described in type 1 GSD
and that was a case of acute myelogenous leukaemia in a patient with type lb GSD
(Simmons et al 1984). Dr David Hopwood in the Department of Pathology in
Dundee has looked retrospectively at liver biopsies of patients with lymphoma and
was unable to demonstrate abnormally high glycogen deposits (personal
communication). Note however that the biochemical analysis of the glycogen
content of the liver in case 8 showed normal glycogen stores, and the histological
estimate of glycogen content can be misleading.
Case 4 showed a chronic active infiltrate involving the fibrous septae and
parenchyma in the liver. The pathogenesis and significance of this is unclear.
Renal impairment (another sinister long-term complication of type 1 GSD [Baker et
al 1989 and Chen et al 1988 & 1990]) has not been seen in any of our patients other
than case 1 at the time of his terminal illness. However the development of renal
failure in type 1 GSD patients can be very rapid and often follows a period of
hyperfiltration similar to that seen in incipient diabetic renal failure (Baker et al
1989). The development of proteinuria (+ hypertension) and renal impairment is
associated with focal segmental glomerulosclerosis on renal biopsy and seems to
begin in the teenage years in patients with severe type 1 GSD and to have been
preceded by poor treatment or frequent feeds only - the early evidence is that the
use of corn starch or nocturnal nasogastric feeding prevents (or delays) the
development of proteinuria (Chen et al 1988). There is also evidence of proximal
tubular disease (amino aciduria, increased 62rnicr°gl°bulinuria, and decreased
phosphate reabsorption) in some type la GSD patients (Chen et al 1990). This was
not, however, evident in case 6 above where it was actively sought - as his glucose-
6-phosphatase abnormality was a defective hepatic microsomal phosphate
transporter, we wondered whether the phosphate transport system in his renal
tubules may also have been affected. The presence or absence of T2 in kidney
microsomes in type lc GSD is not known. There is evidence (Chen et al 1991) that
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renal tubular damage may also be improved by corn starch diets to lessen the
hypoglycaemia.
Another complication of hypoglycaemia is brain damage. It has been shown in
experimental animals that to produce overt "brain damage" profound acute
hypoglycaemia is necessary (Siesjo 1978). However it is likely that long-term or
intermittent milder hypoglycaemia will produce more subtle changes in brain
function - perhaps cognitive rather than focal motor or sensory changes. Cases 1
and 4 above were mentally obtunded and case l's mental development was
questioned several times (although never formally assessed). Children with type 1
GSD appear to show an adaptation to normal brain function at lower-than-normal
blood glucose levels. Four children with type 1 GSD were shown to have a net
uptake of lactate by the brain rather than net production which is the norm
(Fernandes et al 1984). The suggestion therefore is that lactate can be used as a fuel
by the brain in type 1 GSD. Normally ketone bodies are the secondary fuel for
brain tissue, but type 1 GSD is characterised by a lack of ketosis. There is also
animal work showing that transport of hexoses is increased across the blood brain
barrier in animals (rats) exposed to chronic or intermittent hypoglycaemia (McCall
et al 1986) suggesting that this may be another adaptive mechanism for the brain to
derive enough glucose for normal function. There is no evidence that this
mechanism occurs in type 1 GSD. The fact that most of our patients seemed to
achieve normal growth and development may be related to the partial nature of their
deficiencies resulting in less severe hypoglycaemia, or to the success of the adaptive
mechanisms adopted by the brain to ensure a glucose supply.
As children with type 1 GSD approach and go through puberty there is a fall in the
risk of developing hypoglycaemia (Greene et al 1981). The mechanism of this
change is unclear but is associated with a rise in hepatic glucose output (Powell et al
1981, Kalhan et al 1982 and Tsalikian et al 1984). The timing of the change
suggests a hormonal influence, however. None of the female type 1 GSD patients
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previously described have reached the menopause when three of our patients
reported worsening of their hypoglycaemic symptoms (despite unchanged dietary
measures) which later improved with ovarian hormone replacement therapy. There
have been short-lived trials of hormonal therapy (thyroxine and glucagon) for
patients with GSD 1 (Koulisher & Pickering 1956 and Lowe et al 1962) which
produced no clinical benefit. The data on the role of oestrogens above, while
anecdotal as serial measures of glucose-6-phosphatase activity were not made, may
indicate a benefit in giving oestrogen therapy to (female) type 1 GSD patients. The
repeated study of glucose-6-phosphatase activity in man is virtually impossible
because at present it requires repeated liver biopsies. I studied glucose-6-
phosphatase activity in gut mucosa and circulating white blood cells (see below)
with the aim of finding more accessible tissue to use. Further in vitro work is
underway in Dr. Ann Burchell's laboratory to look at the effect of oestrogens on
isolated microsomal rat glucose-6-phosphatase activity.
These cases described above strongly suggest a link between glucose-6-phosphatase
activity and insulin release from the pancreas as has been postulated by Waddell &
Burchell in 1989 following their observation of specific glucose-6-phosphatase
activity in pancreatic islets. The possible controlling effect of glucose-6-phosphatase
activity on cytosolic calcium levels (Benedetti & Fulceri 1986, Benedetti et al 1988
and Fulceri et al 1990) and the known role of calcium as a secondary messenger to
stimulated insulin release (Colca et al 1983a & b, Rorsman et al 1984, Flellman
1985, Morgan et al 1987 and Nilsson et al 1987) are in favour of this association.
Case 6 had non-insulin dependent diabetes mellitus. The absence of the phosphate
transport protein in his liver should have lead theoretically to hypoglycaemia as in
the other reported cases of a type lc GSD. The first reported type lc patient was an
insulin-dependent diabetic girl (Nordlie et al 1983) who had symptomatic
hypoglycaemia unrelated to insulin dosing. Since then other type lc cases have been
described (eg Burchell et al 1989) and all the type lc cases except case 6 above
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have been hypoglycaemic at times. Why case 6 did not have hypoglycaemia is
unclear. The pattern of measured microsomal glucose-6-phosphatase activity in case
6 is not that of uncontrolled diabetes mellitus with increased latency for glucose-6-
phosphate and an increase in the Vmax in disrupted structures. The mechanism of
hypoglycaemia in type lc GSD is postulated to be phosphate accumulation in the
lumen of the endoplasmic reticulum (as phosphate transport to the cytosol is non¬
existent) inhibiting the activity of the catalytic subunit (Arion et al 1980).
Case 7 had impaired glucose tolerance and a very unusual pattern of glucose-6-
phosphatase deficiency previously only seen in premature infants (Burchell 1990 and
Burchell & Gibb 1991). The pattern of "pseudo"-type lb glucose-6-phosphatase
abnormality demonstrated in case 8 has similarly been seen occasionally in
hypoglycaemic infants, and the hyperinsulinism this case showed is further support
for a role for glucose-6-phosphatase in insulin release from the pancreas. However
because case 8 responded so well to a single dose of a somatostatin analogue it is
tempting to postulate that the underlying defect in his pancreatic islets is a
deficiency of or insensitivity to native somatostatin. The nature of the inhibitor of
the hepatic microsomal glucose-6-phosphate transporter in case 8 is unclear, but
may possibly be a peptide related to insulin as such high levels of this protein were
measured in response to glucose loads.
Several defects in islet cell hormone release have been observed in other such
patients with postprandial hypoglycaemia (including hyperinsulinism and blunt
glucagon counter-responses) and some of these patients have responded
biochemically to somatostatin administration (Hadji-Georgopoulis et al 1980, Foa et
al 1980, Lev-ran & Anderson 1981 and Baschieri et al 1989). It is possible that at
least some of these patients had an identical or very similar glucose-6-phosphatase
abnormality as case 8 above.
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Some of the observed glucose-6-phosphatase abnormalities described here may have
been acquired - cases 6, 7 and 8 all had lymphocytic infiltration seen on routine
histology of their liver biopsies suggesting an ongoing pathological process.
The mechanisms of such acquisitions are very unclear and must be purely
speculative. In case 6 one would have to postulate a defect developing at the gene
controlling the production of the T2 protein, how common this is is unknown as
presumably other type lc GSD patients are asymptomatic of hypoglycaemia as this
man was and therefore are not diagnosed. Case 7 would have to have a defect
controlling the regulation of production of all the proteins of the glucose-6-
phosphatase system. The presence of IgG to the Epstein-Barr virus is probably
irrelevant as this is a common finding in a healthy population and infection with this
virus does not cause hypoglycaemic symptoms. However it would have been
interesting to make serial measures of glucose-6-phosphatase activity in case 7 to
see if her glucose-6-phosphatase activity returned to normal. The abnormality in
case 8 is the most obviously acquired of the three, but the nature of the inhibitor to
T1 and the pathogenesis of this inhibitor are as yet unclear.
The glucagon screening test as described and interpreted here I suggest is a very
important tool in the assessment of patients with hypoglycaemia. Without this test 6
of the 7 cases above who had the test done would not have had a correct diagnosis
made (case 6 is the only one where the test was normal). Most of the cases above
had symptoms suggestive of hypoglycaemia, but the hypoglycaemia was very
difficult to prove biochemically. There has been almost an epidemic (especially in
the USA) of patients describing symptoms suggestive of hypoglycaemia such that
some authors have questioned the diagnosis as an entity at all (Ford et al 1976,
Nelson 1985, Anderson & Lev-ran 1985 and Betteridge 1987). Often the symptoms
these patients describe could be functional and in the absence of demonstrable
hypoglycaemia even by prolonged fasting and exercise, a "functional" diagnosis is
even more likely to be made by the physician. However, the addition of a fasting
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glucagon test as described here to the investigation of such patients will hopefully
mean that more of these subjects are correctly diagnosed. Of course the glucagon
test is not in itself diagnostic and must be combined with the careful examination of
a liver biopsy in a laboratory which is used to dealing with such samples and is
prepared to assay the samples with three substrates to ensure a correct diagnosis
(glucose-6-phosphate, pyrophosphate and mannose-6-phosphate) - see Burchell 1990
and Burchell & Gibb 1991.
Case 8 demonstrated hypoglycaemia after his glucagon challenge as did the majority
of cases in a 'pooled' series of type lb GSD patients (Ambruso et aI 1985). Case 8
had a "functional" type lb glucose-6-phosphatase system defect, but did not have a
true type lb GSD - a deficiency of the glucose-6-phosphate transport protein. It
would be interesting to study other so-called type lb GSD patients with more
refined assay techniques than the freeze/thaw method of decreasing the glucose-6-
phosphatase latency which is most commonly used to diagnose type lb GSD, in
order to see if they also have inhibitors of Tl. The freeze/thaw method of
diagnosing type lb GSD does not allow measures of microsomal intactness on fresh
or thawed tissue as do our methods of assaying with mannose-6-phosphate and using
histone to remove the latency of the glucose-6-phosphatase system. This assessment
of microsomal intactness is very important in interpreting glucose-6-phosphatase
activity data. Once the microsomes have been frozen and thawed it is then difficult
to know the intactness of the microsomes and there will have been some loss of
glucose-6-phosphatase activity by the process of freezing and thawing.
There are limitations to the glucagon challenge I have described. A blunt blood
glucose response is not diagnostic of a glucose-6-phosphatase abnormality: we have
described two women (a mother and daughter) who had symptoms suggestive of
hypoglycaemia, blunt glucagon tests and hepatic phosphorylase kinase deficiency
(Appendix C and Pears et al 1992). Also we did not perform liver biopsies (for
ethical reasons) on people with symptoms suggestive of hypoglycaemia who had
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"normal" glucagon tests by the criteria we adopted. This is a further argument for
the use of a more accessible tissue such as blood cells or gut mucosa to study
glucose-6-phosphatase activity. The interpretation of the glucagon test in adults is
open to question. We used the criteria described by Fernandes et al (1969) for
children rather than the more recent recommendations of Dunger and Leonard
(1982). Had we used the latter criteria (described to identify complete type 1 GSD
cases in children) then 4 of the above cases who were given a glucagon test would
have had a "normal" response; subsequent liver biopsy would not have been
performed and a correct diagnosis would not have been made. A rise in blood
glucose of <4 mmol/1 is also arbitrary, but was specific for the group of patients
described above. To establish a normal response to glucagon in adults it would be
necessary to biopsy all patients given a glucagon test or it would be perhaps more
ethically acceptable to perform glucagon tests on all patients undergoing liver
biopsy. However these individuals presumably have a liver abnormality requiring a
biopsy and this may alter the blood glucose response to glucagon. Best of all would
be to study glucose-6-phosphatase activity in all patients with symptoms suggestive
of hypoglycaemia and try to establish a normal glucagon test response in adults. As
mentioned this would practically require examining glucose-6-phosphatase activity
in blood cells.
The routine histological examination of liver samples from these patients proved to
be of little benefit. The histological changes appeared to be very non-specific and
the glycogen often appeared to leach out of the tissue samples during preparation.
Careful preparation of samples of liver for electron microscopy revealed more
abnormalities and gave a better measure of glycogen stores. However the
biochemical assessment of the glycogen content is undoubtedly the most accurate.
The treatment of type 1 GSD is primarily dietary (see Fernandes et al 1988 for
recent review) and the diet differs at different ages. In severely affected infants this
can involve continuous night-time feeding via a nasogastric tube/gastrostomy.
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Portacaval shunting initially showed some benefit (Corbeel et al 1983) but has since
been abandoned as the beneficial effects have been shown to be temporary: liver
transplantation (performed for hepatocellular carcinoma in individual cases in
specialised centres) has been reported to improve growth and well-being (Kirschner
et al 1991). Nasogastric feeding is not necessary now in older patients since the
introduction of uncooked corn starch supplementation of the diet (Chen et al 1984,
Smit et al 1984 and Fernandes et al 1988). Uncooked corn starch is slowly broken
down to glucose in the gut over a period of hours providing a "depot" of glucose for
absorption. This was the dietary manipulation we used for the cases above. For
most of our cases it produced a marked improvement in symptoms. In cases 3,4 and
5 dietary manipulation was supplemented by oral hormone replacement therapy.
Case 8 required drug therapy to alleviate his severe symptoms, however his
abnormality is different to the rest as it is not due to a structural defect in any of the
proteins of the glucose-6-phosphatase system. Case 6 did not develop
hypoglycaemic symptoms despite being on a carbohydrate-controlled, weight-
reducing diet.
The long-term outcome of these described cases will be interesting, and the lessons
learnt from them in terms of the diagnosis of such patients and what they have
shown about the regulation, inter-relationship and physiological role of the glucose-
6-phosphatase system are very important.
Summary
The detailed cases presented above provide valuable new insight into the clinical
problem of hypoglycaemia and the benefit of using a glucagon test in the diagnosis
of patients presenting with symptoms suggestive of hypoglycaemia. They show the
benefit of the refinements in assay techniques described for studying the proteins of
the hepatic glucose-6-phosphatase system and especially the need to assay each
sample with at least 3 substrates (glucose-6-phosphate, mannose-6-phosphate and
109
pyrophosphate, each + histone 2A). These cases also help to interpret previously
published reports of cases of hepatic glucose-6-phosphatase deficiencies which in
retrospect probably represent partial type 1 GSD patients.
Two of the cases presented here are unique (numbers 7 and 8) in the deficiency in
the hepatic glucose-6-phosphatase system that was demonstrated. The abnormal
glucose tolerance of cases 6, 7 and 8 suggest a physiological role for glucose-6-
phosphatase in pancreatic islet cells in the hormonal responses to changing blood
glucose levels. It is also possible to postulate that the glucose-6-phosphatase
abnormality in these cases was acquired as they all had lymphocytic infiltration of
the liver at biopsy. Case 8 had an unusual history in that he presented with reactive
(or postprandial hypoglycaemia). However the hyperinsulinism following a glucose
load, absent glucagon response to the subsequent hypoglycaemia and therapeutic
benefit of somatostatin he demonstrated are identical to a recognised sub-group of
patients with reactive hypoglycaemia, all of whom may have an inhibitor of Tl.
The other recognised features of type 1 GSD patients (hyperlipidaemia, high blood
urate and lactate levels, bleeding tendency, renal impairment and hepatic
adenomata) were lacking in most of these cases, although wherever possible they
are being followed to monitor their renal function and for the presence of hepatic
tumours. The reasons behind the absence of the other abnormalities are not clear,
but may simply indicate that the glucose-6-phosphatase activity was sufficient in
each individual to maintain metabolic 'normality' at non-stressed times. The
hyperuricaemia found in case 1 suggests that the glucose-6-phosphatase deficiency
was more severe in this man, but case 4 also had no catalytic subunit protein
identified by immunoblotting, but had normal plasma urate levels. The stimulatory
effects of oestrogens on glucose-6-phosphatase activity can be postulated from the
worsening of hypoglycaemic symptoms experienced by three of these patients at the
time of the menopause, and the subsequent beneficial effect of hormone replacement
therapy.
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The need for easier access to glucose-6-phosphatase activity in man is shown clearly
by these cases, both in screening people with symptoms of hypoglycaemia with
"normal" glucagon tests and in follow up of the cases described. This is one of the
major reasons for going on to perform the studies described in the next chapter.
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CHAPTER FOUR
GLUCOSE-6-PHOSPHATASE IN HUMAN EXTRA-HEPATIC TISSUE
The liver is the tissue in which glucose-6-phosphatase is best characterised.
However many organ systems are involved in type 1 glycogen storage disease
(GSD) both directly by increased glycogen stores or indirectly with the
complications (for reviews see Hers et al 1989 and Moses 1990 for examples).
Unfortunately access to the liver is difficult and potentially dangerous. A needle
biopsy is the safest technique, but itself still carries a significant morbidity and
requires an overnight hospital stay in adults in whom the procedure is
uncomplicated. Needle biopsy of the liver produces only a few milligrams of tissue,
which in many centres is far too small to allow detailed analysis of enzyme activity
and glycogen content. Even in Dr Ann Burchell's laboratory with expertise in
microassays there is often frustration of full analysis by small sample size. Ethically
it is impossible to repeatedly follow glucose-6-phosphatase activity in a subject
using repeated liver biopsies performed just for this purpose. I was therefore
interested in finding tissue more accessible than liver in which to study glucose-6-
phosphatase activity. I was also looking to further the physiological understanding
of glucose-6-phosphatase function(s) and explain some of the clinical abnormalities
seen in type 1 GSD patients.
Glucose-6-phosphatase activity is claimed to have been demonstrated in a number of
human extra-hepatic tissues (see Nordlie 1971 and Nordlie & Sukalski 1985 for
reviews). As glucose-6-phosphate can be hydrolysed by a number of phosphatases,
detection of specific glucose-6-phosphatase activity relies upon showing the
presence of the characteristic 36.5 kDa doublet (or cross-reactivity with an
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isoenzyme of differing molecular weight) on immunoblot analysis; glucose-6-
phosphate hydrolysing activity with the kinetic characteristics of the hepatic
microsomal enzyme; and inactivation of this hydrolysing ability by incubation at
37°C and pH 5 (Burchell & Waddell 1990b).
The presence of glucose-6-phosphatase in the kidney is well-established (Ashmore
& Weber 1959 and Burchell et al 1988b). The physiological role of glucose-6-
phosphatase in the kidney is unclear, however the enzyme is localised to the
peritubular cells, suggesting a possible role in glucose transport. However glucose-
6-phosphatase activity has been shown to increase in the kidneys of animals where
renal gluconeogenesis is increased, such as after partial hepatectomy (Katz et al
1979).
Colilla et al 1975 also have shown low levels of specific glucose-6-phosphatase
activity in pancreas, adrenals, brain and lung. Recent work using the detailed,
sensitive assays described above and immunoblotting with antibody raised to the
catalytic subunit have confirmed the presence of glucose-6-phosphatase in gall
bladder mucosa (Hill et al 1989) and pancreatic islet cells (Waddell & Burchell
1988) as would be predicted by the data from cases 6, 7 and 8 presented in Chapter
3.
The mucosa of the small intestine is classically thought to be affected in type 1 GSD
(eg Hers et al 1989), but this statement is rarely referenced in review texts
reflecting, perhaps, the uncertainty surrounding the presence of the enzyme in gut
mucosa. There are histochemical studies which claim to show the presence of the
glucose-6-phosphatase enzyme in intestinal mucosa, but this data does not take into
account the presence of non-specific phosphatases (Hugon et al 1970 & 1971,
Chabot et al 1978 and Calvert et al 1979). As yet there is no histochemical data on
gut mucosa using the monospecific IgG raised to the glucose-6-phosphatase catalytic
subunit protein.
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There are reports of glucose-6-phosphatase activity in small intestinal mucosa of
guinea pig, rat, mouse, and chicken (Ockerman 1964, Ashmore & Weber 1959,
Colilla et al 1975, Anderson 1974 and Stritmatter 1972). However there are other
reports that glucose-6-phosphatase activity is not present in rat intestinal mucosa
(Ockerman 1964, Hers & DeDuve 1950 and Williams et al 1963). Similarly there
are reports of the presence of glucose-6-phosphatase activity in human intestinal
mucosa (Hers & DeDuve 1950 and Ginsburg & Hers 1960). Some workers have
even claimed to show differences in intestinal glucose-6-phosphatase activity
between subjects with type 1 GSD and their normal relatives suggesting that the
diagnosis of type 1 GSD could be made from this tissue (Williams et al 1963 and
Ockerman 1964 ). However none of this data allows for the presence of non¬
specific phosphatase activity, and none has used antibody shown to be monospecific
to the catalytic subunit of glucose-6-phosphatase (Burchell et al 1988b).
There is a report of glucose-6-phosphatase activity in platelets (Linneweh et al
1962) and of serum glucose-6-phosphatase activity (Koide & Oda 1959), but in both
of these reports non-specific phosphatase activity has not been allowed for.
The physiological role of glucose-6-phosphatase in extra-hepatic tissues is still
unclear. The kidney has been shown to produce glucose by gluconeogenesis (see
above). In the pancreatic islets the enzyme may play a role in hormone response to
changes in blood glucose concentrations - this is supported by cases 6,7 and 8
above; and by the finding of glucose cycling in the pancreatic islets in mice (Khan
et al 1989) which is increased in hyperglycaemic obese mice (Khan et al 1990). A
role for glucose-6-phosphatase in controlling free intracellular calcium
concentrations has been proposed (Benedetti et al 1985, 1986 & 1988). This latter
role could explain the presence of the glucose-6-phosphatase enzyme in a wide
range of tissues which do not release glucose. The glucose-6-phosphatase stabilising
protein is a calcium-binding protein and calcium is required for normal glucose-6-
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phosphate transport (Waddell et al 1987b & 1990 and Chapter 5 below) so the inter¬
relationship between the two is complex.
I studied normal adult human intestinal mucosa and white blood cells with the aims
of trying to explain some of the abnormalities seen in these tissues in type 1 GSD
patients, to find a tissue more accessible than liver, kidney and pancreas in which to
study glucose-6-phosphatase activity in man and finally to settle the controversy
surrounding the presence of glucose-6-phosphatase in these tissues. The cases
presented in Chapter 3 clearly demonstrate the difficulty of having to biopsy liver to
study glucose-6-phosphatase activity, and that repeated study of the enzyme in man
is impossible on ethical grounds.
4.1 GLUCOSE-6-PHOSPHATASE IN NORMAL HUMAN
GASTROINTESTINAL MUCOSA
Many papers and reviews on type 1 GSD state that glucose-6-phosphatase activity is
present in intestinal mucosa and that gut function is abnormal in this condition. This
statement is never correctly referenced (see Hers et al 1989 for a recent example).
There is an impression that some children with type 1 GSD have diarrhoea (Fine et
al 1969 and Milla et al 1978) but the evidence for malabsorption is not convincing.
In 1964 Ockerman demonstrated absent glucose-6-phosphatase activity in the
jejunum of type 1 GSD patients compared to high levels in normal mucosa and in
1968 Lygre and Nordlie published data taken as showing small amounts of glucose-
6-phosphatase activity in intestinal mucosa cells.
In this present study I aimed to show definitive evidence of specific glucose-6-
phosphatase activity and the presence of the glucose-6-phosphatase catalytic subunit
by immunoblotting in intestinal mucosal homogenates. If high levels of specific
activity were found, I wanted then to assess whether intestinal mucosal biopsies
could reliably be used to screen for glucose-6-phosphatase abnormalities. The use of
this tissue would obviate the need for a liver biopsy in patients suspected of having
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abnormal glucose-6-phosphatase activity. I have learnt that one centre in the United
States routinely uses intestinal rather than hepatic biopsies to diagnose abnormalities
of glucose-6-phosphatase (personal communication).
The main problems of the study were to safely obtain good tissue samples and to try
and inhibit proteolytic degradation of the contents of the mucosal cells after
homogenisation, while still retaining functional (for assay purposes) and structural
(for immunoblotting) integrity of the glucose-6-phosphatase catalytic subunit.
Macroscopically normal mucosal tissue was biopsied from all parts of the gut
accessible to endoscopic scrutiny. The samples were treated as described in 2.5.1
and below. The samples used to assay specific glucose-6-phosphatase and non¬
specific phosphatase activities were treated more 'gently' to try and preserve
enzyme activity. Tissue homogenates, centrifuged to remove nuclear and cell
membrane debris, were used in place of microsomes to shorten the time (and so the
risk of proteolytic damage) between sampling and assaying or denaturing. Tissue
was not examined histologically to ensure its normality to minimise the number of
biopsies taken from any one patient.
Glucose-6-phosphatase assays were performed using a modification of that described
in 2.6.1(a). 80/zl of only 30mM glucose-6-phosphate substrate containing histone
2A was used and the reaction was incubated at 30°C for 15 minutes to amplify the
amount of phosphate produced. 20fj.\ of tissue homogenate (diluted 1 in 4 v/v in SH
pH7.4) was added to start the reaction. The non-specific phosphatase activity of the
samples was obtained using the assay conditions for treatment at pH5 as described
in 2.6.1(e). The specific activity (in ^mol/mg/min) of the glucose-6-phosphatase
enzyme in each sample was then calculated using the following formula:
Specific activity
(ODg20 - non-sp. ODg20) x Dilution x 10
Factor x mg protein added x 15
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Where ODg20 = Absorbance at 820nm of the untreated
homogenate assayed with 30mM G6P + histone
non-sp.ODg20 = Absorbance at 820nm of the pH 5 treated
homogenate assayed with 30mM G6P + histone
Factor = Correction factor for the glucose-6-phosphatase assay using
liver homogenate (approx. = 2)
10/15 = Correction factor for the time of assay (15 rather than 10 minutes)
Results and discussion
The results of the assays are shown in Table 4.1 and two immunoblots are shown in
Figure 4.1
The assay data show low specific glucose-6-phosphatase activity in mucosal cells
from all parts of the intestine. The range of the measured activity from any one site
was large and may represent inter-individual variation, but is more likely to be due
to varying amounts of proteolytic damage to glucose-6-phosphatase. Further support
for this comes from Figure 4.1 (a) which shows samples which had been used for
measuring enzyme activities separated by SDS-PAGE and immunoblotted using
antibody specific to the rat hepatic glucose-6-phosphatase catalytic subunit. The
majority of samples have an apparent molecular weight significantly lower than the
rat hepatic control samples. This was initially possibly thought to represent the
presence of an isoenzyme of glucose-6-phosphatase in gut mucosa; however Figure
4.1(b) where the size of the catalytic subunit in liver and intestinal mucosa have the
same apparent molecular weight makes this unlikely.
The specific activity of glucose-6-phosphatase measured in the mucosal samples is
low compared to human liver (approximately 0.2 in the fed state). Data from other
human tissue is lacking. This may reflect less enzyme activity, but is probably also
a reflection of proteolytic damage.
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Table 4.1 Measures of phosphatase activity in homogenates prepared from normal
human intestinal mucosa sampled at endoscopy.
Specific and non-specific glucose-6-phosphatase activity were measured on the same
sample from each site.
Tissue Specific G6Pase activity Non-specific phosphatase activity












Ascending colon 9.9 0
Ascending colon 11 2.8
Ascending colon 22 6.2
Transverse colon 80 0
Transverse colon 6.6 7.6
Descending colon 7.4 3.9
Sigmoid colon 8 0
118
— 84kDa
abc def g hi
Figure 4.1 a
Immunostained Western blots of 7-20% SDS-polyacrylamide gels using antiglucose-
6-phosphatase catalytic subunit antibody as the primary antibody.
(a) Plate shows samples of normal human intestinal mucosa collected for assay
purposes (details in text). Lanes a,b & c contained 56, 64 and 20/xg of gastric
mucosal protein; lane d contained 34^g of duodenal mucosa protein; lanes e,f & g
contained 54,6 and 20ng of colonic mucosa protein and h & i contained 46 and
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Figure 4.1 b
(b) Plate shows samples of normal adult human mucosa collected specifically for
immunoblotting. Lanes a & j contained 9/xg rat liver microsomes as control. All
sample lanes were loaded with 50pig of protein.Lane b - oesophagus; c & d -
stomach (different subjects); e - duodenum; f - ascending colon; g - transverse
colon; h - descending colon; i - sigmoid colon.
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The blot shown in Figure 4.1 (b) is from samples specifically collected for running
on gels (see 2.5.1) and shows the enzyme band in all samples to have the same
apparent molecular weight as the rat liver controls.
The glucose-6-phosphatase activity of the samples collected specifically for running
on the gels was not tested as these samples were collected into a large number of
protease inhibitors which would themselves interfere with the assay and the samples
when spun were placed immediately into boiling SDS and mercaptoethanol after
homogenisation and centrifugation.
These data presented above indicate the presence of glucose-6-phosphatase in
mucosa cells at all levels of the normal adult gut. The measured specific glucose-6-
phosphatase activity is low in all parts of the gut compared to the liver and shows
inter-sample variability at the same level of the gut. Much of this variability is due
to proteolysis which occurred in my sample processing despite using careful
measures to inhibit it. Therefore there is a danger of incorrectly diagnosing type la
GSD from intestinal mucosa using assay data alone, false negative diagnoses would
be less likely to be made if immunoblotting was performed too. Although type la
GSD can occur in the presence of immunoreactive catalytic subunit (Pears et al
1992). The assay data presented here indicates that diagnosing type lb and lc GSD
could not be diagnosed and subtle partial abnormalities of glucose-6-phosphatase
such as those shown in Chapter 3 could not be proven from intestinal mucosa
biopsies.
Previous studies on glucose-6-phosphatase activity in intestinal mucosa are
consistent with my data (Lygre & Nordlie 1968 and Ockerman 1964) but the data in
these earlier reports does not include immunoblot analysis of samples. Despite his
assay, Ockerman "showed" the absence of glucose-6-phosphatase activity in jejunal
mucosa from 2 cases of type 1 GSD compared to normal controls - while his
methodology includes a method for assaying non-specific phosphatase activity the
results presented on this non-specific data are sparse.
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Diarrhoea is reported by some to be a common finding in patients with type 1 GSD
(Fine et al 1969) especially after a glucose load where there is also increased
glucose excretion in the stool (Milla et al 1978). The evidence for associated
malabsorption is not convincing. There has been a report of abnormal barium enema
findings simulating those seen in colitis in children with type 1 GSD who were
either asymptomatic or had intermittent diarrhoea (Fellows et al 1975). This series
however reported normal small bowel barium investigations on the same children.
There are also reports of Crohn's-like colitis in patients with type lb GSD (Roe et
al 1986, Couper et al 1991 and Sanderson et al 1991). The link between type lb
GSD and Crohn's-like colitis is not clear but may be related to a neutrophil
abnormality rather than to a defect in the intestinal mucosa. In Crohn's disease in
otherwise 'normal' individuals disorders of neutrophil function have been described
(for example Wandell & Binder 1982, Worsaae et al 1982 & Verspaget et al 1984)
although the significance of these defects in the pathogenesis of Crohn's disease is
not established.
The physiological role of glucose-6-phosphatase in intestinal mucosal cells is as yet
speculative. In the stomach and duodenum it may be involved in handling of
glucose absorbed from the lumen of the gut, but in the colon this is unlikely to be a
normal physiological role although glucose can be absorbed from the rectal mucosa
(this method can be employed to resuscitate hypoglycaemic diabetic children). The
metabolism of mucosal cells isolated from several parts of the intestine has been
studied and glucose appears to play a central role in providing energy for these cells
in the fed state (Windmueller 1984 and Ardawi & Newsholme 1985). There are
reports of increased glucose-6-phosphatase activity in mucosal cells isolated from
the intestine of fasted rats compared to fed animals (similar to the situation in the
liver), but these assays do not allow for non-specific phosphatase activity (Ardawi
& Newsholme 1985). The proteins of the glucose-6-phosphatase system bind
calcium (Waddell and Burchell 1987b and Chapter 5 below) and glucose-6-
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phosphatase activity may help to control intracellular calcium levels (Benedetti et al
1988). Therefore the role of glucose-6-phosphatase may be the control of cytosolic
calcium concentrations in intestinal mucosal cells.
4.2 GLUCOSE—6-PHOSPHATASE IN NORMAL HUMAN WHITE BLOOD
CELLS
There were three reasons for studying white blood cells and neutrophils especially.
Firstly they would provide a readily accessible tissue in which to study glucose-6-
phosphatase activity under different metabolic circumstances and in which to
diagnose glucose-6-phosphatase abnormalities. Secondly patients with Type lb GSD
are susceptible to bacterial sepsis and there are reports of abnormal neutrophil
function in some of these patients (for example Anderson et al 1981, Narisawa et al
1983 & 1986, Seger et al 1984 and Bashan et al 1988). Finally there is at present
no practical way to monitor changes in glucose-6-phosphatase activity in a single
individual. This would be attractive for monitoring the metabolic response to
therapy of type 1 GSD patients, diabetic patients (if a correlation between hepatic
and blood cell glucose-6-phosphatase activity could be shown) and might make it
possible to study the turnover times of the protein components of the glucose-6-
phosphatase system.
None of the patients described in Chapter 3 had a history of recurrent sepsis, but
case 1 did suffer from recurrent epistaxes as a child and poorly explained episodes
of rectal bleeding. A bleeding tendency is well recognised in poorly treated type 1
GSD patients which improves with normalisation of ambient glucose levels. Case 3
had a factor XI deficiency but no clinical evidence of a bleeding tendency. The link
between the partial type la GSD and factor XI deficiency is unclear and the two
may have occurred coincidentally.
The development of malignant tumours in man can be related to defects in immune
surveillance by lymphocytes: three of the patients described in Chapter 3 developed
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malignant tumours (case 1 hepatocellular carcinoma; case 4 cervical carcinoma; and
case 6 anaplastic small cell bronchogenic carcinoma). The last two are common
cancers in the community and may be unrelated to the glucose-6-phosphatase
abnormalities in these individuals. Hepatocellular carcinoma is a very common
world-wide carcinoma especially in areas where the hepatitis B surface antigen is
endemic and is a recognised complication of type 1 GSD, but is otherwise relatively
uncommon in Britain. Three of the patients in Chapter 3 had lymphocytic
infiltration on their liver biopsies such that two of them - cases 7 & 8 - were
initially taken to have lymphomatous infiltrates of the liver. There is no data on an
increased risk of developing tumours other than hepatic adenomata and carcinomata
in type 1 GSD and only one other malignancy in a type lb GSD patient has been
described (acute myelogenous leukaemia - Simmons et al 1984).
In 1959 Koide and Oda published data interpreted as showing glucose-6-phosphatase
activity in serum and different levels of this activity in different states. This data
showed a lack of understanding of non-specific acid and alkaline phosphatase
hydrolysis of glucose-6-phosphate and was later shown to be erroneous (Foz 1967).
There is no specific glucose-6-phosphatase activity in serum.
Platelet abnormalities have been implicated in the bleeding tendency of some type
la and b GSD patients (Corby et al 1974 and Ambruso et al 1985) and there has
been a report of decreased glucose-6-phosphatase activity and increased glycogen
stores in platelets from patients with type 1 GSD (Linneweh et al 1962). The
measurement of phosphatase activity in this last paper did not result in specific
glucose-6-phosphatase activity, but included non-specific phosphatase activity. The
bleeding tendency in type 1 GSD patients is thought to resolve with dietary therapy
(Czapek et al 1973) and is therefore thought to be secondary - possibly to the
hypoglycaemia - and not due to an intrinsic platelet defect. However a bleeding




Blood was taken and the cells separated as described in 2.1.1 (d) and 2.5.2.
Initial work centred around immunoblot detection: if this sensitive technique had not
shown the presence of glucose-6-phosphatase catalytic subunit then there would
have been no reason trying to develop an assay to measure glucose-6-phosphatase
activity in blood cells.
From the first cell separation procedure performed all blood cell types were
separated by SDS-PAGE and immunoblotted. This was a preliminary experiment
and did not use protease inhibitors. The resultant immunoblot using polyclonal IgG
to the rat hepatic glucose-6-phosphatase catalytic subunit as primary antibody is
shown in Figure 4.2. There was considerable non-specific staining, but the lane
containing the separated neutrophils (lane 3) showed a doublet which ran alongside
the rat hepatic microsomal control (lane 5). Platelets and monocytes were not
studied further - this blot did not support the earlier claim of the presence of
glucose-6-phosphatase in platelets (Linneweh et al 1962). Figure 4.2 also indicated
that trying to separate whole blood by SDS-PAGE and then immunoblotting with
anti-catalytic subunit primary antibody (lane 6) was not going to show clear protein
bands, probably due to the large numbers of proteins loaded.
Subsequent studies were therefore confined to neutrophils. Yields of neutrophils
from 10 ml of blood varied from 6.1 x 10^/1 to 67.2 x 10^/1 ( n = 40 ) as measured
in the 1 ml final suspension and were at least 91% pure as judged by the Coulter
T540 automated cell counter. Aliquots of neutrophils were treated in various ways
as described in 2.5.3.
Several combinations of protease inhibitors were tried to achieve immunoblots
which did not show evidence of proteolysis (see 2.5.2). Proteolysis resulted in
lower molecular weight peptides than the catalytic subunit being seen on
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Figure 4.2
Immunostained Western blot of a 7-16% SDS-polyacrylamide gel using antiglucose-
6-phosphatase catalytic subunit antibody as the primary antibody. All suspensions
isolated as described from normal human blood with no protease inhibitors. Cell
counts were not performed on these suspensions.
Lanes (1) 50/j.I suspension of platelets; (2) 50/xl suspension of monocytes; (3) 50/j.l
suspension of neutrophil polymorphonuclear leucocytes; (4) prestained molecular
weight markers; (5) microsomes from starved rat liver as control (25fig protein); (6)
50^il normal human whole venous blood.
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Figure 4.3
Western blot from a 7-20% SDS-polyarylamide gel using antiglucose-6-phosphatase
catalytic subunit antibody as the primary antibody. Lanes (a) prestained molecular
weight markers; (b) 25pg microsomal protein from starved rat livers; (c,d & e)
contain dilutions of a preparation of neutrophils isolated from a normal human
volunteer (me!) - numbers of cells contained were 22.4 x 10^, 16.8 x 10^ & 5.6 x
105 respectively. Preparation of neutrophils in protease inhibitors: PMSF, 1,10-
phenanthroline, pepstatin A, trypsin/chymotrypsin inhibitor and aprotinin (details in
text).
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immunostaining of neutrophil samples compared to hepatic microsomal controls
(Figure 4.3). Initially a combination of 1,10-phenanthroline and PMSF (2.5.2 [a])
was used and then other protease inhibitors were added as experience with the
samples increased. The final combination (2.5.2 [c]) of sodium azide and PMSF
was used as this had been shown to inhibit both proteolysis and the respiratory burst
produced as neutrophils were disrupted (Gomez-Cambronero et al 1989). None of
the combinations of protease inhibitors was able to alter the apparent proteolysis
seen on immunoblotting, and none of them were better than using no protease
inhibitors (Figure 4.4). Changing the buffer medium in which the neutrophils were
finally suspended from Hanks to SH pH7.4 also made no difference to the apparent
size of the catalytic subunit seen on immunoblotting.
It is possible that the apparent lower molecular weight of the glucose-6-phosphatase
catalytic subunit from neutrophils compared to rat hepatic microsomal control is a
true difference and that the neutrophil protein is an isoenzyme of the hepatic
catalytic subunit or that the glycosylation states of the rat hepatic and human
neutrophil catalytic subunit are different. However the presence of the low
molecular weight peptides cross-reacting with the anti-catalytic subunit primary
antibody such as in Figure 4.4 makes these suggestions less likely.
Attempts were made to assay glucose-6-phosphatase and non-specific phosphatase
activities in neutrophil preparations, once the immunoblots showed firm evidence of
the presence of glucose-6-phosphatase catalytic subunit. The cell preparations were
assayed with only 30mM G6P containing histone 2A to detect specific activity as
calculated from the equation in 2.6.1. After 15 minutes incubation of fresh,
unfrozen neutrophil preparations very little phosphatase activity could be detected at
all. Any measurable activity was small (see Table 4.2) and was often non-existent.
The corresponding activity for fed rat hepatic microsomes (the least active rat liver
preparation) was approximately 0.3. Modifying the assay conditions by adding more
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Figure 4.4
Immunostained Western blot of a 7-16% SDS-polyacrylamide gel using antiglucose-
6-phosphatase catalytic subunit antibody as the primary antibody. Neutrophils in
each lane separated from different normal human volunteers. No protease inhibitors
used.
Lane (a) 25/j.g microsomal protein from starved rat livers; (b) 13 x 10^ cells; (c) 16
x 105 cells; (d) 15 x 10^ cells; and (e) 20 x 10^ cells.
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colour production (20/d of 120mM G6P substrate, assayed for 15 minutes with SO/xl
of neutrophil preparation before 500/xl of stopping reagent was added) produced
very high blank assay readings due to phosphate in the sample and no increase in
measurable phosphatase activity. Preparing new substrates did not lower the blank
assay readings and so this technique was abandoned.
Worse problems were encountered trying to measure non-specific phosphatase
activity as the pH 5 treatment necessitated a 5-fold dilution of sample resulting in
less detectable activity (Table 4.2).
Disruption of the neutrophil cell membrane prior to addition to the assay medium
was attempted by several techniques - see 2.5.3. The rationale for this was to
remove the additional barrier that the cell membrane provided to G6P entering the
lumen of the endoplasmic reticulum before being hydrolysed. Assays performed
with and without histone 2A in the absence of lubrol did not produce different
measured activity implying that histone did not render the cell membrane permeable
to G6P. Of the methods tried, mixing the neutrophil cell preparation with lubrol 2A
(final lubrol concentration in sample, not assay, = 0.01% v/v) appeared to me to
give the most consistent activity measurements but this was not confirmed by the
meaned data (Table 4.2).
In summary the data from the immunoblotting is very suggestive of the presence of
small amounts of glucose-6-phosphatase catalytic subunit in the neutrophil
preparations. However the assay data, while it does not rule out glucose-6-
phosphatase activity in neutrophils, is not conclusive of significant phosphatase
activity of any nature. The most likely explanations for this are low amounts of
glucose-6-phosphatase activity in neutrophils or proteolysis of the neutrophil
contents during separation and/or assaying. The separation procedure for
neutrophils is a lengthy one and while cells isolated by this technique are
unactivated but functional (Ferrante and Thong 1980), it is possible that some
degradation of internal proteins had occurred before the neutrophils came into
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contact with protease inhibitors. Another problem with the assay could have been
access of extracellular glucose-6-phosphate to the enzyme in the endoplasmic
reticulum. However the neutrophils were completely disrupted (as shown by the
Coulter T540 automated cell counter) by treatment with lubrol as described with or
without freezing and thawing.
The protein bands shown by immunoblotting of neutrophil preparations are very
strong and discrete, suggesting the presence of sufficient glucose-6-phosphatase
catalytic subunit protein to allow assaying by the colourimetric method. This makes
the theory of proteolytic damage the most likely explanation for the unmeasurable
phosphatase activity.
I am not aware of a more rapid method for neutrophil isolation which reliably
produces good yields of individual cell types, and as Figure 4.2 indicates
immunoblot detection of the catalytic subunit of glucose-6-phosphatase on samples
of whole blood is not possible due to large amounts of contaminating protein and
the relatively small number of neutrophils in whole blood compared to, for example
the number of red blood cells.
The physiological role of glucose-6-phosphatase in circulating neutrophils is
speculative. Energy regulation within the cell and the need to produce glucose
rapidly as a fuel for movement of the cell or for the ingestion and destruction of
foreign material is a possibility, but a role in the control of intracellular free
calcium is again likely.
There have been many studies of neutrophils isolated from type lb GSD patients
who are prone to bacterial infections, which have shown reduced numbers, mobility
and function of neutrophils (Beaudet et al 1980, Anderson et al 1981, Gahr &
Heyne 1983, Ambruso et al 1985, Shin 1990 and Moses 1990 for example). More
detailed studies of normal neutrophils have shown that they use internal glycogen as
a carbon source (Stossel et al 1970) and that calcium is an important intracellular
messenger involved in glycogen breakdown, glucose transport and respiratory burst
132
activity (Snyderman & Uhing 1988). Neutrophils isolated from type lb GSD
patients show decreased glucose uptake (Bashan et al 1987 and Shin 1990), normal
glycogen stores (Bashan et al 1988) but decreased chemotaxis (Beaudet et al 1980
and Anderson et al 1981) and poor respiratory burst activity (Kilpatrick et al 1990).
These abnormalities described in neutrophils from type lb GSD patients seems to
relate to calcium mobilisation in the cells. Calcium mobilisation is essential for the
respiratory burst in neutrophils (Heyworth & Segal 1986) and this calcium
mobilisation is much lower in neutrophils from type lb GSD patients (Kilpatrick et
al 1990) when compared to normal controls and type la GSD patients who have
functionally normal neutrophils. Neutrophils contain an isozyme of glucose-6-
phosphate dehydrogenase in the lumen of the ER (Hino & Minakami 1982) which
requires a glucose-6-phosphate transport system. If this glucose-6-phosphate
transport system is the same as that used by glucose-6-phosphatase in type lb GSD
patients the function of this G6PDH isozyme will be impaired, thus further
contributing to the abnormal neutrophil function.
This central role for the glucose-6-phosphatase system in intracellular calcium
mobilisation (as well as glucose production) has been postulated for its role in other
tissues (Benedetti et al 1985, 1986 & 1988, Fulceri et al 1990 and Waddell &
Burchell 1988 and Chapter 3).
There have been three cases of Crohn 's-like colitis developing in patients with type
lb GSD who also had demonstrable abnormalities of white blood cell (specifically
neutrophil) function (Roe et al 1986 and Couper et al 1991). The pathogenesis of
Crohn's disease in patients without type lb GSD may in part be due to neutrophil
dysfunction, and these observations are interesting in the light of the evidence
presented above. Perhaps some patients with Crohn's disease have subtle glucose-6-
phosphatase abnormalities such as are seen in type lb GSD or inhibitors of T1 such
as seen in case 8 in Chapter 3. The patient described in Chapter 3 with pseudotype
lb GSD (case 8) had no symptoms suggestive of intestinal disease, nor did he have
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a history of recurrent sepsis. Neutrophil function tests were not carried out on this
man.
SUMMARY OF DISCUSSION
The data in this chapter has proven the presence of specific glucose-6-phosphatase
activity in normal adult intestinal mucosa at all levels of the gut. Even using the
careful techniques employed, the level of measurable activity was too low and too
variable (because of proteolysis) to make this tissue useful in studying human
glucose-6-phosphatase activity. Therefore I would not recommend the use of
intestinal mucosa cells to diagnose or monitor possible glucose-6-phosphatase
abnormalities.
The presence of glucose-6-phosphatase activity in intestinal mucosa is in keeping
with gut abnormalities being described in type 1 GSD patients (diarrhoea, clinical,
histological or radiographic evidence of colitis). The role of the enzyme in this
tissue may relate to local glucose production for cell metabolism, glucose transport
through the intestinal mucosa cells and/or to regulating intracellular calcium
concentrations.
Immunoblot analysis of neutrophils isolated from normal human blood indicates the
presence of small amounts of the glucose-6-phosphatase catalytic subunit in these
cells, but unfortunately it was not possible to establish an assay procedure which
was able to show specific glucose-6-phosphatase activity. Further work is needed in
this area, as the development of an assay for glucose-6-phosphatase in peripheral
blood would make the study of the enzyme in man very much easier.
Future work involving the staining of tissue histochemically using the antibodies
raised to the component proteins of the glucose-6-phosphatase system will make
assessing the tissue distribution of the enzyme easier. Unfortunately this technique
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will not give a functional assay, but would give an indication as to the relative
amount of the proteins present.
Demonstrating the presence of the glucose-6-phosphatase system in neutrophils
represents an important advance in understanding the physiology of these cells in
health and disease. The role of glucose-6-phosphatase is probably not confined to
controlling intracellular glucose / glucose-6-phosphate concentrations, but may well
include the regulation of intracellular calcium concentrations in response to external
stimuli. This is in keeping with demonstrated abnormalities of neutrophil function
seen in type lb GSD patients being due to an intrinsic cellular defect and not
secondary to chronic hypoglycaemia.
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CHAPTER 5
STUDIES ON THE MICROSOMAL GLUCOSE-6-PHOSPHATE TRANSLOCASE
5.1 INTRODUCTION
The cases presented in Chapter 3 clearly confirm the important role that glucose-6-
phosphatase has in controlling blood glucose levels. Kinetic analysis of hepatic
microsomal glucose-6-phosphatase shows that it is the transport of glucose-6-
phosphate (by a transport protein) across the endoplasmic reticulum membrane from
the cytosol to the lumen of the endoplasmic reticulum which is rate-limiting to the
hydrolytic activity of the glucose-6-phosphatase system as a whole (Arion et al
1980b). Furthermore the capacity of the glucose-6-phosphate transport protein (Tl)
becomes more rate-limiting to the activity of the hepatic microsomal glucose-6-
phosphatase system as the metabolic state of the animal changes from fed to starved
to diabetic (Arion et al 1980b and Burchell & Cain 1985). Less is known of the
regulation, structure and functioning of Tl than of any of the other proteins of the
glucose-6-phosphatase system, despite its crucial position in hepatic glucose
production. The role and key regulating position of Tl makes it an attractive
prospect for pharmacological manipulation in hypoglycaemia (eg the type 1 GSDs
and the cases in Chapter 3) or hyperglycaemia (eg diabetes mellitus where glucose-
6-phosphatase activity and hepatic glucose production are increased). The effect of
the inhibitor to Tl in case 8 described in Chapter 3 above which was to produce a
fall in hepatic glucose production without apparently causing any of the other
metabolic complications seen in type lb GSD patients (Hers et al 1989 and Moses
1990 for reviews) supports this possible pharmacological site of action.
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In 1982 a protein was identified which was thought to be T1 (Zoccoli et al 1982).
Other workers then became hesitant about studying T1 as it was expected that this
group would go on to describe the structure of Tl, and then clone and reconstitute
the transporter. However this information was not forthcoming and it now seems
probable that the protein isolated by Zoccoli was not Tl but a sodium-independent
hepatic transport protein for organic anions (Ananthanorayanan et al 1988).
The glucose-6-phosphate transport protein is one of many thousands of proteins
which are associated with microsomal preparations, and the fact that by necessity it
must be very lipid-dependent for its structure and function produces special
difficulties when trying to isolate and then reconstitute it.
The aims of my studies on this protein were to try and isolate the Tl translocase,
discover its biochemical regulation and whether it was possible to pharmacologically
alter its capacity for glucose-6-phosphate transport.
5.2 MATERIALS AND METHODS
5.2.1 Studies on the Tl protein
Microsomes were prepared from livers of streptozotocin induced diabetic rats as
described in 2.2 and 2.5. The postulated Tl protein was isolated by affinity
chromatography as described in 2.7. An antibody to this protein was raised in a
Cheviot sheep as described in 2.8.
To examine the effect of the antibody raised to an isolated protein on the glucose-6-
phosphatase system, microsomes were mixed and incubated on ice with a given
amount of IgG for 20 minutes before being assayed by the usual method with
glucose-6-phosphate substrates without histone (after Waddell et al 1991). Pre-
immune sheep serum was used as a control for these assays.
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5.2.2 Studies on the effects of ions on microsomal glucose-6-phosphate
transport
In order to identify an isolated protein as T1 it would be necessary to demonstrate
glucose-6-phosphate transport by this protein. Before doing this it would be
necessary to identify the mechanism of glucose-6-phosphate transport across the
endoplasmic reticulum membrane. It seemed likely that glucose-6-phosphate
transport is associated with the flux of other ions as glucose-6-phosphate transports
as an anion. Sodium was the first cation studied.
A "low sodium" assay system for glucose-6-phosphatase /pyrophosphatase
colourimetric assays and for radionuclide transport assays was developed to study
the effect of cations on microsomal glucose-6-phosphate transport. Great care was
taken to exclude as much sodium from the preparation of microsomes as possible.
This was done by using the purest non-sodium salts available (for example the
potassium salt of glucose-6-phosphate, pyrophosphoric acid, Aristar or Spectrosol
grade salts of calcium, magnesium, cobalt, zinc and nickel chloride). When sodium
chloride was added to this "low-sodium " system Aristar grade sodium chloride was
used to minimise contamination with other cations. Milli-Q pure water (double
distilled and purified through filters) was used to prepare all substrates and buffers
and to wash all equipment (including assay tubes, tubes for storing microsomes and
pipette tips) before use. EDTA was omitted from the colourimetric assay substrates
as only the sodium salt was available. The concentrations of substrates used were 1,
1.4, 2 and 2.6 mM glucose-6-phosphate as at higher concentrations the Lineweaver-
Burke plots became non-linear, presumably due to contaminants in the substrates
reaching a sufficient concentration to affect the assay.
U^C-glucose-6-phosphate sodium salt was mixed with an exchange resin (Dowex
50W-X8[H], BDH Chemicals) to exchange the sodium for H+ .
The sodium concentration of solutions was estimated where indicated using a
Corning 4IOC clinical flame photometer.
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5.2.3 Studies using amiloride hydrochloride
Once the requirement for sodium co-transport with glucose-6-phosphate became
apparent a sodium transport inhibitor (amiloride) was used to try and modify
glucose-6-phosphate transport.
Amiloride hydrochloride (Sigma Chemicals, Poole , UK) was prepared for use in
assays by dissolving it in dimethylsulfoxide (DMSO) added dropwise at 46°C. The
solution was then diluted to the required volume by the slow addition of SH pH 7.4
buffer (also at 46°C) and used fresh. The final concentration of DMSO in the
colourimetric assay was 1%. 10/lJ of amiloride (or 1% DMSO to controls) was
added to each assay tube at the preincubation stage and 10yu.l of microsomal dilution
was then added. The final dilutions (v/v) in the assay were: fed rat liver microsomes
1 part in 75, starved rat liver microsomes 1 part in 100, diabetic rat liver
microsomes 1 part in 150.
5.3 IDENTIFICATION OF A PEPTIDE: Tl?
5.3.1 Isolation of a protein
In an attempt to isolate a protein with known affinity for glucose-6-phosphate,
phlorizin and DIDS it seemed logical to use these compounds as ligands bound to
Sepharose beads and utilise the technique of affinity chromatography as described in
Chapter 2. Initially all three ligands were used: glucose-6-phosphate; phlorizin, a
compound which binds to several proteins and selectively inhibits glucose-6-
phosphate transport by Tl (Arion et al 1980a and Waddell & Burchell 1987a); and
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), which is known to bind to
several microsomal proteins and inhibits glucose-6-phosphatase activity at low
concentrations in intact microsomes (Arion et al 1975 & 1980b, Speth & Schulze
1988 and Zoccoli et al 1980 & 1982).
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The first affinity column used was that with Sepharose bound glucose-6-phosphate
as ligand. Microsomes were initially solubilised by Triton X after treatment with
concanavalin A to remove cell membrane debris. Fractions from the glucose-6-
phosphate/Sepharose affinity column did not produce any protein bands when run
on SDS-PAGE and tested for protein with Coomassie or silver stains. On one gel
only a single protein band in all fraction and standard lanes was seen at 65-70kDa
molecular weight. This probably represented contamination: the nature of the band
is unclear, but it is a recognised feature of silver stains and it has been attributed to
keratin proteins derived from the skin of the person preparing and running the gels
(Morrissey 1981). More likely it was a contaminant, possibly microbial, in one of
the buffer solutions used.
Both the glucose-6-phosphate/Sepharose and phlorizin/Sepharose affinity columns
were run several times and did not produce any other peptides than the contaminant
on silver-staining of SDS-PAGE gels.
In contrast the third run of the DIDS/Sepharose affinity column using lubrol-
disrupted microsomes from livers of diabetic rats (see 2.7.1) produced positive
Bradford reagent tests for protein in fractions 1 to 4 (fraction 1 was the strongest).
It was also noted that lubrol produced a positive Bradford reaction, but the fractions
collected came off the DIDS/Sepharose column before any TBS containing lubrol
was added to it. The silver stained gel of these fractions showed several faint bands
in the fraction lanes and a strong single band at an apparent molecular weight of
approximately 66kDa. The Coomassie stain was blank. With every run of the
DIDS/Sepharose affinity column the 66kDa peptide became more obvious and the
band on the silver stain gel more discrete until the stains looked like Figure 5.3.1.
The concentration of the peptide was highest in fraction 3 and decreased in
subsequent fractions (fractions were 0.25ml) making the band unlikely to be a
contaminant, but a peak of protein eluted early from the column.
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a b c d e f
Figure 5.3.1
Silver stained 10% SDS-polyacrylamide gel. Lanes (a to e) each contained 50^1 of
fractions 1,2,3,4 & 5 respectively eluted from a DIDS/Sepharose affinity column
loaded with microsomal protein from diabetic rat liver microsomes. Protein content
of each fraction not determined.
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Ten subsequent runs of this column were performed and all produced fractions
which eluted early with 1M NaCl. After 6 runs other fragments of protein were
demonstrated in the fractions after SDS-PAGE and silver staining of the gels. These
contaminating fragments disappeared after the column was washed alternately in
low (Na acetate, pH 4) and high pH (NaOH, pH9) to remove all protein bound to
the column. A larger DIDS/Sepharose column was prepared and used on an FPLC
system to produce larger quantities of protein.
When approximately lOOyug of the protein had been isolated it was decided to raise
an antibody to it in a sheep. Sheep are good at reliably forming antibody to injected
protein, are relatively easy to care for and have a large enough circulating blood
volume to allow repeated large volume sampling for serum separation. The isolated
protein was concentrated by repeated treatments in a Speedivac system which
centrifuges solutions in a vacuum at a temperature of 30°C. In the later stages of
this concentration process, white cuboidal crystals were grown in the fractions
which were taken to be sodium chloride as this was used to elute the protein from
the column.
The decision to use the isolated protein to raise a polyclonal antibody was made in
the hope that the antibody would be more specific than DIDS as a ligand when
bound to Sepharose for isolating more of the protein for further study; the antibody
could be added to assays to screen for any effects on glucose-6-phosphatase activity
and could be used for immunoblot analysis of liver samples. The antibody could
also be used to try screen proteins produced by, for example, a lambda-Zap library,
sequence the protein and isolate the RNA and DNA encoding it.
Later I planned to try and reconstitute the protein into liposomes and demonstrate
glucose-6-phosphate uptake by the treated liposomes as this is the best method for
demonstrating the protein to be Tl.
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5.3.2 Studies with polyclonal IgG to the isolated protein
Three inoculations of equal size (approximately 30/*g each) containing concentrated
protein from the DIDS/Sepharose column fractions were injected into a Cheviot
sheep, each one 4 weeks after the last.
Serum (10ml sample, then 400ml collection) was isolated from 4 weeks after the
third injection and every 4 weeks after that until a total of 1200ml serum was taken.
The serum was screened by immunostaining a dot-blot of microsomal protein and
fractions from the DIDS column used to prepare the inoculate with the whole serum
diluted 1 in 500 (v/v) in TBS as the primary antibody. The presence of a positive
reaction in the relevant well was taken as proof of polyclonal antibody raised to the
injected protein and a microsomal protein (Figure 5.3.2). The first 400ml of serum
was treated with 90% ammonium sulphate as described in 2.8 to purify the IgG
fraction. This was the antibody used to perform the rest of the studies and is called
here anti-Tl IgG.
Figure 5.3.2
Immunostained dot blot using, as the primary antibody, untreated serum from an
adult Cheviot sheep previously inoculated with protein isolated from diabetic rat
liver microsomes by affinity chromatography with DIDS/Sepharose as ligand. Dots
(a,b & c) contained protein from three fractions isolated by DIDS/Sepharose affinity
chromatography known to contain the protein used for inoculation. The protein
content of these fractions was not determined. Dots (d & e) contained 3.8mg and
2.9mg microsomal protein from the livers of diabetic and starved rats respectively.
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a) Immunoblot analysis The anti-Tl IgG was used as the primary antibody (diluted
1 in 250 [v/v] in TBS) to immunostain blots of rat liver microsomal proteins
separated by SDS-PAGE.
As shown in Figure 5.3.3 several major proteins were recognised by anti-Tl. The
fact that the microsomal proteins identified by the anti-Tl IgG were glycoproteins is
clear from the shape of the bands which are shown - turned up ends and smearing
running up the blot.
These microsomal proteins were at approximately 35kDa (about the same molecular
weight as the glucose-6-phosphatase catalytic subunit [36.5kDa]); 45kDa which may
be a biotin-binding protein in the microsomes (it was not found if a blot was
"blocked" with biotin after milk - see 2.10.3) and is therefore recognised by the
streptavidin/hydrogen peroxidase complex, not by the anti-Tl IgG. There was also a
very strong protein band at an approximate molecular weight of 50kDa. However as
Figure 5.3.3 shows the resolution of the molecular weight standards is poor and
recently Amersham, one of the major producers of such standards, has published a
warning that its molecular weight standards are not accurate even with good
resolution on a gel. From a 7-16% gradient gel it is also not possible to determine
the molecular weight of this heavily staining band accurately, although it is smaller
than the 66kDa band originally isolated.
The fact that DIDS binds to glucose-6-phosphate binding sites and that a protein of
molecular weight approximately 35kDa was identified with anti-Tl IgG by
immunoblot analysis from a 7-16% acrylamide gel raised the possibility that the
antibody was recognising the glucose-6-phosphate binding site on both T1 and
catalytic subunit (if that is what the 50 and 35kDa proteins represent). However
anti-Tl IgG did not show positive immunostaining with samples of purified catalytic
subunit run on SDS-PAGE and blotted onto nitrocellulose. This was disappointing
as if there had been cross-reactivity it would have been proof that the initial isolated
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Figure 5.3.3
Immunostained Western blot of a 7-20% SDS-polyacrylamide gel using anti-Tl IgG
as primary antibody. Lanes (a,b & d) contained 100/xg, 60/xg and 10/xg of
microsomal protein from livers of diabetic rats. Lane (c) contained prestained
molecular weight markers.
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anti-Tl IgG did not recognise the microsomal glucose-6-phosphatase catalytic
subunit.
Equal amounts of protein from fed, starved and diabetic rat liver microsomes were
separated by SDS-PAGE, blotted and immunostained with anti-Tl IgG (not shown).
There was more protein (shown as darker, stronger bands) at both approximately 35
and 50kDa cross-reacting with the antibody in the microsomes from diabetic
animal's livers than in the microsomes from starved and fed animals. If the protein
at approximately 35kDa recognised by anti-Tl IgG is the glucose-6-phosphatase
catalytic subunit this would be consistent with there being more glucose-6-
phosphatase catalytic subunit protein in microsomes from livers of diabetic animals
(Cain & Burchell 1985). However, the increased latency of microsomes from livers
of diabetic animals has been suggested as indicating that there is no increase in
number of T1 protein units in diabetes (Arion et al 1980b) rather than differing
relative capacities for glucose-6-phosphate transport and hydrolysis. However if one
of the two strong bands was T1 there was undoubtedly more of it in the diabetic
microsomes (the band was darker).
When normal human liver homogenate was immunoblotted and stained using anti-
Tl IgG (Figure 5.3.4) the antibody cross-reacted most strongly with the protein of
approximately 35kDa - the 50kDa band was recognised, but less strongly. Many
antibodies raised to proteins in one species do not cross react strongly with the same
protein in another species; however the antibody to the rat catalytic subunit cross
reacts well with the human protein which indicates strong preservation of sequence
of the protein between the two species. It may be expected therefore, that the
sequences of other proteins of the glucose-6-phosphatase system are also well
preserved across species.
Unfortunately I did not get the opportunity to immunostain with the anti-Tl IgG on
a sample of liver from a patient shown by standard kinetic analysis to have type lb
GSD as such patients are rare.
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a b c d e
Figure 5.3.4
Immunostained Western blot of a 7-20% SDS-polyacrylamide gel using anti-Tl IgG
as the primary antibody. Lanes (a to e) contained 80, 40, 24, 8, & 4 /xg protein
respectively from homogenate of normal human liver.
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b) Affinity chromatography with anti-Tl Anti-Tl IgG was bound to Sepharose
beads as described in 2.7. Lubrol solubilised diabetic rat liver microsomes were
passed down a Sephadex G-25M column (to remove the lubrol) and then onto the
anti-Tl/Sepharose column. Protein was eluted from the anti-Tl/Sepharose column
(after 1 hour incubation at room temperature) with glycine.
Fractions from the anti-Tl/Sepharose column were separated on 10% SDS-PAGE
and then silver stained. As Figure 5.3.5 shows a number of protein bands were
seen. This is a common finding with early runs of an affinity column where all non¬
specific binding sites on the Sepharose may not have been blocked. In later fractions
one strongly staining band was seen at an approximate molecular weight of 66kDa
(Figure 5.3.6) - the same apparent molecular weight as the original protein isolated
by the DIDS column.
c) Assay data with anti-Tl Glucose-6-phosphatase activity in the presence of
differing amounts of anti-Tl IgG was measured in microsomes prepared from
starved and diabetic rat livers. The results of the assays performed are shown in
Table 5.3.1. Time only allowed for a small number of "range-finding" assays to be
performed hence the marked incompleteness of this data. No statistical analysis of










Silver stained 10% SDS-polyacrylamide gel. Lanes (a to e) each contained 100/xl of
fraction numbers 1,7,9,11 and 13 respectively eluted from the first run of an anti-
Tl/Sepharose affinity column loaded with microsomal protein from diabetic rat
livers. The protein content of the fractions was not determined.
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Silver stained 10% SDS-polyacrylamide gel. Lanes (a,b & c) contained 100/d each
of fractions 8,12 and 14 eluted from a later run of the anti-Tl/Sepharose affinity
column than those in Fig. 5.3.5. The protein content of each fraction was not
determined.


























































No real conclusions can be drawn from these data. The anti-Tl IgG did not show an
obvious effect on the glucose-6-phosphatase system in either type of microsome
used.
The direct radionuclide assay of glucose-6-phosphate transport capacity (as
described in 2.6.2) was not used as the biggest effect of anti-Tl IgG on microsomal
glucose-6-phosphate transport should have been seen in microsomes from diabetic
rat livers, where T1 capacity is most limiting to total glucose-6-phosphatase
activity. It has not proved possible to perform this radionuclide assay using
microsomes from diabetic livers as these microsomes rapidly block the
nitrocellulose filter. Using nitrocellulose with a bigger pore size did not help this as
a significant proportion of the microsomal protein appeared to not then bind to the
filter but passed straight through into the effluent.
There is no reason why the anti-Tl IgG should affect T1 capacity. However if an
obvious effect had been seen it would have been further confirmatory evidence that
the antibody was indeed directed against Tl. The antibodies to two other
components of the rat hepatic microsomal glucose-6-phosphatase system do not
affect the activity of these components - the anti-catalytic subunit and anti-
phosphate/pyrophosphate transport protein (T2) antibodies have no inhibitory effect
on their target proteins. The recently isolated antibody to T3/Glut 7 however does
appear to inhibit the function of this glucose transporter (Waddell et al 1991)
5.3.3 Discussion
The presence of a single protein band at an apparent molecular weight of 66kDa on
an SDS polyacrylamide gel when stained by the silver staining technique I used
would be accepted by most workers as proving that a single protein had been
isolated. This protein was probably a glycoprotein as shown by the up-turned ends
of the band seen by immunostaining and the smearing running up the blot when
immunostained with a polyclonal IgG (Figure 5.3.3).
151
However not all proteins take up silver stains when denatured in SDS gels, so it is
possible that these fractions contained more than one protein. This may explain why
a polyclonal antibody raised to these fractions recognised more than one protein on
immunoblotting of microsomes. Alternatively the polyclonal antibody may be
recognising similar amino acid sequences on more than one protein.
There is no proof that the 66kDa protein isolated by affinity chromatography with
DIDS/Sepharose or either the 50 and 35kDa proteins then immunostained is the
glucose-6-phosphate transport protein or even a component of the glucose-6-
phosphatase system. There is some circumstantial evidence that the antibody raised
to this protein is recognising at least one component of the glucose-6-phosphatase
system (Figure 5.3.3). The cross-reactivity of the antibody raised to the 66kDa
protein with a glycoprotein of approximate molecular weight 35kDa and the fact
that by immunoblot analysis there is more of the 35kDa protein in microsomes from
diabetic rat livers than in microsomes from starved and fed animals is compatible
with the fact that there is more catalytic subunit protein (molecular weight 36.5kDa)
in microsomes isolated from diabetic rats livers than from the livers of starved
animals (Burchell & Cain 1985). DIDS binds to glucose-6-phosphate binding sites
therefore it is possible that both T1 and catalytic subunit were bound by the
DIDS/Sepharose affinity column. The glucose-6-phosphatase catalytic subunit
protein dose not take a silver stain well and so may in fact have been present in the
fractions. There is no evidence for increased amounts of T1 protein in diabetic rat
liver microsomes, and Arion et al (1980b) claimed that the capacity of T1 is not
increased in microsomes from diabetic rat livers compared to microsomes from
starved animals: hence the increased latency of glucose-6-phosphatase activity in
microsomes from diabetic animals.
It is possible that the original protein isolated from the DIDS/Sepharose affinity
column and the larger of the two proteins strongly reacting to anti-Tl IgG on
immunoblot analysis (Figure 5.3.3) represent the same protein and the apparent
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difference in molecular weight is due to the immunoblots being performed on
gradient gels, the inaccuracy of the molecular weight markers, differing
glycosylation states of the proteins or any combination of these three reasons.
However as suggested above, affinity chromatography using DIDS/Sepharose as
ligand may have bound more than one protein component of the glucose-6-
phosphatase system from solubilised microsomes but only one of which then
appeared on silver stained SDS polyacrylamide gels. Countaway and Arion (1986)
showed labelling of (at least) six hepatic microsomal proteins using tritiated DIDS
and from this concluded that the purification of T1 could not be achieved using
DIDS. However they also demonstrated that washing microsomes markedly
increased DIDS binding sites (I deliberately did not wash the microsomes I used)
and that DIDS bound covalently to the glucose-6-phosphate binding site.
Very recently work in Ann Burchell's laboratory on the rapid binding of
glucose-6-phosphate to microsomal proteins has identified a protein of molecular
weight approximately 35kDa (smaller than the glucose-6-phosphatase catalytic
subunit). This work is, at the time of writing, very preliminary and is not
published, however it agrees with my data above and would be compatible with the
postulation that the fractions from DIDS/Sepharose binding did contain a protein
which (as is the case with the catalytic subunit) does not silver stain. Antibody
raised to these fractions recognised a microsomal protein of molecular weight
approximately 35kDa (Fig 5.3.3) which may in fact turn out to be T1 and not the
glucose-6-phosphatase catalytic subunit as I initially assumed. (In retrospect the
early fraction lanes in Figure 5.3.1 may show a faint band at an approximate
molecular weight of 30kDa).
The protein I identified by silver staining was larger than the 54kDa protein
described by Zoccoli in 1982. This 54kDa protein isolated by Zoccoli et al using
tritiated DIDS binding and which was postulated as T1 is not likely to be so.
Zoccoli et al did not produce any subsequent corroborative evidence that the protein
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they had isolated was the glucose-6-phosphate transporter. Countaway and Arion
(1986) showed that this protein was not T1 and then Ananthanorayanan et al (1988)
showed that it was likely to be a hepatocyte cell membrane sodium independent
transporter for organic anions such as bilirubin and bromsulphthalein. DIDS cross-
reacts with many microsomal and cell membrane proteins - especially anion
transporters (Countaway & Arion 1986 and Cabantchik & Rothstein 1972
respectively). It is likely that Zoccoli et al had hepatic cell membrane contamination
in their microsomal preparation. I was aware of the increase in microsomal DIDS
binding sites shown by Countaway and Arion (1986) and so tried to treat the
microsomes that I used as little as possible. It is encouraging that in my microsomal
preparations very few proteins were recognised by the anti-Tl antibody - if the
DIDS column had isolated a common protein or a cell-membrane protein it is
unlikely that this pattern of 2 strong bands on immunoblot analysis would have been
seen.
The definitive proof of any isolated protein being a microsomal transport protein
would be the reconstitution of the protein into lipid vesicles and the subsequent
demonstration of substrate (glucose-6-phosphate) uptake into vesicles which have
had the protein incorporated into them. This kind of work is complicated and very
time-consuming (see Racker 1985 for a review). It was felt that, at least initially, it
would be worthwhile doing the simpler screening tests of the protein shown above
using the polyclonal antibody raised to it in the sheep. Unfortunately time was a
major limiting factor to completing even the initial work on identifying the protein.
In retrospect it may have been better to use later batches of serum to produce IgG as
the antibody production to the inoculated protein may have been greater. However
none of the serum was disposed of and further work is under way with it and the
proteins described above.
Subsequent studies on an isolated protein would be performed on the peptide
isolated by the anti-Tl column, the peptide being eluted from the gel. It is unlikely
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that a protein isolated in this fashion would be active, but the structure or sequence
of the peptide could be found and antibodies more specific to the protein component
of T1 could then be raised.
5.4 STUDIES ON THE MECHANISM OF GLUCOSE-6-PHOSPHATE
TRANSPORT
5.4.1 Biochemical mechanism
In order to prove that an isolated protein was T1 it would be necessary to
demonstrate glucose-6-phosphate uptake when the protein was reconstituted into
liposomes. As well as having a protein it would be necessary to know the
biochemical mechanism of glucose-6-phosphate transport. Also, in order to target
pharmacological agents to manipulate T1 activity in vivo, a knowledge of this
mechanism would be vital. Nothing was known at all of the mechanism of
microsomal glucose-6-phosphate transport when this thesis started.
Arion et al (1980b) had suggested that glucose-6-phosphate transports across the
microsomal membrane as a divalent anion. In order to maintain charge and pH
neutrality on both sides of the microsomal membrane it would be necessary
therefore that glucose-6-phosphate either cotransports with a cation or exchanges
with another anion.
It was decided to investigate the former possibility, and to concentrate on sodium as
the cotransported cation. The reasoning behind this decision was that
transmembrane sodium transport is a common method of controlling intra- and
extracellular milieu and sodium is not the predominant intracellular cation making it
a logical ion to control transport across the endoplasmic reticulum membrane. The
effect of sodium on microsomal glucose-6-phosphate transport had not been
properly examined. DIDS is also recognised to interact with anion transport proteins
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(Cabantchik & Rothstein 1972) and has a marked effect on T1 function (Arion et al
1978 & 1980b and Zoccoli et al 1980 & 1982).
To investigate the effect of sodium on hepatic microsomal glucose-6-phosphate
transport it seemed logical to remove as much sodium as possible from the assay
media and observe the changes in glucose-6-phosphatase activity.
When this "low sodium" system (prepared as in 5.2.2) was first used the effects on
glucose-6-phosphatase activity, and especially glucose-6-phosphate transport seemed
clear (Table 5.4.1). The Km of the intact microsomes rose markedly (implying
decreased glucose-6-phosphate transport capacity) when assayed with potassium
glucose-6-phosphate substrates compared to microsomes assayed with sodium
glucose-6-phosphate substrates. This Km change was reversed by the addition of
ImM NaCl to the potassium substrate before the "low-sodium" microsomes were
added. There was no significant difference in glucose-6-phosphatase activity
between the "low sodium" and "normal" disrupted microsomes using sodium
glucose-6-phosphate substrate.
Another difference between the "low-sodium" and normal assays was the absence of
EDTA in the potassium salt substrates. This has been shown to not significantly
alter glucose-6-phosphatase activity (Mithieux et al 1990). Assaying "normal"
microsomes with potassium glucose-6-phosphate substrates showed virtually normal
activity, also implying that potassium was not inhibiting glucose-6-phosphate


































Disruptedmicrosomes Km (mM) 0.5±.05 0.7±1 0.6+1 1.6±0 3 0.7±1 0.76+.1
Vmax (jumol/min/mg) 0.26±02 0.24±02 0.26+.01' 0.66±07 0.53±05 0.50+.1
Datareme n+SEMof4ss ys(9sf rthl wodiumwithnoadditive)
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The range for the measured Km in both microsomal preparations using potassium
glucose-6-phosphate substrates was large (8.1 to 6.9xl0^mM for the starved and
8.7 to 3.5xl0^mM for the diabetic microsomes). These numbers are meaningless as
values; Kms as high as these are theoretical rather than a practical measurement, but
the data do demonstrate quite clearly that in the "low sodium" system very little
glucose-6-phosphate transport is occurring.
Microsomal preparations usually maintain their kinetic activity for around 3 months
when stored at -70°C. These "low-sodium" microsomes, however started losing
their activity after about 4 weeks storage at -70°C. I wanted to be sure that this data
was reproducible. Therefore I prepared another batch of "low-sodium" microsomes
from livers of starved rat livers. Only starved animals were used to prepare these
microsomes as I wanted to perform radionuclide glucose-6-phosphate transport
assays and it has not yet proved possible to perform this assay on microsomes from
diabetic livers as they choke the nitrocellulose membrane. This choking blocks the
filter meaning that the drainage of incubation mix is very slow or non-existent, but
always unpredictable. In order to interpret the results of retained radionuclide in
terms of glucose-6-phosphate transport it is necessary to know the time of
incubation of microsomes with the radionuclide. Attempts were made with
nitrocellulose with a larger pore size using microsomes from livers of diabetic
animals, but the microsomal protein passed straight through the filter without
binding.
The second preparation of "low-sodium" microsomes appeared identical to the first
and the same buffers and salts were used (but freshly prepared). The intact
microsomes again demonstrated a high Km when assayed with potassium glucose-6-
phosphate, however this was not restored to normal by adding up to 20mM sodium
chloride. This batch of microsomes appeared even less stable on storage at -70°C
than the first batch as they started losing their activity within 2 weeks of
preparation. Therefore a third batch of "low sodium" microsomes was prepared
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from the livers of starved rats using the technique described above. This batch
showed the by now expected high Km in intact structures using potassium G6P
substrate which appeared "normal" in disrupted structures and when assayed with
sodium G6P (and EDTA containing) substrates.
By this time I had stopped performing full kinetic analysis on each batch of
microsomes with each additive. The ImM glucose-6-phosphate substrate without
histone was used to screen all microsomes and additives. When the measured Km
increases, the activity at low substrate concentrations becomes very low.
The addition of up to lOmM sodium chloride did not reduce the high Km of low
metal ion microsomes (ie increase the activity measured) assayed with 1mM KG6P.
The effects of adding other anions than sodium to these "low sodium" microsomes
was investigated (Table 5.4.2) and resulted in little or no increase in the activity
with ImM KG6P as substrate.
Table 5.4.2
The effect of adding other anions than sodium to "low sodium" microsomes
prepared from livers of starved rats. All assay data presented is glucose-6-
phosphatase activity (pimol Pi produced/minute) using ImM KG6P as substrate.
Anion added Activity Range Number of assays
nil 0.02 0.02-0.02 5
5mM KC1 0.03 0.02-0.04 4
5mM CsCl 0.02 0.02-0.02 3
5mM NH4C1 0.025 0.02-0.03 4
The addition of ImM sodium acetate to the "low sodium" microsomes had the same
effect as adding ImM sodium chloride indicating that it was the sodium that was
missing rather than an excess of chloride which was the underlying problem
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(activity in the presence of ImM Na acetate = 0.027 /xmol/min and of ImM NaCl
= 0.02;umol/min: activity with ImM Na G6P = 0.09|iimol/min on the same
preparation).
The addition of 5mM potassium chloride to "low sodium" microsomes prepared
from starved rat livers showed no evidence of glucose-6-phosphate transport
inhibition indicating that the lack of T1 activity was not due to potassium inhibition
of the microsomes assayed with KG6P (activity with ImM Na G6P =
0.07/xmol/min and with ImM Na G6P + 5mM KC1 = 0.08/xmol/min on the same
preparation).
It was also clear that these "low sodium" microsomes were exhibiting extreme
temperature instability (the glucose-6-phosphatase activity was decaying much faster
at -70°C than in "normal" microsomes). As the glucose-6-phosphatase stabilising
protein (required for normal catalytic subunit activity) is a calcium-binding protein
(Waddell & Burchell 1987b) and the preparation of these "low sodium" microsomes
involved the removal of all cations as far as possible except potassium, the additive
effect of small amounts of calcium chloride to the "low sodium" microsomes was
tried. The results of these assays are presented in Table 5.4.3.
Initially ImM nitrilotriacetic acid (NTA) was added with the calcium in an attempt
to control the concentration of free calcium in the assay (after Scott et al 1980).
Waddell et al had already reported the effects of lOOmM NTA on glucose-6-
phosphatase activity - increased disruption of intact microsomes and inhibition of
the catalytic subunit activity in disrupted microsomes (Waddell et al 1990). I hoped
f
that these effects would not be seen at the smaller concentration of NTA (ImM)
used here. From the data in Table 5.4.3 it is obvious that this hope was not
justified, but more importantly it appeared that the addition of NaCl and CaCl2
(even in microsomes which were losing their glucose-6-phosphatase activity in the
presence of NTA) was sufficient to restore normal glucose-6-phosphatase activity to
intact "low sodium" microsomes when assayed with potassium glucose-6-phosphate.
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Table 5.4,3
Effect of assaying "low metal ion" microsomes prepared from livers of starved rats
assayed with the additives and substrates indicated in the table.
al ImM K G6P as substrate:




NTA + Ca2+ ** 0.054 0.179
NTA + NaCl*** 0.063 0.187
NTA + Ca2+ + NaCl 0.107 0.172
bl ImM Na G6P as substrate
Additive Activity no histone Activity +histone
Nil 0.085 0.228
Key: * NTA = ImM Nitrilotriacetic acid
** Ca2+ = sufficient CaCl2 to have 1.41/xM free Ca2 +
*** NaCl = ImM NaCl
These microsomes will now, therefore, more properly be called "low metal ion"
microsomes.
The amount of free calcium used in the above assays was determined by adding
increasing amounts of calcium to ImM KG6P and assaying the "low metal ion"
microsomes in the presence of ImM NTA. The amount of calcium which was the
lowest to give the maximal increase in glucose-6-phosphatase activity was chosen.
This was equivalent to a free calcium concentration of 1.41juM in the assay (see
161
Scott et al 1980) but does not allow for the non-specific binding of calcium by
microsomes.
NTA was used in an attempt to control free calcium concentrations as there is a lot
of non-specific calcium binding to microsomes and high calcium concentrations
(mM) will cause clumping and precipitation of the microsomes.
From the results of the above experiments I designed a set of experiments to test the
hypothesis that both sodium and calcium are required for microsomal glucose-6-
phosphate transport. On the same day three different types of microsomes were
prepared from starved Wistar rats. One preparation was of normal microsomes;
another was of "low metal ion" microsomes as described above; and the third was
of "low metal ion" microsomes prepared in the presence of 100/iM calcium chloride
in the 0.25M sucrose/5mM HEPES buffer. These microsomes were assayed on the
day of preparation or were frozen immediately at -70 °C and assayed within 48
hours. No NTA was used. The results of all these assays are shown in Tables 5.4.4
a, b and c. The concentrations of sodium and calcium chloride used in these assays
were chosen to be deliberately excessive based on the assays with the earlier batches
of "low sodium" microsomes. I was not, in these experiments, as much interested in
the fine tuning of the relative concentrations of the two cations required as in the
demonstration of a combined effect.
The data in Tables 5.4.4 a,b & c demonstrate clearly that the addition of millimolar
concentrations of sodium chloride and micromolar amounts of calcium chloride to
the "low metal ion" microsomal glucose-6-phosphatase system successfully restored
the Km of intact microsomes to normal, but that the addition of just sodium or
calcium chloride at these concentrations has a less marked effect. From the kinetic
analysis of glucose-6-phosphatase activity of starved liver microsomes demonstrated
first by Arion et al (1980a) the Km of intact microsomes is an indirect estimate of
the capacity of the glucose-6-phosphate transport protein, Tl.
Table5.4.4 Resultsofglucose-6-phosphatasea sayp rformednmicr somesp epar dfrst rv dtliv nt ed ya y dfr hrft r onefreeze/thawat-70°Cwithin48h ursfpreparation.





3.3±0 5 6.6±3 1 3.7+1 9
Vmax (/Limol/min/mg) 0.16±02 0.14±05 0.12+04
Disruptedmicrosomes
Km (mM)
0.5±1 1.4±0 3 1.4+0 8
Vmax (^mol/min/mg) 0.26±03 0.31±03 0.31+.
CT\
Table5.4.4continued Glucose-6-phosphatasea sayd tonspeciallyrepar dstarv tliv rmicro omes,






































































Therefore the above data (Tables 5.4.4 a,b & c) suggests that these concentrations
of sodium and of calcium are required for normal hepatic microsomal glucose-6-
phosphate transport. The relative amounts of sodium and calcium that were required
to restore normal glucose-6-phosphate transport capacity suggested that sodium was
co-transporting with glucose-6-phosphate and that calcium was required to enable
the microsomal protein(s) to transport both. The exact amount of both of these
cations that are required is not clear from this data. The amount of free ionised
calcium in the assay conditions here is impossible to estimate as there is significant
non-specific binding of calcium by "normal" microsomes and presumably even
more by "low metal ion" microsomes. It is possible that less than micromolar
amounts of calcium are sufficient for normal microsomal glucose-6-phosphate
transport. The glucose-6-phosphatase stabilising protein is a calcium-binding protein
with an affinity for calcium in the micromolar range (Waddell & Burchell 1987b)
raising the possibility that the stabilising protein is not only necessary for catalytic
subunit activity but is also required for normal activity of the glucose-6-phosphate
transport protein.
The data in Tables 5.4.4 b & c also shows that the Km of the disrupted microsomes
is higher with potassium than sodium glucose-6-phosphate. This implies that the
catalytic subunit has less affinity for the potassium salt. Perhaps there is potassium
inhibition of glucose-6-phosphate binding to the catalytic subunit. This is a
significant finding as it had been previously thought that the kinetics of microsomal
glucose-6-phosphatase activity was the same irrespective of the salt of glucose-6-
phosphate used as substrate.
In order to demonstrate that the above hypothesis of sodium co-transport with
glucose-6-phosphate was correct the radionuclide assay of microsomal glucose-6-
phosphate transport described in 2.6.2 was used.
As glucose-6-phosphate transport has been demonstrated across the microsomal
membrane (Waddell & Burchell 1987) but sodium transport has not, initially
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attempts were made to follow time-dependent sodium influx across the membrane of
"normal" and "low metal ion" microsomes in the presence and absence of glucose-
6-phosphate using lubrol-disrupted microsomes as controls. These assays were very
inconclusive. Figure 5.4.1 shows the best and worst of these attempted assays. The
background levels of sodium measured in both intact and disrupted microsomes was
often high and masked any glucose-6-phosphate-induced effect.
It also became clear that in the presence of lubrol, mannose-6-phosphatase latency
was not a reliable indicator of microsomal intactness. This proved to be due to
detergent inhibition of mannose-6-phosphatase activity at a lubrol concentration
much greater than 0.3% (see Figure 5.4.2). Following this discovery (which was
made after the observation that mannose-6-phosphatase activity which was
apparently low in the presence of lubrol did not increase in the presence of histone
2A) I used the increase in activity of the microsomal 1-naphthol
glucuronosyltransferase as an assessment of microsomal intactness as this enzyme is
much less sensitive to lubrol inactivation (see Figure 5.4.2).
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I then compared the accumulation of Na in intact microsomes before and after a 2
minute incubation in the presence of ImM G6P and 4mM NaCl using, as controls,
the same microsomes in the absence of G6P as control rather than detergent-
disrupted microsomes. This was a truer control than the disrupted microsomes and it
made the G6P-dependent sodium uptake more obvious. Figure 5.4.3 shows the
results of these incubations in the three microsomal preparations described above:
normal; low metal ion; and low metal ion plus lOO^tM CaCl2- The graph shows the
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percentage Na retained by the microsomes after 2 minutes incubation taking an
incubation time of 15 seconds as 100%. (15 seconds after the start of the incubation
was the shortest possible sampling time to allow for adequate mixing). Any
significant sodium uptake by the microsomes in the first 15 seconds would amplify









Results from two apparently identical assays following the glucose-6-phosphate-
99
dependent flux of Na into low metal ion microsomes as described in the text.
Plate (a) clearly shows glucose-6-phosphate dependent uptake. However plate (b)
shows high uptake of sodium even in the absence of added glucose-6-phosphate.
The only difference between the two assays can only have been some contamination
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Figure 5.4.2





















99Results of assays measuring uptake of Na by three different preparations of
microsomes prepared from livers of starved Wistar rats. The clear requirement for
calcium is shown. Details of the three microsomal preparations are given in the text.
99Results are expressed as a percentage of total Na in the reaction mix using the
uptake in control assays (no glucose-6-phosphate) as 100%. Data is mean ± SEM
of at least 4 assays.
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The effect of other divalent cations on microsomal glucose-6-phosphatase activity
was examined using a single concentration (1.4mM) of glucose-6-phosphate and the
colourimetric assay. 1.4mM glucose-6-phosphate was used as substrate so that low
glucose-6-phosphatase activity could be more accurately measured. The results of
these assays are shown in Table 5.4.5. The 1.4mM G6P substrate would also be
more accurate than ImM G6P at assessing falls in glucose-6-phosphatase activity
but not too high that any change would reflect a Vmax effect rather than a Km one.
The data in Table 5.4.5 shows that several divalent metal cations can affect the
activity of both intact and disrupted normal and "low metal ion" microsomes using
sodium and potassium glucose-6-phosphate substrates. A higher percentage value in
Table 5.4.5 infers a lower Km and thus a greater affinity of the glucose-6-phosphate
transporter or glucose-6-phosphatase catalytic subunit for the glucose-6-phosphate
salt. The change in glucose-6-phosphatase activity was largest in intact microsomes
using potassium glucose-6-phosphate as substrate and there was little difference
between the metal cations used. However the data presented above and the data on
the glucose-6-phosphatase stabilising protein make it likely that calcium is the cation
involved in vivo. There was also little difference between the normal and low metal
ion microsomes in terms of percentage increase in activity with the added metal ions
(the absolute values were still very different). Why there is an increase at all in the
glucose-6-phosphatase activity of normal microsomes is not clear. The affinity for
the potassium salt of glucose-6-phosphate by T1 is lower than for the sodium salt
and this may be overcome by the addition of small amounts of divalent cation.
Alongside this it may be that metal ions themselves increase glucose-6-phosphatase
activity, especially in the presence of potassium glucose-6-phosphate.
Table5.4.5 Relativeglucose-6-phosphatasectivitywit1.4mMglucose-6-phosphateinriv ricro om sfr mt rv drw hd fferentv l t metalcationsadded.V lurp rc tageofc rolgl ose-6-phosphataseactivity1.4mMG P.Allmicr somesw rrt n 96%intactsc lculatedfrommannose-6-phosphatelatency.
a)Intactmicrosomes Additive Control CaCl2MnCl2MgCl2CoCl2NiCl2
blDisruptedmicrosomes Control CaCl2MnCl2MgCl2CoCl2NiCl2
Normalmicrosomes SodiumG6P 100,94 162 149 no,97** tt # 100 90*104,94a113/89
Normalmicrosomes PotassiumG6P 100 278mIII« 241 254 100 129 119 137 126 130## # m tttt **
"Lowmetalion"microsomes PotassiumG6P ##100 179 217 247## 252S262 ***100 111 116 127™ 122## 137
Key:
* p<0.5# .05**p< 05**p< .01## . 005 pvaluescalc latedforeachssayconditionag instthontrolv lueft aco dition
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The inter-relationship between hepatic microsomal glucose-6-phosphatase activity
and divalent metal ions (especially calcium) is a complex one (see, for example
Benedetti et al 1985 & 1987, Fulceri et al 1991, Mithieux et al 1990, van de Werve
1989 & Waddell et al 1990). Waddell did show that calcium (at high concentrations
up to lOmM) increased T1 capacity in normal microsomes, but at the concentrations
used had a more marked stimulatory effect on the activity of the T2
phosphate/pyrophosphate transport protein. At ambient calcium levels above lOmM
microsomes clump thus a decrease in glucose-6-phosphatase is measured (Beaufay
& de Duve 1954 and Kamath et al 1971).
The increase in glucose-6-phosphatase activity seen in disrupted microsomes with
added cations and potassium glucose-6-phosphate as substrate is less than that in
intact microsomes and probably reflects a decrease in affinity of the catalytic
subunit for potassium glucose-6-phosphate which can be overcome by small
amounts of added divalent cations. This change in activity was not seen in normal
disrupted microsomes with sodium glucose-6-phosphate substrate.
As well as showing the importance of sodium and calcium ions in microsomal
glucose-6-phosphatase activity, these data also indicate that the use of differing salts
of glucose-6-phosphate will produce different glucose-6-phosphatase kinetics.
Therefore workers should stipulate which salt they have used, or if directly
comparing results this comparison should be done on data using the same salt as
substrate.
5.4.2 Discussion
This data demonstrates for the first time the ionic dependence of glucose-6-
phosphate transport across the hepatic microsomal membrane. It is important to
understand this key step in hepatic glucose production and will make the assessment
of the glucose-6-phosphate transport capacity of an isolated T1 protein possible.
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Designing agents to pharmacologically manipulate T1 capacity could also be
targeted at this.
Sodium co-transports with glucose-6-phosphate across the rat hepatic microsomal
membrane and a divalent cation (probably calcium) is required for the normal
transport of one or both. The data on sodium transport using trace amounts of
radioactive sodium implied that this is not the only mechanism for sodium transport
across the microsomal membrane.
The assumption made by Arion that glucose-6-phosphate transports as an anion
appears correct. However in the same paper (Arion et al 1980b) it was suggested
that sodium was not involved in glucose-6-phosphate transport. This statement was
based on data showing a lack of change in glucose-6-phosphatase activity in intact
rat hepatic microsomes by removing sodium from the buffers used to prepare the
microsomes which were then assayed in substrates containing 20mM sodium salts as
buffers of pH (and presumably other contaminating cations). The data above shows
that 4mM sodium and only contaminant trace amounts of a divalent cation are
sufficient for normal activity which explains Arion's error.
Sodium is the predominant extracellular cation with low intracellular concentrations,
making it the logical cation to control transport across the endoplasmic reticulum
and thus preserve electrostatic neutrality. The stoichometric ratio of sodium to
glucose-6-phosphate transporting via T1 has not been determined: on a purely
electrostatic basis it should be 2:1. No extrinsic source of energy was added (eg
ATP or GTP), therefore the transport of glucose-6-phosphate is facilitative down a
concentration gradient. Sodium presumably follows the glucose-6-phosphate to
preserve ionic charge balance.
The data above does not demonstrate whether glucose-6-phosphate and sodium co-
transport using the same or a different protein. The glucose-6-phosphate transport
system of E. coli has been well characterised and DNA analysis has shown that it
comprises at least 4 subunits (Weston & Kadner 1987). The evidence at present is in
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favour of E. coli glucose-6-phosphate transport occurring down a phosphate
concentration gradient rather than being driven by cation co-transport (Sonna et al
1988). If the mammalian system has developed from this then it is possible that the
regulatory sodium transport system demonstrated above is a separate but closely
linked protein to the glucose-6-phosphate transport protein.
Divalent metal cations decreased the Km of intact and disrupted microsomes (even
normal microsomes) assayed with potassium glucose-6-phosphate. It seems that T1
and the glucose-6-phosphatase catalytic subunit have less affinity for potassium
glucose-6-phosphate than for the sodium salt and divalent cations appear to
overcome this decrease in affinity. The mechanism of this effect is unclear. Possible
effects of the metal ions could be conformational changes in the glucose-6-
phosphate binding sites or activation of "latent" molecules thereby changing the
affinity of these molecules.
Previous studies examining the relationship between calcium and microsomal
glucose-6-phosphatase activity have been confusing, largely, it has transpired
because the effects of the buffers used. However recently it has been clearly shown
that NTA (Waddell et al 1990) and EGTA (Mithieux et al 1990) will both affect
glucose-6-phosphatase activity in intact and disrupted microsomes as well as
controlling free calcium levels. Therefore work using these buffers (for example
van de Werve 1989) cannot be accurately interpreted and the conclusion of van de
Werve in this paper that physiological levels of calcium inhibit T1 activity in
microsomes and in permeabilized hepatocytes is wrong as he did not appreciate the
effect of the EGTA. However EDTA appears to have little effect on microsomal
glucose-6-phosphatase activity (Mithieux et al 1990).
There is significant and variable binding of calcium by rat liver microsomes
(Sampson & Karler 1963 and Sanui & Pace 1967). As it is difficult to control levels
of free calcium in glucose-6-phosphatase assays without the buffers interfering with
the assays (Mithieux et al 1990), workers who have shown inhibition of microsomal
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glucose-6-phosphatase activity with calcium (Beaufay & De Duve 1954 and Nordlie
& Arion 1965) have often used so much calcium (> lOmM) that microsomal
aggregation will have occurred (Kamath and Narayan 1972 and Waddell et al
1990).
Waddell et al showed that calcium activates both glucose-6-phosphatase and
pyrophosphatase activity in intact microsomes (Waddell et al 1990), but it appeared
then that from rapid filtration transport assays (using normal microsomes) that the
major effect was on pyrophosphate transport and the effect on T1 activity was taken
to be secondary to increased phosphate removal from the lumen of the microsomes
by T2. Waddell's data appears initially to contradict the data presented above,
however Waddell used "normal" microsomes and showed no effect with <0.5mM
added calcium, in contrast to the "low metal ion" microsomes above which showed
an effect on glucose-6-phosphate transport with 50/nM added calcium in the
presence of > ImM sodium. At "physiological" calcium and glucose-6-phosphate
levels, calcium has been shown to have no effect on glucose-6-phosphatase activity
in intact hepatic microsomes (Fulceri et al 1991) which again were not prepared in
low calcium conditions. However glycogenolysis in hepatocytes is increased when
the concentrations of free intracellular calcium are raised (Cohen 1983) in response
to extracellular (eg hormonal) stimuli.
The relationship between glucose-6-phosphatase and calcium is even more complex
as it has been shown that glucose-6-phosphatase activity alters free intracellular
calcium concentrations (Benedetti et al 1985); and that in the presence of high
intracellular glucose-6-phosphate concentrations calcium uptake by microsomes is
increased (Benedetti et al 1985). Further, this pool of intra-microsomal calcium is
mobilised in response to increased inositol-l,4,5-triphosphate levels (Benedetti et al
1987). Inositol-l,4,5-triphosphate is a postulated second messenger in hepatocyte
responses to external stimuli such as hormones like insulin (Haring 1991). Similar
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effects of glucose-6-phosphate on endoplasmic reticulum calcium uptake in rat
kidney microsomes have been shown (Benedetti et al 1989).
The role of glucose-6-phosphatase and calcium in insulin release from the pancreas
are discussed in Chapter 3. Three of the cases reported above (Chapter 3) had
abnormalities of insulin metabolism as well as abnormalities of glucose-6-
phosphatase (Cases 6,7 & 8) and all three of these cases had defects of microsomal
membrane transport: further support for the role of the proteins of the glucose-6-
phosphatase system in insulin release. Insulin secretion by beta cells in the pancreas
is modulated by intracellular calcium levels changing in response to fluctuations in
blood glucose (Colca et al 1983 a & b, Rorsman et al 1984, Hellman 1985, Morgan
et al 1987 and Nilsson et al 1987). No other hormonal abnormalities were measured
in any of the above cases.
In type lb GSD (deficiency of the microsomal glucose-6-phosphate transport
protein), where the neutrophils have abnormal function, defective intra-neutrophil
calcium mobilisation has been demonstrated in response to certain external stimuli
again suggesting that T1 may be an important controller of intracellular calcium
mobilisation.
It therefore seems likely that the microsomal glucose-6-phosphate transport protein
requires calcium for normal activity and plays an important role in controlling free
intracellular calcium concentrations. It is also possible that increases in calcium
concentration can enhance the activity of the catalytic subunit and T1 (Table 5.4.5)
in the presence of > ImM potassium (which will represent the physiological state
where potassium is the predominant intracellular cation).
The requirement of calcium for the stability of glucose-6-phosphate transport and
the glucose-6-phosphatase catalytic subunit suggests that both are closely associated
with the 21kDa stabilising protein described by Burchell & Waddell (1987b).
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It did not prove possible to assess the sodium/calcium dependence of the
microsomal phosphate/pyrophosphate transport protein (T2) due to the insolubility
of potassium pyrophosphate when added to the "low sodium" microsomes.
It is possible that the reason that type lb GSD is so severe is because as well as
there being defective glucose-6-phosphate transport there is an associated reduction
in hepatic endoplasmic reticulum sodium transport. It is also possible to speculate
that the observed phenotypic differences in patients with type lb GSD (see
discussion in Chapter 3) may be explained by the fact that in some patients the T1
protein is defective, in others the sodium co-transport is abnormal and in yet others
both systems are abnormal. At present there is no evidence to support this.
5.4.3 Studies on the pharmacological manipulation of T1
The ability to pharmacologically manipulate T1 has obvious advantages. In all the
variants of the type 1 GSDs an increase in T1 capacity would increase the activity
of the glucose-6-phosphatase system as a whole (if the protein is present), thus
increasing hepatic glucose output.
Conversely in diabetes mellitus the ability to down-regulate T1 capacity would
reduce the high hepatic glucose output which is found in this condition. This theory
works in practice (at least in the non-diabetic) as proven by Case 8 in Chapter 3 -
however hyperinsulinaemia such as was found in case 8 pretreatment would not be
advantageous, as hyperinsulinaemia has been implicated in the (macro)vascular
complications of diabetes mellitus (see Reaven 1988 for review). Other secondary
effects on neutrophil function and lipid and purine metabolism may also be induced
which would make such drugs impractical for (long-term) use. However Case 8 was
not shown to have any of these abnormalities which can be found in type lb GSD.
The effect of the diuretic drug amiloride hydrochloride [3,5-diamino-6-chloro-A-
(diaminomethylene) pyrazine carboxamide] was examined. There were two main
reasons for studying this compound. Firstly it is a potent inhibitor of several trans-
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membrane sodium transport mechanisms (Sariban-Sohraby & Benos 1986 and
Grinstein & Rothstein 1986) and the data above which showed the co-transport of
sodium and glucose-6-phosphate suggested that amiloride may affect glucose-6-
phosphate transport. Secondly, amiloride has been shown to affect the
phosphorylation state of several proteins in hepatocytes as it is a non-specific
inhibitor of protein kinases (LeCam et al 1982 and Holland et al 1983) and in
particular amiloride inhibits insulin-stimulated phosphorylation of proteins. While
there is no evidence that T1 activity is modulated by phosphorylation or by insulin it
would be a logical site for insulin to exert effects on hepatocyte glucose production.
This data was published (Pears et al 1989) and a copy of the paper can be found in
Appendix A).
The effects of adding amiloride to the colourimetric assay of microsomal glucose-6-
phosphatase activity in microsomes prepared from livers of fed, starved and diabetic
microsomes are shown in Table 5.4.6.
Five millimolar amiloride hydrochloride was the smallest amount of the drug which
produced maximal effect on microsomal glucose-6-phosphatase activity. No effect
on glucose-6-phosphatase activity in any rat liver microsomal preparations was seen
with the addition of less than 0.1mM amiloride to the assay. The most obvious
effect of amiloride on rat liver microsomes was to decrease the Km of intact
microsomes to a value approaching that of the catalytic subunit - ie reducing the
latency of the microsomes. This effect was most marked in microsomes from livers
of diabetic animals where T1 capacity is most rate-limiting. The mechanism of
action of amiloride is obscure, but is not due to disruption of microsomes, rather
due to activation of T1.
Table5.4.6 Resultsofglucose-6-phosphataseac ivityinmi r omespre r dfroiv rfd,st vedans reptozotocininduc ddiab t cra ss describedinChapter2.Allmicrosomesw rm rthan89%int ctthabsencedpresencefa iloridea sess dyann se-6- phosphataseactivity. Intactmicrosomes
a)Fedanimals Control ImMamiloride 5mMamiloride b)Starvedanimals Control ImMamiloride 5mMamiloride
5jC
p=0.01;<
Km (mM) 3.3±0.4 1.8+0.1 1.4+0.2 3.8+0.5 2.3+0.4 1.6+0.3
** ** **
Vmax
(jiiM/min/mgprotein) 0.09+0.002 0.09+0.02 0.11+0.02 0.18+0.02 0.14+0.01 0.17+0.01
Disruptedmicrosomes KmV ax (mM)(/LtM/min/mgprotein) 0.5+0.10.12+0 02 0.5+0.20.11+0 02 0.5+0.10.12+0 02 1.2+0.50.32+0 05 0.9+0.40.28+0 04 0.7+0.20 25+0 01
Datareme n±SEMof>4pr p rations,eachp eparcomprisingliv rsfr6r t
Table5.4.6continued
Intactmicrosomes KmV ax (mM)(/nM/min/mgprotein)





Disruptedmicrosomes KmVmax (mM)(/zM/min/mgprotein) 1.6+0.30. 6+ .07 1.2+0.20 50+ 07 0.8+0.1*0 43+ .04
*
p=0.01;<
Datareme n±SEMof>4preparations,eachpr ti ncomprisingliv rsfr6
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The effect of amiloride on glucose-6-phosphate transport (and accumulation of
inside microsomes) as assessed by the radionuclide assay is shown in Figure 5.4.4.
The curves in Figure 5.4.4 show that in the presence of amiloride the capacity of
the glucose-6-phosphate transport protein was increased: indicated by the more
rapid initial rise in retained to a higher peak. There was a further rise in
retained to peak at about 2 minutes in the presence of amiloride. This second
rise (which was not seen in the control microsomes) reflected an increase in total
trapped in the microsomes. This measured was likely to be a mixture of
labelled glucose-6-phosphate and glucose product, suggesting inhibition of T3 by
amiloride as well as activation of Tl.
A small decrease in the Km of the catalytic subunit was also seen in fully disrupted
microsomes in the presence of amiloride. The mechanism of this is unclear and is
associated with a fall in Vmax and probably represents an inhibition of the catalytic
subunit by amiloride.
Attempts at measurements of microsomal pyrophosphatase activity using the
colourimetric assay were unsuccessful. A precipitate formed in the low-sodium
system and the assays with amiloride. This was most likely to be phosphate salts
and their presence invalidated the assay.
The therapeutic concentrations of amiloride in serum are 3-20^M (Benos 1982) and
micromolar amounts are used in vitro to inhibit transmembrane sodium channels
(see Sariban-Sohraby & Benos 1986 and Frelin et al 1987 for example). If
amiloride was inhibiting microsomal glucose-6-phosphate-linked sodium transport
then the measured effect should be an increase in the Km of intact microsomes
rather than the fall which was actually measured. This suggests that amiloride is
not, in fact, affecting Tl activity in the microsomal glucose-6-phosphatase system













Results of measurements ofU^C glucose-6-phosphate uptake by microsomes
prepared from starved rat livers in the presence and absence of 5mM amiloride as
described in the text. Data given of mean of > 4 assays ± SEM.
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This was confirmed by the addition of amiloride to colourimetric glucose-6-
phosphatase assays of "low metal ion" microsomes. The results of these assays are
shown in Table 5.4.7.
In the "low metal ion" assay system the addition of 5mM amiloride was sufficient to
remove the rate-limitation placed on the activity of the glucose-6-phosphatase
system by T1 capacity. The Km of intact microsomes in the presence of amiloride
approached that of disrupted microsomes - a situation identical to amiloride's effect
on "normal" microsomes (Table 5.4.6). Again amiloride is not working by
disrupting microsomes - the intactness of all intact microsomes as assessed by
mannose-6-phosphatase activity was greater than 85% in both "normal" and "low
metal ion" assay systems and the data in Tables 5.4.6 & 5.4.7 has been corrected
for intactness.
It is also unlikely that amiloride is acting by altering microsomal protein kinase
activity and, therefore, the phosphorylation state of T1 as no extrinsic source of
high-energy phosphate (eg ATP or GTP) was added to the system.
The simplest explanation of these data therefore is that amiloride is directly
interacting with T1 and T3 rather than affecting sodium transport. It is not clear
from this data if amiloride is increasing the capacity of a fixed number of T1
molecules, or increasing the number of active T1 molecules, each of which works at
a fixed capacity. The mechanism of the effect on T3 is likewise unclear.
The importance of this data is the first demonstration that T1 can be acutely
manipulated.
Table5.4.7 Resultsofcolourimetricglucose-6-phosphataseassayf" wm t li n"microsomespr r dfrotiv ftarvedn streptozotocin-induceddiabetira sus ngp tassiumgluco e-6-phosphatesubstrathpresencedab fmiloridecompar d "normal"microsomesassayedwiths diumgluco e-6-pho phate. Microsomal preparation a)St rvednimals Normal Lowmetali n Lowmetalion blDiabeticanimals Normal Lowmetalion LowmetalionSubstrate NaG6P KG6P KG6P+5mMamiloride NaG6P KG6P KG6P+5mMamilorideIntactmicrosomes KmV ax (mM)(/xmol/min/mg) 3.8+0.5 16.3+2.1 2.3+0.4 5.2+0.7 14.4+2.4 2.0+0.30.18+0.02 0.39+0.1 0.23+0.04 0.28+0.05 0.45+0.08 0.23+0.03
Disruptedmicrosomes KmV ax (mM)(/i ol/min/mg) 1.2+0.5 0.5+0.1 1.0+0.3 1.6+0.3 1.1+0.2 0.8+0.1




Amiloride does not affect glucose tolerance in man, unlike other diuretics, and is
unlikely to accumulate in hepatocytes to the concentrations required to in vitro
affect T1 and T3 as it has been reported not to cross cell membranes (Benos 1982).
However this is the first demonstration of in vitro pharmacological manipulation of
Tl. It may therefore become possible to pharmacologically manipulate T1 capacity
in vivo thereby increasing hepatic glucose production in patients such as those in
Chapter 3 above, and reducing the hyperglycaemia of diabetes mellitus.
The data in Table 5.4.6 also suggests that amiloride was inhibiting T3, the
microsomal glucose transporter. The fact that the Vmax of intact microsomes from
the livers of starved and diabetic rats fell in the presence of increasing
concentrations of amiloride rather than rising to approach the Vmax of the catalytic
subunit (when the Km was almost at the level of the Km of the catalytic subunit)
suggests inhibition of the catalytic subunit in intact microsomes in the presence of
amiloride by reaction product. The simplest explanation for this data and the
retention of shown in Figure 5.4.4 is that amiloride is inhibiting T3 also
resulting in an increase in glucose concentrations in the lumen of the endoplasmic
reticulum. Arion et al (1980b) demonstrated a 52% fall in the Vmax of the glucose-
6-phosphatase catalytic subunit with high glucose levels (5mM amiloride caused a
51% fall in the Vmax of the catalytic subunit) and a 53% increase in the Km of
glucose-6-phosphatase activity of intact microsomes (in the presence of 5mM
amiloride the Km in intact microsomes was 50% higher than in disrupted
structures).
Several agents have been described which will modulate microsomal glucose-6-
phosphatase activity (see Nordlie & Sukalski 1985 for a review). Most of these
effects are inhibitory and the mechanism of the effect is not clear except for
pyridoxal phosphate, phlorizin and DIDS which (amongst many protein
interactions) are known to be inhibitors of Tl (Gold & Widnell 1976, Arion et al
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1978, 1980 a & b, Zoccoli et al 1980 and 1982 and Waddell & Burchell 1987).
However polyamines and histone 2A have been shown to have stimulatory effects
on glucose-6-phosphatase activity in intact microsomes (Benedetto et al 1979,
Nordlie et al 1979a and Vergnes et al 1981). These latter effects have recently been
shown to be due to disruption of the integrity of the microsomal membrane and
removal of the rate-limitation imposed by the transport proteins rather than to
actions on parts of the glucose-6-phosphatase system. This is the basis for the
incorporation of histone 2A in the glucose-6-phosphatase assays used in this work to
assay the activity of the catalytic subunit (Blair & Burchell 1988).
The effect of amiloride as a specific activator of T1 is the first description of a
compound definitely activating T1 rather than poisoning it (with a number of other
transport systems) as DIDS, pyridoxal phosphate and phlorizin do.
Since the effect of amiloride was demonstrated on microsomal glucose-6-phosphate
transport capacity, the effect of other agents has been examined. This later data
however does not present clear effects of most of these compounds on glucose-6-
phosphatase activity and more work with them will also be needed to establish the
precise mechanism by which these compounds affect glucose-6-phosphatase. In my
opinion in order to clearly demonstrate T1 activity both the kinetic data of the
colourimetric glucose-6-phosphatase assay and the direct measure of trace
radioactive isotope uptake by microsomes is required. This data from these two
assay techniques will also be useful for characterising the inter-reactions of the
protein components of the glucose-6-phosphatase complex.
The following data summarises the effects of some compounds on the glucose-6-
phosphatase system which are suggested as being T1 effects and which have been
measured since my work with amiloride. Unfortunately most of this work does not
contain data using the direct radioisotope measure of T1 capacity.
The sulphated derivatives of dehydroepiandrosterone (DHEA-S) and oestrone (E-S)
have been demonstrated to have in vitro inhibitory effects on hepatic microsomal T1
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and, to a lesser extent, T2 capacity (Scott et al 1991). The unsulphated forms had
no such effects, but DHEA when fed to rats is well recognised to be anti-
hyperglycaemic in animal models of diabetes (Coleman et al 1982 & 1984). It is
possible that the mechanism of action for this is inhibition of T1 ± T2 by DHEA-S.
Of further interest is that the inhibitory effect of DHEA-S and E-S was reversible in
vitro by preincubation with lOmg/ml BSA (as was the microsomal T1 inhibitor
found in case 8 in Chapter 3).
Pentamidine (at pharmacological concentrations) appears to affect microsomal T1
activity in the same way as amiloride, (Scott & Burchell 1991a). The prostaglandins
T>2, E2 and F2a were shown to produce a very slight decrease in the Km of
microsomal glucose-6-phosphatase activity in intact microsomes (Orme et al 1990)
and the tricyclic antidepressant imipramine and verapamil (a calcium channel
antagonist) cause activation of glucose-6-phosphatase in intact microsomes (Scott &
Burchell 1991b). Similarly alamethicin (a pore forming antibiotic) activates glucose-
6-phosphatase in intact microsomes without apparently disrupting them (Voice &
Burchell 1991).
The in vitro effect of glycogen on the glucose-6-phosphatase system was a marked
inhibition of glucose-6-phosphatase activity in intact microsomes from livers of
starved rats (Grant & Burchell 1990a). This inhibition (a marked fall in Vmax with
a lesser fall in Km) is different to the pattern I demonstrated in the "low metal ion"
system presented above where inhibition of T1 resulted in a very high Km and a
smaller increase in Vmax. Differing methods of inhibition (eg competitive vs non¬
competitive) will result in differing patterns of kinetic constants: it is not yet known
what the inhibitory mechanisms of glycogen excess and sodium lack are. Glycogen
blocks the pores of the nitrocellulose membrane, making direct T1 capacity
measurement difficult.
The effects of ATP and GTP were assessed however by the direct radionuclide T1
assay, and both produced an increase in retained by intact microsomes. This
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peak in retained was after about 2 minutes incubation (the same time as the
second peak seen in microsomes incubated with amiloride - Figure 5.4.4) and I feel
more properly represents inhibition of T3 as indeed was postulated by the authors
(Grant & Burchell 1990b).
Amiloride (and pentamidine) added to intact hepatocytes (Grant et al 1991) showed
an apparent inhibition of glucose-6-phosphatase catalytic subunit activity. However
closer examination of this data suggests that there was in fact an activating effect of
amiloride on T1 capacity in these hepatocytes, but that this was masked by a
marked inhibitory effect on the enzyme.
The effect of pentamidine is interesting as it is well recognised to cause
hyperglycaemia in vivo (occasionally due to pancreatic beta cell toxicity - Bouchard
et al 1982 and Zhon & Ipp 1989) which may be permanent or transient and
followed by prolonged hypoglycaemia (Kapusnik & Mills 1986). The mechanisms
of the actions of pentamidine on glucose tolerance in man are unclear. Based on the
data above it would be interesting to study glucose-6-phosphatase activity in patients
with disturbed glucose tolerance induced by pentamidine. Similarly the action of
diazoxide in reducing pancreatic insulin secretion is not clear and may possibly be
via an effect on islet cell glucose-6-phosphatase. In patients taking pentamidine,
diazoxide or any drugs affecting glucose metabolism and patients with Addison's
disease (adrenal hypofunction associated with low blood glucose levels) and
Cushing's syndrome (glucocorticoid excess) the study of microsomal glucose-6-
phosphatase activity is difficult as liver biopsy is still required and impossible to do
routinely or repeatedly (for example before and after treatment). The ability to
perform such measures would give important data on the physiology of glucose-6-
phosphatase and glucose homeostasis and was, therefore further impetus to the
attempts to develop an assay of glucose-6-phosphatase activity in circulating
neutrophils described in Chapter 4 above.
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SUMMARY OF DISCUSSION
The capacity of the hepatic microsomal glucose-6-phosphate transport protein, Tl,
is rate-limiting to the activity of the whole glucose-6-phosphatase system and,
therefore, to hepatic glucose production. Little was previously known of this key
protein in glucose homeostasis. I was interested in it for two reasons: firstly because
of its key role understanding its structure and function is important to understanding
hepatic glucose production and secondly understanding the protein and its
mechanism of action will be important in trying to pharmacologically manipulate
the capacity of Tl to alter hepatic glucose production in, for example, the eight
cases presented in Chapter 3.
A rat hepatic microsomal protein of molecular weight approximately 66kDa (as
assessed from a silver stained 10% SDS gel) was isolated by affinity
chromatography using Sepharose-bound DIDS as ligand. DIDS is known to bind to
glucose-6-phosphate binding sites and is a specific inhibitor of the hepatic
microsomal glucose-6-phosphate transport protein, Tl. An antibody to the isolated
protein was raised in a sheep and the IgG fraction of serum was used to try and
identify the protein. The antibody had no obvious effect on microsomal glucose-6-
phosphatase activity in intact preparations from starved and diabetic rats. This does
not mean that the IgG antibody is not recognising the glucose-6-phosphate transport
protein as the polyclonal antibodies to the glucose-6-phosphatase catalytic subunit
protein and T2 do not affect the function of their target proteins. Immunoblot
analysis of microsomes separated by using the isolated IgG as primary antibody
identified several proteins: one at a molecular weight of approximately 35kDa and
another at about 50kDa were the most strongly recognised. There was more of both
of these proteins in microsomes from diabetic animals than starved and fed animals.
The 35kDa protein has approximately the same molecular weight as the glucose-6-
phosphatase catalytic subunit and there is more catalytic subunit protein in
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microsomes from diabetic rat livers, suggesting that the antibody has possibly
recognised the glucose-6-phosphatase catalytic subunit. However, perhaps of more
relevance is the very recent identification of a microsomal protein of approximate
molecular weight 35kDa which strongly binds radiolabeled glucose-6-phosphate
(Ann Burchell, personal communication). This suggests that the 35kDa protein
identified by the antibody I prepared may turn out to be Tl. It is possible that the
35kDa protein was present in the original fractions from the DIDS/Sepharose
affinity chromatography but did not (like the glucose-6-phosphatase catalytic subunit
protein) show well on a silver stain.
There is as yet no clear evidence that the 66kDa, 50kDa or 35kDa proteins are in
any way related to the microsomal glucose-6-phosphatase system.
Much further work on these proteins is necessary to definitely identify them. The
next major step is to reconstitute the protein(s) into liposomes and try and identify
glucose-6-phosphate uptake. This reconstitution and demonstration of glucose-6-
phosphate uptake would rely on the clarification of the biochemical mechanism of
glucose-6-phosphate transport.
In parallel with this work on isolating a protein I was able to show, using a novel
"low metal ion" method of producing microsomes and assay system, that hepatic
microsomal glucose-6-phosphate transport is associated with sodium co-transport
across the microsomal membrane. This possibility had been examined before
following the assumption that glucose-6-phosphate exists as an anion, but the earlier
investigators had added more sodium to microsomes and buffers already containing
sodium and shown no effect. Only by removing "all" sodium (by using potassium
salts) was I able to demonstrate the requirement for sodium co-transport both by
inference from the kinetics of the colourimetric glucose-6-phosphatase assay and
directly by measuring increased sodium uptake by "low metal ion" microsomes in
the presence of glucose-6-phosphate. This co-transport of a cation will preserve
electrostatic neutrality across the endoplasmic reticulum membrane and as sodium is
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not the predominant intracellular cation it would appear the logical choice to control
glucose-6-phosphate transport. The stoichiometry of glucose-6-phosphate and
sodium transport was not investigated.
As well as showing this co-transport I showed that the transport of either one or
both of glucose-6-phosphate and sodium requires a divalent metal cation (at < ptM
concentrations), probably calcium (although a number of other cations were shown
to have an effect). This raised the possibility that T1 requires the calcium-binding
stabilising protein identified by Burchell & Waddell for normal function.
The relationship between calcium and the microsomal glucose-6-phosphatase system
has been the source of much interest over many years, since the observations by
Nordlie & Johns in 1967 and 1968 that metal-binding agents inhibited catalytic
subunit activity. Much of the work has been complicated by the use of EGTA and
NTA as buffers which themselves have recently been shown to affect glucose-6-
phosphatase activity and by the fact that there is significant and variable non¬
specific binding of calcium to microsomes, such that at added calcium
concentrations approaching lOmM microsomes clump together and precipitate out.
The data above is the first on "low metal ion" microsomes. Apart from the
requirement of the stabilising protein for calcium it seems clear that glucose-6-
phosphatase (including, from my data,Tl) have a role to play in mobilising
endoplasmic reticulum calcium stores in response to extracellular stimuli such as
hormones in hepatocytes and pancreatic islets.
Following from this work on sodium I was then able to demonstrate that the
capacity of T1 could be pharmacologically manipulated in vitro by the sodium
channel inhibitor amiloride. Amiloride also appeared to inhibit the microsomal
glucose transporter T3/Glut 7. However the effect of amiloride on T1 transport was
shown to be not due to an effect on microsomal sodium transport. Since the effects
of amiloride was demonstrated, there have been attempts to show that other agents
effect T1 capacity, but this data has not always been convincing. The observed
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effects of pentamidine on glucose metabolism in man, however, would be consistent
with its demonstrated activation of T1 in the test tube. However, without using a
liver biopsy, it is still not possible to reliably study changes in glucose-6-
phosphatase activity in man (see Chapter 4).
Case 8 in Chapter 3 had already indicated that T1 could be inhibited and that the
effect of this inhibition may be beneficial to the increased hepatic glucose output
seen in diabetes mellitus.
However it is important to realise that T1 capacity can be manipulated as this can be




In this thesis I have presented the data from my studies over 2 years on the glucose-
6-phosphatase system in both man and the rat. These studies have improved the
understanding of both the clinical relevance of glucose-6-phosphatase in man and of
the biochemistry of the enzyme system with particular emphasis on the microsomal
glucose-6-phosphate transport protein, Tl.
The presentation of the ten adult cases with newly diagnosed glycogen metabolising
enzyme abnormalities in Chapter 3 and Appendix C is the most detailed description
to date of such individuals. Such patients are undoubtedly more common than has
previously been recognised. With the publication of the descriptions of these
individuals (Pears et al 1992) and the ability to investigate such patients, more cases
will be diagnosed, further helping to increase our understanding of the
glycogenolytic enzymes. Two of the cases described (numbers 7 and 8) are of
previously unrecognised abnormalities of glucose-6-phosphatase activity. Case 7 has
similar low levels of activity of all assayed components of the glucose-6-
phosphatase system to some premature infants (these data were subsequently
published by Burchell et al 1990) implying that case 7 may have had abnormal
development of the hepatic glucose-6-phosphatase system in utero. The reason for
this interruption in development is not clear from the history of her mother's
pregnancy. The patient was born 3 weeks prematurely, but so are many babies who
go on to have no problem with glycogen metabolism - possibly the development of
glucose-6-phosphatase in case 7 could not be or was not resumed after the insult
which caused the initial delay. Despite the data on the ontogeny of the human
glucose-6-phosphatase presented by Burchell et al (1990) it is not clear at which
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point her development was affected. An alternative explanation for the low assayed
glucose-6-phosphatase activity in her liver sample is a defect in the regulation of
turnover of the proteins of the glucose-6-phosphatase system. Nothing is yet known
of the turnover times of the glucose-6-phosphatase system proteins nor of the site
and regulation of expression of the genes involved. As more cases are recognised
and the regulation of the genes involved becomes apparent the nature of the
underlying defects will become clearer. Similarly case 8 was, and still is, unique in
an adult: not in his presentation with reactive hypoglycaemia but in the diagnosis of
the inhibitor of the microsomal glucose-6-phosphate transport protein, Tl, in his
liver (and presumably pancreas). This abnormality (which, interestingly did not
cause glycogen accumulation in his liver) has been identified in infants and has been
called pseudo-type lb GSD by Ann Burchell (Burchell & Gibb 1991). There are a
recognised sub-group of patients with reactive, post-prandial hypoglycaemia who,
like case 8, have marked hyperinsulinism, and a further sub-group of these in whom
somatostatin abolishes the abnormality (Baschieri et al 1989). It seems highly likely
that at least some of these people will have an identical underlying defect to case 8,
and we would be very interested to study liver biopsy samples from them. This case
is different to the other seven in that he does not appear to have a defective protein
component of the glucose-6-phosphatase system. As he was well until his late
twenties it is also possible that his abnormality was acquired. It has not been
possible to identify the nature of the Tl inhibitor in this man or in any of the infants
shown to have an inhibitor of Tl (Burchell et al 1990 and Burchell & Gibb 1991).
Many of these cases point to the role of glucose-6-phosphatase in other tissues,
especially pancreatic islets, where the proteins of the glucose-6-phosphatase system
may play an important role in the regulation of insulin secretion (and possibly
glucagon or somatostatin - see the discussion in Chapter 3).
The symptoms described by these patients were vague and often difficult to ascribe
to a single abnormality such as hypoglycaemia worsened by fasting and exercise. In
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our experience, it has often been very difficult to biochemically prove
hypoglycaemia. It is likely that patients such as these have not previously been
recognised as having an organic disease as the diagnosis was (understandably) not
considered or the appropriate investigations were not performed.
The investigations of the patients presented here indicate a clear and logical method
for investigating patients with symptoms which may be caused by hypoglycaemia. A
high index of suspicion must exist that the vague symptoms may be organic in
origin and referral to a clinical psychologist should be made after all organic disease
has been excluded (not as in the mother in Appendix C). A temporal relationship of
onset of symptoms to fasting followed by exercise and/or their improvement by
ingestion of food should especially be sought. Although liver enzyme defects such
as these may be commoner than previously recognised, there are still other, possibly
commoner causes of hypoglycaemia, such as insulinoma. A 48 hour fast with blood
samples every 12 hours (and at the time of symptoms) for glucose and insulin levels
will exclude the vast majority of insulinomas. The patients with partial glucose-6-
phosphatase (or phosphorylase kinase) abnormalities may not become
hypoglycaemic after a 48 hour fast and exercise: the investigations should proceed
in the absence of proven hypoglycaemia. A standard 75g oral glucose tolerance test
should be performed (extended if reactive hypoglycaemia such as in Case 8 is
suggested) to examine for impaired glucose tolerance or diabetes as demonstrated by
cases 6, 7 and 8 above. A glucagon test after an overnight fast as described in
Chapter 2 is the screening test which we propose and use for patients suspected of
having hepatic glycogenolytic enzyme defects. A rise in blood glucose of
>4mmol/l is taken as normal, and less than this is suspicious. This criterion of
normality is something we have arrived at after the description of Fernandes et al
(1969) and is less strict than that applied routinely to children (Dunger & Leonard
1982). The sensitivity and specificity of the glucagon test as we use it is unknown.
We have not performed liver biopsies on patients who do not meet the criterion for
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a normal response to glucagon which we have applied and nor have we performed
glucagon tests on subjects undergoing liver biopsy for other reasons. The
reproducibility of the glucagon test within the same individual on different
occasions, or the importance of the feeding state of the subject when the glucagon
test is performed is not known. It is possible, for example, that for maximum
responsiveness to injected glucagon there is a threshold time that a subject must fast
before the test is carried out. I plan to answer some of these questions regarding
glucagon test reproducibility in healthy volunteers in the near future. However until
a less invasive way of studying glucose-6-phosphatase becomes possible, most of
these problems will remain unsolved.
Three of the cases described in Chapter 3 demonstrated biochemical hypoglycaemia
after glucagon administration. Interestingly so did the majority of a pooled series of
type lb GSD patients described by Ambruso et al (1985). Unfortunately there is no
data on insulin secretion in response to a glucose load in type lb GSD patients, it is
possible that some, if not all, demonstrate hyperinsulinism to a rise in blood sugar
levels.
If a patient's symptoms are severe enough in the face of a blunted glucose response
to glucagon then a liver biopsy should be considered and discussed with the patient.
Some patients take the view that knowing the exact hepatic defect (if it exists) is not
going to alter their management and choose to have a trial of dietary therapy. This
decision is entirely understandable in view of the invasive nature of a liver biopsy,
but is frustrating for those trying to identify enzyme defects and collect as much
data as possible on these subjects (including blood for DNA analysis when the
specific gene probes for the proteins of the glucose-6-phosphatase system become
available).
Before the liver biopsy, arrangements must be made with a pathologist (for electron
microscopy) and a laboratory who regularly and reliably assay such samples for
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glucose-6-phosphatase and other enzyme activities as necessary, for rapid handling
of the liver sample.
The mainstay of treatment for these subjects has been dietary manipulation - a diet
during the day high in refined carbohydrate with uncooked corn starch
supplementation as has routinely been used for older children with type 1 GSD
patients for a number of years now. This therapy was sufficient alone for most of
the cases presented above. Case 8 was again unusual in that he required drug
treatment which was targeted at reducing his hyperinsulinism: diazoxide is a
standard therapy for pancreatic nesidioblastosis in children (hypoglycaemia due to
excessive insulin secretion from diffuse hyperplasia of pancreatic islets rather than
from a discrete insulin-secreting tumour).
The beneficial effect of oestrogen hormone replacement therapy on the symptoms of
hypoglycaemia in three women after the menopause has stimulated in vitro work on
the effects of steroid hormones on glucose-6-phosphatase activity, and some effects
have been shown (Scott et al 1991). This effect of sex hormones on glucose-6-
phosphatase is consistent with observations by clinicians of an improvement in
symptoms of hypoglycaemia (Greene et al 1981) and increased hepatic glucose
output in children with type 1 GSD around the time of puberty (Powell et al 1981,
Kalhan et al 1982 and Tsalikian et al 1984).
In all the cases described it would have been useful to have been able to make
repeated assay measurements of glucose-6-phosphatase activity in, for example, the
same individual on a number of days; in different feeding states; and especially
while on treatment with either diazoxide or oestrogen replacement. Data collected
this way would be invaluable not least to give an idea about the day-to-day
reproducibility of the assay data in the same individual. The effects of treatment
measured by changes in glucose-6-phosphatase activity would have given useful
information on the in vivo regulation of glucose-6-phosphatase.
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The natural history of these patients is unclear (apart from cases 1 and 6 above), but
they are, wherever possible, being followed as out-patients with special reference to
the development of hepatic tumours (and possibly other tumours) and the other
recognised complications of type 1 GSD.
As well as being new diagnostic entities these patients provide important
information about the glucose-6-phosphatase system and inter-relationship of the
proteins in the system in vivo.
The use of a tissue more accessible than liver for studying patients such as these,
patients with other conditions associated with abnormal glucose tolerance and
patients using treatments which interfere with glucose homeostasis is unfortunately
still not possible.
Normal adult human intestinal mucosa was proven for the first time in this thesis to
contain specific glucose-6-phosphatase (using immunoblot analysis with antibody
monospecific for the glucose-6-phosphatase catalytic subunit - Chapter 4). However
the problem of proteolysis of the samples even in the presence of several
combinations of protease inhibitors has yet to be resolved to allow reliable assay
measurements of the low levels of specific glucose-6-phosphatase activity. It is
therefore clear that intestinal mucosa is not at present a suitable tissue on which to
diagnose abnormalities of glucose-6-phosphatase in vivo.
A blood fraction would be the most convenient tissue of all for the patient and
physician on which to study glucose-6-phosphatase activity. The glucose-6-
phosphatase enzyme was proven above to be present in neutrophils separated from
normal adult serum by immunoblot analysis (Chapter 4). However the problem of
proteolytic damage again occurred when trying to study the enzyme in these cells. It
seems likely that the activity of all phosphatases (including glucose-6-phosphatase)
is so low (or sensitive to proteolysis) that the colourimetric phosphatase assay
employed in this work is not sensitive enough. For assay purposes a method of
amplification of the colour produced by the released inorganic phosphate would be
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required to allow glucose-6-phosphatase activity in neutrophils to be demonstrated.
The use of higher concentrations of substrate and/or longer assays did not solve the
problem - a more sensitive way of detecting free phosphate is needed. This work is
important and, once these problems have been overcome, will make the in vivo
study of this important part of glucose homeostasis much easier.
The presence of glucose-6-phosphatase activity in intestinal mucosa and neutrophils
explains some of the clinical abnormalities seen in patients with type 1 GSD (see
Hers et al 1989 and Moses 1990 for reviews). Many type 1 GSD patients have
diarrhoea, especially after a glucose load, however malabsorption is not seen
clinically (Fine et al 1969 & Milla et al 1978). There are recognised radiographic
findings identical to those seen in colitis in some patients with type 1 GSD even in
the absence of gastrointestinal symptoms (Fellows et al 1975). More recently
histologically proven Crohn's-like colitis has been described in a a number of type
lb GSD patients (for example Sanderson et al 1991). The pathogenesis of this
colitis is unclear as is the physiological role of glucose-6-phosphatase in intestinal
mucosa. There is evidence from rat colonocytes that glucose-6-phosphatase activity
is central to providing energy for the normal metabolism of these cells which
differentiate very rapidly (Ardawi & Newsholme 1985 for example). Another
possible role of the enzyme would be in the transport of absorbed glucose across the
intestinal mucosa.
Neutrophil dysfunction is a characteristic finding in type lb GSD (Anderson et al
1981) and recently defective calcium mobilisation in neutrophils separated from
patients with type lb GSD in response to some stimuli has been shown (Kilpatrick
et al 1990). Calcium mobilisation is important for producing the respiratory burst in
neutrophils (Heyworth & Segal 1986) all of which is consistent with the
observations of decreased neutrophil function in type lb GSD. The role of glucose-
6-phosphatase in the pancreatic islets was postulated by Waddell & Burchell (1989)
to be related to control of insulin secretion secondary to an effect on free
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intracellular calcium levels. This is consistent with other data on the relationship in
vivo between glucose-6-phosphatase activity and cytosolic free calcium levels
suggesting that glucose-6-phosphatase activity somehow controls calcium levels in
response to extracellular (hormonal) stimuli rather than vice versa (Benedetti et al
1985, 1986 & 1988, Waddell & Burchell 1988 & Fulceri 1990). A lot of the
literature presenting so-called effects of calcium on glucose-6-phosphatase activity is
erroneous in that some of the effects described were due to the buffer systems used
(mainly EGTA, but NTA also has a significant effect) affecting the microsomal
glucose-6-phosphatase activity (see Waddell et al 1990 and Mithieux et al 1990).
Before the work presented in this thesis the only proven biochemical interaction
between calcium and the glucose-6-phosphatase system was the requirement of the
21kDa stabilising protein for /xM concentrations of calcium to allow normal
glucose-6-phosphatase catalytic subunit activity (Burchell & Waddell 1990b). The
data in Chapter 5 here indicates a role for calcium (also at /jlM concentrations) in the
normal transport of glucose-6-phosphate across the microsomal membrane. It is not
yet clear if the glucose-6-phosphate transport protein, Tl, is closely associated with
the stabilising protein or whether Tl itself requires calcium for normal function.
The model of the glucose-6-phosphatase system may in fact be best represented with
the stabilising protein at the centre (see Figure 6.1). Perhaps the stabilising protein
also acts as a regulating protein - in the presence of high free intracellular calcium
concentrations secondary to hormone receptor stimulation more calcium binds to the
glucose-6-phosphatase stabilising protein thus increasing intracellular glucose-6-
phosphatase activity (both Tl capacity and catalytic subunit activity), which
increases glucose production and also reduces free calcium levels again. This theory
is consistent with the observation that glycogenolysis is increased in hepatocytes
when the levels of free cytosolic calcium are raised (Cohen 1983) and the work of
Benedetti showing that calcium uptake by microsomes is increased in the presence
of high intracellular glucose-6-phosphate concentrations (Benedetti et al 1985).
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Figure 6.1
Representation of the hepatic microsomal glucose-6-phosphatase system as it was
visualised at the end of the work in this thesis.
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Subsequent to my data the effect of supra-physiological levels of calcium on the
capacity of the phosphate/pyrophosphate and glucose-6-phosphate transport proteins
added to normal microsomes was described (Waddell et al 1990). The capacity of
the T2 transport protein under those circumstances increased more than that of Tl.
Unfortunately I was unable to study T2 activity in the "low metal ion" system which
I developed due to the insolubility of the non-sodium pyrophosphate salts. However
I did not observe an effect which could be taken as phosphate inhibition of
microsomal glucose-6-phosphatase activity in the low metal ion system suggesting
that T2 was functioning to some extent under those conditions.
The rate-limitation of the capacity of the glucose-6-phosphate transport protein Tl
to glucose-6-phosphatase activity in intact microsomes is well recognised (Arion et
al 1980b) and therefore understanding its structure and function is important in the
physiology of health and disease.
For the first time I have demonstrated (in Chapter 5) the biochemical mechanism
for microsomal glucose-6-phosphate transport - glucose-6-phosphate co-transports
with sodium and this transport is dependent upon calcium. It was not established
here whether glucose-6-phosphate and sodium co-transport by the same or by
closely associated proteins and the stoichiometry of the co-transport has still to be
established; lx glucose-6-phosphate : 2x sodium would be the most likely.
The 66kDa protein which I isolated from microsomes from diabetic rat livers
(Chapter 5) has yet to be properly identified. There is as yet no firm evidence that it
is even part of the glucose-6-phosphatase system. Very recently work in Ann
Burchell's laboratory using radiolabelled glucose has suggested that Tl may in fact
be a protein of molecular weight 35kDa (the same size as a protein recognised by
the polyclonal antibody raised to fractions from affinity chromatography which
contain the isolated protein). The absolute proof as to whether a protein is Tl is its
reconstitution into liposomes and the subsequent demonstration of glucose-6-
phosphate transport. Work such as this could easily occupy several years'
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continuous effort - the isolated protein may well not be in the tertiary structure
necessary to allow glucose-6-phosphate transport, and if the sodium co-transport
occurs via a separate protein the two proteins would have to be reconstituted
together, both in working structures, to allow the demonstration of glucose-6-
phosphate transport. This work has not yet been started.
The 66kDa isolated protein was used to raise an antibody which, on immunblot
analysis, recognised 2 main rat hepatic microsomal proteins one of apparent
molecular weight 35kDa and another of 50kDa. There was more of both of these
proteins in microsomes from diabetic compared to starved rat livers which could
support the 35kDa protein being glucose-6-phosphatase catalytic subunit. However
kinetic analysis has suggested that there is no increase in T1 capacity in microsomes
from the livers of diabetic animals. The fractions from the DIDS/Sepharose affinity
chromatography may have contained more than one protein, and only the one at
66kDa took up the silver stain. Looking at Figure 5.3.1 in retrospect and with the
recent knowledge of the radiolabeled glucose-6-phosphate data, there may be a
protein band at about 30kDa. However this band was definitely not present on
stained gels of other fractions which contained the 66kDa protein although the
protein may have been present in the fractions.
A useful indicator to the identity of the isolated protein would be to immunoblot
microsomes prepared from the liver of a patient with type lb GSD with IgG raised
to the original isolated protein. This has not yet been possible.
The IgG to the isolated protein was added to a small number of microsomal
glucose-6-phosphatase assays and had no effect. This does not mean that the
antibody is not binding to Tl. The antibody was also used as a ligand on an affinity
column and isolated a single peptide which on a silver stained 10% polyacrylamide
SDS gel had an apparent molecular weight of 66kDa. No other proteins were
stained.
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The original protein I isolated is larger than the protein identified by Zoccoli et al
(1982) using radiolabeled DIDS which was 54kDa and was subsequently shown to
be a hepatocyte cell membrane transport protein (Ananthanorayanan 1988). My
microsomal preparations contained little cell membrane contamination (as shown by
the presence of little precipitate when they were incubated with concanavalin A),
nor did I wash the microsomes which had previously been shown to increase the
binding of DIDS to microsomes (Countaway & Arion 1986). Although DIDS does
bind to many microsomal proteins (Countaway & Arion 1986) and to anion
transporters (Cabantchik & Rothstein 1972) the methods I used appeared initially to
be successful at isolating only one protein.
One of my aims was to demonstrate that T1 capacity could be pharmacologically
regulated. The ability to do this in vivo could have a number of important
applications. The cases with hypoglycaemia presented in Chapter 3 (and possibly
those in Appendix C) could have all benefited from the increased hepatic glucose
output which would occur if T1 capacity was increased, removing its rate-limitation
to glucose-6-phosphatase activity, and allowing even low levels of glucose-6-
phosphatase catalytic subunit to produce increased amounts of glucose. Secondly in
patients with diabetes mellitus, where hepatic glucose output is increased, if the rate
limitation imposed by T1 on glucose-6-phosphatase activity could be increased (ie
induction of partial pseudo type lb GSD) then hepatic glucose output could be
decreased. However decreasing T1 capacity could in theory cause all the other
metabolic problems seen in type lb GSD patients (see Hers et al 1989 and Moses
1990), or at very least the exaggerated insulin and blunted glucagon responses to
fluctuations in blood glucose demonstrated in case 8 in Chapter 3. These effects of
such an agent, if they occurred, could make its use unacceptable. It is possible in
time that glucose-6-phosphatase in different tissues represent isoenzymes and that
the proteins of the systems in these isomorphs have differing specificities for
pharmacological agents, thus these agents could be targeted to each tissue. At
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present there is no evidence of isoenzymes of glucose-6-phosphatase, the smaller
molecular weight glucose-6-phosphatase catalytic subunit seen on immunoblots of
gut mucosa and neutrophils represents proteolytic damage.
Before I started my work no agents had been shown to definitely manipulate T1
activity. A number of translocase poisons (eg phlorizin and DIDS) had been
demonstrated and some agents which removed or decreased the rate-limitation
imposed by T1 (eg histone 2A and detergents). These latter effects were
subsequently shown to be due to disruption of the integrity of the microsomal
membrane. I studied the diuretic amiloride for two reasons. Firstly it is a potent
inhibitor of transmembrane sodium channels and, after the data demonstrating co-
transport of sodium with glucose-6-phosphate, it seemed a logical agent to use.
Secondly amiloride affects the phosphorylation states of several insulin-sensitive
proteins within hepatocytes (LeCam et al 1982 and Holland et al 1983). While T1
has not been shown to be under the control of insulin or be regulated by
phosphorylation, it would be a logical site of insulin action in hepatocytes to
decrease hepatic glucose production. The effects of high concentrations of amiloride
were dramatic: the activation of T1 was profound (as demonstrated by the
colourimetric assay and the specific assay of T1 capacity) and there is evidence that
amiloride also inhibited T3, the glucose transport protein of the glucose-6-
phosphatase complex. However this is the opposite effect on T1 than was expected
if amiloride was inhibiting the sodium co-transport mechanism and the
concentration of amiloride required to produce maximal effect (5mM) is very much
higher than has been needed before to inhibit transmembrane sodium channels.
Amiloride was subsequently incubated with intact freshly isolated hepatocytes and a
profound effect on glucose-6-phosphatase activity was seen which may have masked
any effect on glucose-6-phosphate transport (Grant et al 1991). Amiloride does not
affect glucose metabolism in vivo in man, presumably because the concentration of
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the drug does not get high enough inside hepatocytes (if amiloride enters these cells)
or because T1 is not insulin regulated.
Since this work on amiloride demonstrated clearly that T1 could be acutely
regulated workers in Ann Burchell's laboratory have shown effects of a number of
other compounds on rat liver microsomal glucose-6-phosphatase which they claim to
be a T1 effect (see Chapter 5).
Of these agents the one which is known to effect glucose metabolism in man is
pentamidine and it would be interesting to see if in vivo measures of T1 capacity
confirmed the activation described in vitro (Scott & Burchell 1991a) to explain the
action of this drug on glucose metabolism. Unfortunately this is also unrealistic until
a method of assaying glucose-6-phosphatase activity in, for example, circulating
neutrophils becomes available.
The model of the glucose-6-phosphatase enzyme system as discussed in the
introduction to this thesis has, during the time of my work, moved more and more
towards the multicomponent model (see Burchell 1992 for a review). The sequence
of the rat microsomal glucose-6-phosphatase catalytic subunit has been published.
The T3 (or Glut 7) transport protein has been sequenced, cloned and expressed
(Waddell et al 1992). A recent paper has also challenged the concept of a single T2
transporter by examining the difference between the observed and predicted
inhibition of glucose-6-phosphatase activity by accumulated luminal phosphate in
hepatic microsomes from a patient with type lc GSD (Nordlie et al 1992). The
conclusion drawn in this paper is that there is more than one microsomal protein for
transporting phosphate from the lumen of the ER, and that pyrophosphate counter-
transport does not necessarily occur through all these proteins. This data could be
interpreted as suggesting that many if not all of the transport proteins of the
glucose-6-phosphatase system are involved in other enzyme processes also. The
demonstration of a glucose-6-phosphate dehydrogenase isoenzyme in the lumen of
microsomes (Hino & Minakami 1982) which presumably requires a transmembrane
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glucose-6-phosphate transporter is also in favour of this. If T1 is necessary for
G6PDH activity then the neutrophil defects seen in type lb GSD patients may be (at
least in part) be due to inactivity of G6PDH.
Ian Waddell has also performed painstaking topographical studies of the glucose-6-
phosphatase system in the microsomal membrane which pulls together all the known
data regarding glucose-6-phosphatase and confirms the existence of a number
proteins associated with glucose-6-phosphatase activity on both surfaces of the ER
membrane (Waddell & Burchell 1991). However the data I have presented on the
activating effect of calcium on glucose-6-phosphate transport raises the possibility
that calcium binding to the stabilising protein induces a conformational change in it
or the other closely associated proteins of the glucose-6-phosphatase system thereby
increasing their functional capacity. This links together the multicomponent and
conformational theories of glucose-6-phosphatase function as presented in Chapter
1. It should be noted that this reconciliatory theory was first proposed in 1981
(Nordlie et al 1981) in an attempt to bring the then mutually exclusive ideas
together and pool the investigational resources of the two factions.
In summary I have fallen a little short of two of the objectives I set out with:
purifying the glucose-6-phosphate transport protein and developing an assay of
glucose-6-phosphatase in a blood fragment. In retrospect both of these aims were
very ambitious for a 2 year project. However both of these lines of investigation
have been explored as described above and I have paved the way for these problems
to be solved.
I did, however, achieve many of my aims: I described in detail several cases of
glycogenolytic enzyme defects diagnosed in adult patients. All these patients are
unusual and two of them demonstrated unique hepatic glucose-6-phosphatase
abnormalities. The cases give insight into the physiological role of glucose-6-
phosphatase in the liver and pancreas where its role appears to be related to insulin
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secretion. I also proved for the first time that intestinal mucosal cells from all parts
of the gut accessible to endoscopy contain specific glucose-6-phosphatase activity. I
demonstrated that the activity in this tissue is too low and is too susceptible to
proteolysis to allow diagnoses of glucose-6-phosphatase abnormalities to be made.
The biochemical mechanism of microsomal glucose-6-phosphate transport was
shown to involve sodium co-transport and require calcium, although the number of
proteins involved remains to be clarified. For the first time also I was able to
demonstrate that it is possible to pharmacologically alter T1 capacity thus raising the
possibility of a novel drug treatment for diabetes mellitus and a drug treatment for
the described cases with hypoglycaemia which can increase hepatic glucose output.
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SUMMARY
Glycogen storage diseases are usually identified in childhood. We present the clinical,
biochemical and histological features of 10 patients first diagnosed in adult life. Five had
glycogen storage disease type la, one type lc, two type IX, and in two patients there were
previously unreported abnormalities of hepatic glucose-6-phosphatase system activity. Of the
latter, one patient had an inhibitor of liver glucose-6-phosphatase (pseudo-lb glycogen storage
disease) the other having abnormal glucose-6-phosphatase activity and microsomal pyrophos¬
phate transport. A glucagon test is suggested as a useful screening procedure. Glycogen storage
disease should be considered in adults with symptoms suggesting hypoglycaemia.
INTRODUCTION
The first instance of a specific enzyme abnormality causing a glycogen storage disease was
reported in 1952 by Cori and Cori [1] and was shown to be due to glucose-6-phosphatase
deficiency. Since that time, a number of other congenital disorders of enzymes involved in
glycogen metabolism have been recognized. The glycogen storage diseases are usually
thought to be identified only early in childhood: we report 10 adults in whom we have
demonstrated abnormalities of hepatic glucose production. Their diagnosis over a short
period of time in one Health Board region (approximate population 400,000) suggests that
disorders of hepatic glycogen metabolism are probably less rare than had previously been
recognized.
CASE REPORTS
Patient 1 presented at the age of 54 years with a severe metabolic acidosis (plasma lactate
12.5 mmol), profound hypoglycaemia (1 mmol/1), massive hepatomegaly and deranged liver
function tests (Table 1) and blood clotting (prolonged bleeding time but normal KCCT and
prothrombin time). Hepatomegaly had been noted at age 7 years and a bleeding diathesis
shortly after. He developed gout at age 38. Two siblings died in infancy; three others were
well. He had always been mentally 'slow'. Liver ultrasound suggested a large hepatocellular
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carcinoma (confirmed by liver biopsy). Serum a-fetoprotein was undetectable. Biopsy of
noncancerous liver indicated an underlying type la glycogen storage disease.
Patient 2 had a recent history of hypoglycaemic symptoms exacerbated by exercise and
relieved by food. She had been born prematurely and had required frequent day and night
feeds in early infancy. She was given food frequently until she left home when she ate less
often and symptoms began. Glucagon test showed a reduced glucose response (Table 2).
Prothrombin time was normal but KCCT was prolonged (Table 1). A liver biopsy revealed a
partial type 1 a glycogen storage disease. The patient's symptoms resolved with regular meals
containing cornstarch.
Patient 3 complained of episodes of sudden tiredness in the mid-afternoon exacerbated by
activity and by the absence of a midday meal. The symptoms, which were relieved by
chocolate, had been occurring for many years and had worsened after the menopause. There
was a blunted blood glucose response to glucagon (Table 2) but no hypoglycaemia during a
48-hour fast conducted in hospital. Prothrombin time was normal but KCCT was prolonged
(Table 1) due to a partial deficiency of Factor XI. Liver biopsy revealed a partial type la
glycogen storage disease. She had no family history of similar symptoms and an uneventful
obstetric history. Her symptoms were helped by cornstarch, regular meals and post¬
menopausal hormone replacement therapy.
Patient 4 noted post-menopausal sweating for 2 years associated occasionally with
syncope. These episodes were precipitated by exercise and could be prevented by ingestion of
carbohydrates. Some 11 years previously she had had radiotherapy for cervical carcinoma
but recent cervical smears were class 2, showing mild dyskaryosis only. Liver function tests
were abnormal (Table 1) but clotting tests were normal and she was hepatitis B surface
antigen negative. An isotope liver scan showed an enlarged liver with uniform uptake. The
glucagon test revealed a blunted glucose response (Table 2) and liver biopsy indicated a type
1 a glycogen storage disease. Treatment with cornstarch, regular meals and post-menopausal
hormone replacement therapy relieved her symptoms.
Patient 5 had a 13-year history ofepisodic weakness, especially of her legs, associated with
incoordination, light headedness and tremulousness. These episodes were invariably
associated with exercise and relieved by glucose tablets. Their frequency had increased since
the menopause. Clotting tests were normal as were liver function tests (Table 1). A 48-hour
TABLE 2. Results ofglucagon tests




Peak Rise in blood glucose Time to peak
(mins)
1 la ND
2 Partial la 4.4 7.4 3 60
3 Partial la 5.2 7.4 2.2 30
4 la 5.6 9.1 3.5 60
5 Partial la 5.3 7.4 2.1 30
6 lc 5.9 11.1 5.2 60
7 Partial 1 u/c 4.6 6.1 1.5 30
8 Pseudo lb 4.6 6.6 2 30
9 Partial IX 4.7 6.9 2.2 30
0 Partial IX 4.5 6.1 1.6 30
1 mg Glucagon was given intramuscularly. Results are venous plasma glucose levels in mmol/1.
4ormal rise > 4 mmol/1 in blood glucose level, usually at 30 minutes.
ND: glucagon test not performed; U/C: type 1 disease, abnormality unclassified.
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TABLE 3. Results of oral glucose tolerance tests
Patient Fasting Time (mins)
30 60 90 120
* 1 3 6 6.9 5 3.7
2 4.5 7.4 9.4 9.4 8.5
5 4.1 5 3.9 3.6 3.5
6 5.6 11.6 13 9.8 6.8
7 4.2 10.1 12.2 12.2 9.3
8 4 2 <0.5 2.6 2.7
9 4.4 7.1 6.9 5.2 NS
10 4.6 7.9 6.7 7.4 9.1
75 g Glucose given orally after 10 hour overnight fast. Results
are venous plasma glucose levels in mmol/1.
* GTT performed in 1966. Amount of glucose given not
known.
NS = No sample.
Patient 6 Insulin 30, 54, 105, 5 mU/1 at 0, 30, 60, 90, 120 mins.
Patient 8 Insulin 11, 720, 108, 53, 36 mU/1 at 0, 30, 60, 90, 120
mins.
fast did not precipitate the symptoms (Table 1) and a glucagon test indicated a blunted
glucose response (Table 2). Liver biopsy revealed a partial type la glycogen storage disease.
Frequent meals with additional cornstarch reduced the frequency of hypoglycaemia, and
subsequent post-menopausal hormone replacement therapy further relieved the symptoms.
The patient's mother and sister had similar symptoms.
Patient 6 had a past history of heavy alcohol consumption (30 units/day) but had
abstained for 2 years, despite which his liver enzyme levels had remained elevated and he had
a palpable liver. He complained of polyuria and glycosuria. His glucose tolerance test (Table
3) had a diabetic pattern. Clotting tests were normal as was the blood glucose response to
glucagon (Table 2). Liver biopsy showed fatty change and a high glycogen content.
Subsequent biochemical analysis revealed type lc glycogen storage disease. Blood glucose
control was satisfactory on a diabetic weight-reducing diet and he never developed
symptoms of hypoglycaemia. Three years after diagnosis he developed a painful lytic lesion
in the left acromion process. Biopsy revealed a metastatic deposit from a bronchogenic
primary tumour and bone scan indicated widespread bony metastases from which he
subsequently died. He had one brother who died at 3 weeks of age, but three other siblings
remain healthy.
Patient 7 developed hypoglycaemic symptoms when she left home to enter university and
began to eat less regularly. The symptoms usually occurred before meals and were relieved
by eating. During some of these attacks, blood sugar levels of < 2 mmol/1 had been recorded.
A 48-hour fast was not associated with hypoglycaemia (Table 1). Clotting studies were
normal, as were liver function tests. Glucose response to glucagon was blunted and she
exhibited an impaired glucose tolerance test. Liver biopsy showed lymphocytic infiltration
suggestive of a viral illness but there was no serological evidence to support this. Enzymatic
analysis showed abnormally low activity of the glucose-6-phosphatase enzyme and very low
transport capacity of the transport protein T2, similar to that previously found by us in
human liver samples early in gestation [2] and is without defined classification. It is of interest
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that this patient had been born 3 weeks prematurely. Symptoms resolved with regular
polycarbohydrate meals.
Patient 8 had a 5-year history at presentation of hypoglycaemia which occurred shortly
after the ingestion of glucose or sucrose. A 48-hour fast did not precipitate hypoglycaemia
(Table 1). A fasting glucagon test showed a blunted glucose response (Table 2) and an
intravenous glucose tolerance test resulted in hypoglycaemia with a blood glucose of
1.1 mmol/1 at 90 min following a large insulin rise (peak level of 1520 mU/1 at 60 min and
absent glucagon rise (peak < 11 pg/ml). An oral glucose tolerance test also induced
hypoglycaemia some 60 min post ingestion (Table 3) associated with a similar rise in insulin
to >750 mU/1. Liver biopsy indicated some lymphocytic histiocytic infiltration but no
evidence of lymphoma. Enzymatic analysis of the liver tissue biopsy revealed the presence of
an inhibitor ofTl, the glucose-6-phosphate transport protein of the glucose-6-phosphatase
system, in the patient's liver. This is similar to the pattern of glucose-6-phosphatase seen in
some infants and is named pseudo-type lb glycogen storage disease. Glycogen stores were
normal. Treatment was aimed at reducing the insulin peak response to glucose by diazoxide
therapy. Octreotide was also effective in reducing the hyperinsulinaemia.
Patient 9 had a 3-year history of episodes of hunger followed by loss of memory,
uncontrollable upper limb jerking and occasional syncope. Her symptoms worsened when
she began working and began eating less frequently. Liver function tests, clotting studies and
=EEG were normal. A 48-hour fast did not precipitate hypoglycaemia (Table 1), but her
.glucose response to glucagon was blunted. Liver biopsy indicated excess glycogen, but the
.glucose-6-phosphatase assay showed all parts of the system to be present in normal
proportions, although to a slightly reduced degree. A muscle biopsy was undertaken to
further identify the abnormality: histology was normal. Biochemical analysis of liver and
muscle indicated reduced phosphorylase kinase activity indicative of partial type IX
glycogen storage disease. The patient's symptoms responded to regular polycarbohydrate
neals. Her obstetric history was unremarkable.
Patient 10, the daughter of Patient 9, suffered episodic dizziness and light headedness
before a midday meal, especially if she had not had breakfast, relieved by eating. The results
}f an oral glucose tolerance test were unusual, with a double peak of glucose levels (Table 3).
The glucose response to glucagon was blunted (Table 2). Liver and skeletal muscle histology
.vere unremarkable, but biochemical analysis indicated reduced phosphorylase kinase
ictivity of partial type IX glycogen storage disease. The patient's symptoms responded to
iietary manipulation.




\ 75 g oral glucose tolerance test was performed with patients in the fasting state. Glucagon
ests used 1 mg glucagon (Novo Laboratories) given intramuscularly, blood samples being
aken for glucose estimation 0, 30, 60 and 90 minutes later. Normal blood glucose rise was
aken as >4 mmol/1 above the fasting level. The analysis was undertaken using a Beckman
;lucose analyser. Total serum insulin was measured by radioimmunoassay (MAIA, Serono
Diagnostics, Woking, UK).
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Biopsies
Liver biopsies were obtained under local anaesthesia unless otherwise indicated using
Surecut needles (TSK Laboratories, Japan). Samples for biochemical analysis were
maintained in ice-cold 0.25 M sucrose/5 mM HEPES buffer, pH 7.4 (SH buffer). Skeletal
muscle biopsies (Patients 5, 9 and 10) were taken from the tibialis anterior under locai
anaesthesia using Tilley-Henkel forceps. Biopsies were transported fresh for histology and ir
SH buffer for biochemical analysis.
Biochemical Analysis of Biopsies
Assays were performed on fresh (unfrozen) tissue [5]. Tissue samples were homogenized b>
hand in SH buffer using Jencons glass homogenizers to a final volume 10 times the origina:
tissue weight. Homogenates were centrifuged (10,000 xg for 1 min) and phosphorylase
kinase activity in the supernatant was determined where indicated. The supernatant was
spun again (105,000xg for 1 hour at 4°C) and the resulting microsomal pellet was
resuspended in SH buffer using a Jencons glass homogenizer to a final volume equal to the
wet tissue weight. The final suspension contained the microsomal fraction used for glucose-
6-phosphatase assay.
Glucose-6-phosphatase, mannose-6-phosphatase and pyrophosphatase activities were
assayed as described previously [6], but modified by the use of 0.1 M HEPES pH 6.5 as buffei
in the substrates, glucose-6-phosphate concentrations of 1, 1.4, 2, 2.6, 5 and 30 mM and
pyrophosphate concentrations of 0.5, 1, 1.4, 2, 2.6 and 5 mM. Microsomal intactness was
estimated and corrected for using mannose-6-phosphatase activity and UDP glucuronosy
transferase activity towards 1-naphthol [5, 6]. Total phosphorylase (a+ b) activity was
assayed in the direction of glycogen synthesis in the presence of 5'-AMP [7]. Phosphorylase
FIG. 1. Electron micrograph of control liver. Magnification x4000. Normal glycogen stores (blacl
speckles) between organelles which are distributed throughout the hepatocytes.
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kinase activity was measured by the methods of Krebs as modified by Cohen [8]. Glycogen
levels were assayed as previously described [9] and protein levels by the method of Peterson
[10].
Light microscopy was undertaken on tissue fixed on phosphate-buffered formaldehyde/
phenol-formaldehyde [11], Paraffin sections were stained with haematoxylin and eosin and
PAS [12]. For electron microscopy the tissue was fixed in 0.2 M cacodylate-buffered 3 per
cent glutaraldehyde and embedded in Epon. Thin sections were stained with uranylacetate
and lead citrate and examined with a JEOL 100 CX electron microscope at 60 kV. An
electronmicrograph of a control liver section is shown is Fig. 1.
Immunoblot and immunodot analysis. SDS/PAGE was carried out in a 7-16 per cent (w/v)
polyacrylamide gels as described by Laemmli [13]. Proteins separated on SDS/polyacryl-
amide gels were electrophoretically transferred to nitrocellulose, as described by Towbin et
al. [14], The Western blot and dot blots were immunostained with antibodies previously
shown to be monospecific for the catalytic subunit of glucose-6-phosphatase or for T2 the
microsomal phosphate/pyrophosphate transport protein [2, 15]. Immunoreactive polypep¬
tides were detected using a biotin-streptavidin-peroxidase linked detection system with
4-chloro-l-naphthol as the substrate [16]. In the immunodot experiments human liver
cytosol was used as a negative control since it does not contain the components of the
microsomal glucose-6-phosphatase system.
RESULTS
Liver Histochemical and Electron Microscopic Features
In normal human adult liver biopsy samples (n = 60) glycogen levels are always <40 mg/g
liver (Table 4): Patients 1-7, 9 and 10, but not Patient 8 had abnormally high glycogen levels,
TABLE 4. Glucose-6-phosphatase activity in hepatic biopsy specimens
Patient Intact microsomes Disrupted microsomes Glycogen content
(mg glycogen/g
Vmax Km Vmax Km wet weight liver)
fiimol/min/mg) (mM) (^mol/min/mg) (mM)
1 0 ND 0 ND 134
2 0.01 1.7 0.02 1.1 70
3 0.01 3.3 0.04 1 82
4 0 ND 0 ND 166
5 0.03 3.3 0.08 1.3 96
6 0.09 6.9 0.53 1.1 80
7 0.01 2.2 0.06 1 54
8 0.03 16.2 0.2 0.9 28
0.15* 2.2 0.2 0.9
9 0.16 2.1 0.3 0.4 70
10 0.1 2.7 0.14 0.4 62
Mean control values 0.23 + 0.02 2.6 + 0.2 0.35 + 0.03 0.8 + 0.08 <40
(n = 60)
ND = Not determinable.
* Microsomes incubated with 1% bovine serum albumin.
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1 Hepatocellular carcinoma. Massive glycogen store in remaining liver 3 4-
2 Normal liver +
3 Normal liver +
4 Marked fatty change in liver. Portal fibrosis (moderate) +
Moderate chronic active inflammatory infiltrate +
5 Increased perivenular lipofuscin in liver 3 +
6 Mild fatty change in liver. Increase in portal tract lymphocytes +
7 Excess lymphocytes in portal tracts of liver 3 +
8 Mixed lymphocytic histiocytic infiltration 3 +
9 Liver and muscle both normal +
10 Liver and muscle both normal 3 +
* + Represents normal glycogen stores; 3+ markedly increased glycogen stores.
in the range previously found in liver from patients with glycogen storage disease [3, 17-19],
Glycogen content of liver samples as assessed by routine histological PAS staining (Table 5)
did not always correlate well with the biochemical determination of liver glycogen,
presumably due to the loss of glycogen into the formaldehyde during tissue processing.
However, the electron microscopic appearance of the liver samples correlated well with the
biochemical determinations. Ultrastructural abnormalities seen by electron microscopy in
the livers of these patients ranged from mild excess of glycogen in the cytoplasm to increased
FIG. 2. Electron micrograph of liver biopsy from Patient 4. Magnification x 10,000. Glycogen stores
are abundant and the two mitochondria in the centre of the field contain paracrystalline arrays (which
are indicated by arrows).
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FIG. 3. Electron micrograph of liver biopsy from Patient 5. Magnification x 5000. Hepatocytes
contain marked excess of glycogen which has displaced the organelles to the peripheries of the cells.
Lipid droples are also seen.
FIG. 4. Electron micrograph of liver biopsy from Patient J. Magnification x 10,000. This plate is a
field from Fig. 4 and shows more clearly the large amount of stored glycogen (indicated by arrows).
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amounts displacing the organelles in the hepatocytes (Figs. 1-4). Other non-specific findings
were of lipid droplets and mitochondrial paracrystalline arrays. The liver biopsy ofPatient 8
showed mixed lymphocytic histiocytic infiltration initially suggesting lymphoma. CT
scanning showed no evidence of lymphoma, haematological findings were normal and the
patient is now well. A subsequent review of liver biopsies of patients with lymphoma in
Dundee has not shown an increase in glycogen stores. Apart from Patient 1 (hepatocellular
.carcinoma) and Patient 6 (fatty liver of diabetes) the liver biopsy histology was non-specific
(Table 5).
Liver Glucose-6-Phosphatase Kinetics and Immunochemistry
The kinetics of glucose-6-phosphatase activities using glucose-6-phosphate as substrate are
shown in Table 4. Disruption of microsomes removes the controlling influence of the
transport proteins of the glucose-6-phosphatase system and is a direct measure of the
glucose-6-phosphatase enzyme itself. In Patients 1 and 4 the glucose-6-phosphatase enzyme
activity was absent, indicating type la glycogen storage disease. The defect in these patients
cannot, however, be the same as immunological analysis revealed the complete absence of
the glucose-6-phosphatase enzyme in Patient 1 (Fig. 6, d6), whereas normal amounts of
apparently normal molecular weight enzyme protein were present in Patient 4. Patients 2, 3
and 5 all had some glucose-6-phosphatase enzyme activity, but with an abnormally low Fmax
and normal Km in both intact and disrupted microsomes, indicating partial type la glycogen
storage disease (Table 4). In all three patients immunological analysis revealed normal
amounts of normal molecular weight glucose-6-phosphatase enzyme protein (Fig. 6, d4, d7,
e centre). In Patients 1-5 all of the other components of the glucose-6-phosphatase system
were normal (Fig. 6, f, 2, 6 and 7). Patient 7 also had abnormally low glucose-6-phosphatase
enzyme activity (Table 4) with a normal Km in intact and disrupted microsomes. The
situation was quite different from that of Patients 2, 3 and 5 since abnormally low levels of
the glucose-6-phosphatase enzyme were found on immunoblot analysis (Fig. 6a, lane 1 and
e4; note much more microsomal protein was loaded than for other samples in order to
distinguish clearly whether or not even low levels of protein were present). In addition, the
activity of the glucose-6-phosphatase enzyme in intact microsomes with pyrophosphate as
substrate (Table 6) was also abnormally low in this patient, indicating low transport capacity
ofT2, the phosphate/pyrophosphate transport protein of the glucose-6-phosphatase system
(see Fig. 5). The pattern of activity and protein levels in this patient are very similar to those
TABLE 6. Pyrophosphatase activity in hepatic biopsy specimens
Patient Intact microsomes Disrupted microsomes
Vmax Km Vmax Km
(/tmol/min/mg) (mM) bimol/min/mg) (mM)
1 0 ND 0 ND
5 0.01 3.2 0.04 2.3
6 0 ND 0.29 1.9
7 0.004 1.7 0.07 1
Mean control values 0.08±0.001 2.5±0.32 0.24 + 0.02 0.7±0.1
(n = 25)
ND = Not determinable.
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seen previously early in human gestation [2] so a regulatory developmental defect cannot be
ruled out.
Patient 6 had normal glucose-6-phosphatase enzyme activity in disrupted microsomes but
an abnormally high Km in intact microsomes (Table 4), indicating a defect in one of the
transport proteins. To determine which transport protein was involved, pyrophosphatase
activity was measured (Table 6). The lack of any activity in intact microsomes demonstrated
that T2, the phosphate/pyrophosphate transport protein, was deficient (type lc glycogen
storage disease). Immunoblot analysis revealed the complete absence of the T2 protein in
this patient (Figure 6, b2 and f5). Patient 8 had normal glucose-6-phosphatase enzyme
activity in disrupted microsomes (Table 4) but a very high Km in intact microsomes,
indicating a transport protein defect. However, this patient does not have a genetic
deficiency of the glucose-6-phosphatase system: an inhibitor of the T1 protein (the glucose-6-
phosphate transport protein, see Fig. 5) was found in the liver of this patient, and the enzyme
activity could be restored to normal by incubating microsomes in the presence of bovine
serum albumin (Table 4). The livers of Patients 1-7, 9 and 10 did not contain T1 inhibitor.
Liver and Muscle Phosphorylase Kinase Kinetics
Patients 9 and 10 had normal liver glucose-6-phosphatase enzyme activity (Table 4) and
normal protein levels (Fig. 6). There is no glucose-6-phosphatase activity in normal skeletal
muscle. In Patient 9, total phosphorylase a and b levels were within the normal range in both
liver and muscle (0.5 U in liver, 1.6 U in muscle). However, phosphorylase kinase activity
was reduced to approximately 10 per cent of normal in liver and muscle (at pH 6.8, = 0.008 U
and muscle = 0.01 U). These data suggest a partial defect of liver and muscle phosphorylase
kinase (partial type IX glycogen storage disease). Electromyography showed a slightly
abnormal interference pattern, thought to be appropriate for a myopathic process (increase
Endoplasmic
FIG. 5. Diagrammatic representation of the hepatic microsomal glucose-6-phosphatase system.
Catalytic subunit (E); stabilising protein (SP); transport proteins for glucose-6-phosphate (Tj),
phosphate (T2) and glucose (T3).
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FIG. 6. Immunological analysis of human liver microsomes showing the presence or absence of the
glucose-6-phosphatase catalytic subunit and T2 the microsomal phosphate/pyrophosphate transport
protein.
(a) Immunoblot analysis using an anti glucose-6-phosphatase catalytic subunit antibody.
Lane 1—Patient 7—hepatic microsomes (40 y<g);
Lane 2—Patient 8—hepatic microsomes (12 /rg);
Lane 3—Patient 9—hepatic microsomes (12 jug);
Lane 4—Patient 10—hepatic microsomes (12 /rg);
(b) and (c) Immunoblot analysis using an anti T2 antibody.
Lane 5—Patient 1—hepatic microsomes (20 fig);
Lane 6—Patient 6—hepatic microsomes (80 pg);
Lane 7—Patient 5—hepatic microsomes (20 /^g);
Lane 8—Control adult human hepatic microsomes (20 ^g);
Lane 9—Patient 7—hepatic microsomes (21 /rg);
Lane 10—Patient 8—hepatic microsomes (20 ^g);
Lane 11—Patient 9—hepatic microsomes (19 ng)\
Lane 12—Patient 10—hepatic microsomes (21 ^g).
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(d) and (e) Immunodot blot analysis using anti glucose-6-phosphatase antibody.
d1 Control rat hepatic microsomes (5 /<g);
2 & 3 Control adult human hepatic microsomes (5 /(g);
4 Patient 2 hepatic microsomes (5 fig);
5 Patient 6 hepatic microsomes (5 fig);
6 Patient 1 hepatic microsomes (5 fig);
7 Patient 5 hepatic microsomes (5 /(g);
8 Control human hepatic cytosol (5 fig);
Centre Control microsomes from an infant with classical type 1a glycogen storage disease.
e1 Control rat hepatic microsomes (5 fig);
2 & 3 Control human adult hepatic microsomes (5 fig);
4 Patient 7 hepatic microsomes (15 fig);
5 Patient 8 hepatic microsomes (5 fig);
6 Patient 9 hepatic microsomes (5 fig);
7 Patient 10 hepatic microsomes (5 fig);
8 Control liver hepatic cytosol (5 fig);
Centre Patient 3 hepatic microsomes (5 fig).
(f) Immunodot blot analysis using anti T2 antibody.
f1 Control rat liver microsomes (5 fig);
2 & 3 Control human adult hepatic microsomes (5 fig);
4 Patient 2 hepatic microsomes (5 fig);
5 Patient 6 hepatic microsomes (5 /<g);
6 Patient 1 hepatic microsomes (5 fig);
7 Patient 5 hepatic microsomes (5 fig);
8 Control human hepatic cytosol (5 fig);
Centre Control microsomes from an infant with classical type 1a glycogen storage disease (5 /(g).
in high frequent components). Biochemical analysis of biopsies from Patient 10 showed high
(liver) or high normal (skeletal muscle 19.9 mg/g) glycogen stores and low normal hepatic
glucose-6-phosphatase activity. Total phosphorylase (a + b) activity was normal in liver and
in muscle (1.1 and 5.3 units respectively). Phosphorylase kinase activity at pH 6.8 (0.09 u
liver, 0.12 u muscle) and at pH 8.6 (0.11 u liver, 0.23 u muscle) were within 'normal ranges',
but at these levels the assay cannot unfortunately distinguish 'half normal', from 'normal'. In
view of the history, the evidence of glycogen accumulation and her mother's abnormalities, a
diagnosis of partial type IXc glycogen storage disease was made.
Patients 9 and 10 are also very unusual in that type IXc glycogen storage disease, in which
both hepatic and skeletal muscle phosphorylase kinase are deficient, has been thought to be
inherited in an autosomal recessive manner [20, 21]—very unlikely in mother and daughter.
A sibling of Patient 10 also had a blunted glucagon test but is asymptomatic and liver biopsy
has, therefore, not been undertaken.
DISCUSSION
We have diagnosed a variety of defects leading to type 1 glycogen storage disease in adults, as
well as two cases of type IX glycogen storage disease. Although there have been a few reports
of type 1 glycogen storage disease in adults [22, 23] this condition is generally thought of as a
disease that is diagnosed early in childhood [24, 25], Some of the patients, for example,
Patient 1, might reasonably have been expected to be diagnosed in early childhood but many
had such mild symptoms in earlier years that further investigation was not undertaken.
Until recently a large wedge liver biopsy would have been needed to diagnose such
deficiencies; the microtechniques used in these studies now make it possible to diagnose type
1 glycogen storage disease deficiencies using a needle liver biopsy taken under local
anaesthesia. This makes it probable that many more of the milder deficiencies will be
220 JS Pears and others
diagnosed in adults in the future. The recent purification and cloning of several of the protein
components of glucose-6-phosphatase (see [26-28] for recent reviews) will also lead to easier
diagnosis of type la, laSP, lb, lc and Id glycogen storage diseases in all patients.
All of the patients (except Patient 6) had symptoms which could be attributed to
hypoglycaemia. In only three of the patients was hypoglycaemia proven biochemically, even
during exercise stress undertaken after a 48-hour fast. The lack of proven hypoglycaemic
episodes in many type 1 glycogen storage disease patients, even in those with classic type 1
glycogen storage disease diagnosed early in childhood, is well recognized [29-34].
In patients with hypoglycaemia of uncertain aetiology the value of the glucagon test (1 mg
administered intramuscularly) as a screening procedure is clear. Only one of the nine patients
in whom the test was performed had an increase in blood glucose > 4 mmol/1 above fasting.
This patient also had no symptoms of hypoglycaemia and was indeed diabetic (in keeping
with the first case of type lc glycogen storage disease described [35]). We have used an
increase in blood glucose of 4 mmol/1 above fasting as a cut-ofif, as suggested by Fernandes et
al. [36] rather than 2 mmol/1 as advocated by Dunger and Leonard [37] as we are screening
for partial, less severe defects in glycogen metabolism than those described in infants with
complete enzyme abnormalities. Conversely it appears that the oral glucose tolerance test is
of little diagnostic benefit, being normal in seven of 10 of our patients.
The diagnosis of partial glycogen storage diseases is unlikely to be aided by routine
histopathological examination of liver biopsies as provided in most centres. There may be
large discrepancies in estimation of glycogen content of a sample between PAS staining,
electron microscopy and the biochemical method (described in [9]) due to its loss into the
formaldehyde and during tissue processing. However, electron microscopic examination of
liver samples may be helpful and we did find a correlation between the ultrastructural
estimation of glycogen stored and the biochemical estimates.
These patients indicate that partial defects in hepatic glycogen-metabolizing enzymes are
probably less rare in the adult population than has previously been thought and we
recommend that patients with symptoms which suggest hypoglycaemia should be screened
with a glucagon test as described, even if hypoglycaemia cannot be proven. If the glucagon
test is abnormal, such patients should undergo a needle liver biopsy at a centre capable of
performing the necessary biochemical analyses. The diagnosis in patients such as these
cannot be made on routine histological examination of liver samples but must rely on
analysis in laboratories regularly carrying out the required complicated assays.
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CASE REPORT Dm
Reactive Hypoglycaemia in Association
/vith Disordered Islet Function and
\bnormal Hepatic Glucose-6-
'hosphatase Activity: Response to
Diazoxide
Pears3, R.T. Jung3, M.C.K. Browningb, R. Taylord, A. Burchel!c
epartments of"Medicine, bBiochemical Medicine and cObstetrics
id Gynaecology, Ninewells Hospital and Medical School, Dundee
id dDepartment of Medicine, University of Newcastle upon Tyne,
K
Severe reactive hypoglycaemia was confirmed in a non-diabetic male patient by a counter-
regulatory hormone (GH, Cortisol and catecholamine) response to profound hypoglycaemia
induced by an intravenous glucose load. There was also evidence of disordered pancreatic
islet cell paracrine regulation with hyperinsulinaemia and absent glucagon response to
hypoglycaemia. A defect in the patient's hepatic glucose-6-phosphatase enzyme system
was documented. Because of severe symptoms, dietary control was insufficient, but the
patient responded clinically and biochemically to 18 months of oral diazoxide therapy.
He also showed good biochemical response to a single dose (100 pg IM) of the somatostatin
analogue octreotide.
key words Reactive hypoglycaemia Hyperinsulinaemia Glucose-6-phosphatase
Diazoxide Somatostatin Octreotide
itroduction
eactive (postprandial) hypoglycaemia is an uncommon
isorder comprising hypoglycaemic symptoms usually
ccurring 1 to 4 h after a meal. It can be caused by
astrointestinal disease, hormonal abnormalities, and
irely by deficiency of fructose 1:6 diphosphatase,
hepatic gluconeogenic enzyme.1 In many patients,
awever, a precise cause is never established. The
lanagement of reactive hypoglycaemia is based on small
leals low in refined carbohydrate, and several drugs have
aen tried where dietary management is insufficient.2
We report a case of severe reactive hypoglycaemia
ivolving both abnormalities of pancreatic islet hormone
icretion and an unreported abnormality of hepatic
ucose-6-phosphatase activity, with clinical response to
</o drugs not previously used in treating reactive
/poglycaemia.
ase Report
Caucasian farmer led a very active working and
lorting life, playing rugby and cricket into his thirties,
e presented aged 42 years with neuroglycopenic and
Jtonomic symptoms of hypoglycaemia, worst between
irrespondence to: Dr ). Pears, Department of Medicine, Ninewells
ispital Medical School, Dundee, DDI 9SY, Scotland.
1000 and 1030 h after an early rise (0500 h) and heavy
breakfast (0900 h). These symptoms were precipitated
by physical activity and were relieved by the ingestion
of food. There was no past medical history or family
history of note. He did not smoke and alcohol consump¬
tion was < 1 U day-1. Physical examination was
unremarkable.
A prolonged fast showed a 48-h insulimglucose ratio
of 0.12 mU mmol-1 (normal <0.3 mU mmol-1). A
prolonged 75 g oral glucose tolerance test (OGTT) (Figure
1) produced symptomatic hypoglycaemia. A diagnosis of
reactive hypoglycaemia was made and dietary advice
given.
At age 47 years, he was re-referred with worsening
hypoglycaemic symptoms in the same pattern as before.
Other history and clinical examination were unremark¬
able. OGTT demonstrated a large rise in total serum
insulin (peak 720 mU I-1) (MAIA assay, Serono Diagnos¬
tics, Woking, UK) with a small rise in plasma glucose
(Figure 2). An intravenous glucose tolerance test (IVGTT)
(0.5 g kg-body-weight-1) was performed. This produced
severe, profound hypoglycaemia after 90 min, following
a period of hyperinsulinaemia, and a virtually absent
glucagon counter-response (Table 1). Other counter-
regulatory hormone responses to hypoglycaemia were
normal (including adrenaline and noradrenaline, peak
levels of both 3 nmol I-1 at 120 min). The hypoglycaemia
could only be reversed by small boluses of IV glucose
until he was able to ingest carbohydrate. A short
38 0742—3071/91/030268-04$05.00
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:igure 1. Extended OGTT in the patient aged 42 years with
eactive hypoglycaemia; □ □ plasma glucose, + ♦
erum insulin, * serum insulin levels given as >200 mU I-1,




























Fable 1. Results of an intravenous GTT (0.5 g kg-body-
A/eight 1) in the patient with reactive hypoglycaemia
Fime Plasma Serum Serum Serum Serum
min) glucose insulin growth Cortisol glucagon
(mmol (mU I"1) hormone (nmol (pmol
1"') (mU 1"') I"') I"')
0 4.1 20 3.6 178 5
15 14.3 408 1.1 507 5
30 9.5 400 1.0 554 <5
45 6.6 479 0.9 537 5
60 3.5 1520 0.8 454 5
90 1.2 268 0.8 360 5
120 1.1 96 >62.5 885 11
ynacthen test (250 fxg IM) was normal (baseline serum
ortisol 355 nmol I-1, peak 1000 nmol I"1).
A fasting glucagon test (1 mg glucagon IM) showed a
ilunted rise in blood glucose levels (normal rise
> 4 mmol I-1) followed by hypoglycaemia (Figure 3).
"he test suggested abnormal hepatic glucose production
o a needle liver biopsy was performed after an overnight
ast. Liver histology was normal as was the measured
Jycogen content of 27.2 mg-glycogen g-liver-wet-
veight"1 (normal < 40 mg g"1). Hepatic glucose-6-
ihosphatase kinetics were measured on a microsomal
ubfraction (Table 2).3
Assaying glucose-6-phosphatase activity in intact
nicrosomes gives a measure of the activity of the catalytic
ubunit in conjunction with the three transport proteins
"igure 4). Kinetic analysis has shown that it is the
lucose-6-phosphate (T,) transporter which is rate-limiting
a glucose-6-phosphatase activity in intact structures.4
disrupting the microsomes with histone allows direct
teasure of catalytic subunit activity.5 Microsomal prep-
rations are heterogeneous and contain a portion of
isrupted structures, the extent of disruption being
EACTIVE HYPOCLYCAEMIA AND DIAZOXIDE THERAPY
Time (mln)
Figure 2. Plasma glucose and serum insulin concentrations
during an OGTT in the patient with reactive hypoglycaemia
(same patient as in Figure 1, now aged 47 years); □ □
pre-treatment; ♦ ♦ diazoxide 900 mg day"1, D B
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Figure 3. Results of fasting glucagon test (1 mg IM) in the
patient with reactive hypoglycaemia
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Table 2. Hepatic glucose-6-phosphatase activity in a hepatic




Unax Km Unax Km
(|j.mol (mmol (|o.mol (mmol
min-1 I"1) min-' I"1)
mg-1) mg-1)
Patient 0.03 16.5 0.20 0.90
Patient + E5SAa 0.15 2.2 0.20 0.90
Control6 0.26 2.3 0.49 0.80
"Bovine serum albumin solution 10 g I"1.
bControl data from assaying glucose-6-phosphatase activity in adult
liver biopsies (n = 40) taken for diagnostic reasons other than
abnormalities of carbohydrate metabolism. Study approved by Tayside
Health Board Ethical Committee.
2+
(Endoplasmic reticulum membrane)
Figure4. A diagrammatic representation of the hepatic microso¬
mal glucose-6-phosphatase system. The catalytic subunit (E)
lies on the luminal surface of the endoplasmic reticulum
membrane (ERM) associated to a calcium-binding stabilizing
protein (SP). There are three transport proteins, allowing the
passage of substrate glucose-6-phosphate to the lumen of the
ER (7,), and the efflux of reaction products phosphate (T2) and
glucose (T3)
calculated by assaying with mannose-6-phosphate which
is a substrate of the catalytic subunit, but is not transported
by 7,. The Km of the intact microsome is inversely
proportional to the affinity of T, for glucose-6-phosphate.
Thus a high Km indicates inhibition of 7,. Our patient's
high Km in intact microsomes, restored to normal by pre-
incubating the microsomes with bovine serum albumin
(BSA) 10 g I-1, implies that there is a reversible inhibitor
of 7, binding to the transport protein in this patient's
liver preparation. BSA is a non-specific binder of many
ions and peptides and thus the nature of this inhibitor is
not clear. The activity of the catalytic subunit (as indicated
by the disrupted microsomal assays) is normal.
CT scan of the pancreas before and during rapi
infusion of contrast medium did not reveal any abno
mality.
In view of the marked hyperinsulinaemic response t
glucose, treatment with oral diazoxide was commence
at 900 mg day-1. This gave good relief of hypoglycaemi
symptoms within 14 days. Repeat OCTT performed afte
14 days of 900 mg day-1 diazoxide showed raised fastin
and peak plasma glucose levels but a reduced rise i
serum insulin concentration (peak 485 mU I"1) (Figur
2).
The dose of diazoxide was reduced to 50 mg twic
daily to alleviate side-effects (fluid retention) and the
gradually increased to 200 mg twice a day with clinic;
improvement. OGTT was repeated 8 weeks after startin
400 mg day-1 diazoxide and, although fasting and pea
plasma glucose levels were elevated compared wit
levels prior to therapy, the peak rise in insulin we
reduced (Figure 2).
While on 400 mg day-1 diazoxide the patient wa
given a single dose of 100 p.g octreotide (Sandostatir
Sandoz, Camberley, UK) IM and the OGTT repeatec
The insulin response to oral glucose was abolished (Figur
2), but the patient suffered abdominal discomfort. Thre
years later the patient remains symptomatically well o
diazoxide 200 mg twice daily and has octreotide at horn
for emergency use (as yet unused).
Discussion
The diagnosis of reactive hypoglycaemia rests class
cally on the demonstration ofWhipple's triad of hypogl>
caemic symptoms after meals, proven hypoglycaemia ;
the time of symptoms and the relief of symptoms by th
ingestion of glucose. Patients with reactive hypoglycae
will often show delayed, exaggerated insulimia
secretion (termed 'dysinsulinism') in response to an or;
glucose tolerance test especially if the aetiology i
gastrointestinal disease or 'idiopathic'.6-8 Also, abnoi
malities of glucagon response to hypoglycaemia hav
been described along with the dysinsulinism.8- 9 Som
patients with reactive hypoglycaemia demonstrate exag
gerated gastrointestinal peptide (GIP) response to oral bi
not intravenous glucose, the implication being that th
increased GIP response results in the dysinsulinisr
observed in these patients.10
Our patient is unusual in several respects. Firstly
he displayed marked dysinsulinism and subsequer
hypoglycaemia in response to both oral and intravenou
glucose loads, implying that stimulation of excessive G1
release is not the underlying defect. The absent glucago
response to hypoglycaemia seen in this patient is furthe
evidence of a disorder of pancreatic islet cell intei
regulation as the underlying defect. For example,
deficiency of, or insensitivity of, the paracrine respons
to native somatostatin could be postulated.
Secondly, we have demonstrated a previously unknow
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phatase activity in this patient's liver biopsy. Hepatic
glucose-6-phosphatase plays a vital part in glucose
homeostasis" and is known to exist as a multicomponent
protein system which it has only recently been possible
to study on small liver samples.3 It is not possible at
presentto identify the inhibitor of the glucose-6-phosphate
translocase (Id indicated by this patient's results (Table
2). There are no known physiological inhibitors of Tu
but it is possible that the inhibitor of 7, present in this
patient is insulin, C-peptide or another peptide involved
in insulin metabolism.
The pattern of reactive hypoglycaemia in this report is
unlike that of fructose 1:6 diphosphatase deficiency
where hypoglycaemia can be induced by fructose,
alanine, and glycerol, but not by hyperglycaemia. These
individuals usually show normal response to a glucagon
test after 12 h fasting, but an absent response after 14 h
fasting.
It is possible that the occurrence of reactive hypoglycae¬
mia and the demonstrated hepatic glucose-6-phosphatase
abnormality is a chance association in this patient. The
hepatic enzyme abnormality will worsen the reactive
aypoglycaemia as hepatic glucose output will not be
able to increase in a normal fashion in response to
normal stimuli (such as the glucagon test, Figure 3).
nterestingly glucose-6-phosphatase activity has recently
aeen demonstrated in pancreatic islet cells, where its
ahysiological role is unclear.12 If the same abnormality
s present in the pancreatic as in the hepatic glucose-6-
ahosphatase enzyme system, it might imply a role for
'lucose-6-phosphatase in pancreatic islet cell response
o blood glucose levels.
Recently somatostatin infusions have been shown to
mprove idiopathic reactive hypoglycaemia during an
DGTT" and the present study suggests that octreotide
nay also be effective. Octreotide has been shown to be
effective in the short-term control of hyperinsulinaemia
lue to benign and malignant insulinomas in adults and
onger-term in infants with nesidioblastosis.13-15 Our
jatient developed unpleasant abdominal discomfort after
he single dose of 100 p.g octreotide and it is planned
o use octreotide only should he not respond to, or
ihould he develop side-effects to diazoxide.
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j mechanism of activation of hepatic microsomal glucose-6-phosphatase (EC 3.1.3.9) in vitro by amiloride has been
estigated in both intact and fully disrupted microsomes. The major effect of amiloride is a 4.5-fold reduction in the
of glucose-6-phosphatase activity in intact diabetic rat liver microsomes. Amiloride also decreased the Km of
cose-6-phosphatase activity in intact liver microsomes isolated from starved rats 2.5-fold. Kinetic calculations, direct
yme assays and direct transport assays all demonstrated that the site of amiloride action was Tl, the hepatic
rosomal glucose 6-phosphate transport protein. This is, to our knowledge, the first report of an activation of any of
proteins of the multimeric hepatic microsomal glucose-6-phosphatase complex.
oduction
Hepatic glucose-6-phosphatase (EC 3.1.3.9) is a mul-
imponent enzyme complex comprising the glucose-
hosphatase enzyme, with its catalytic site in the
ten of the endoplasmic reticulum (ER) [1], a regu-
>ry calcium binding protein termed 'stabilising' pro-
t [2 and 3], and three transport proteins which allow
influx of glucose 6-phosphate and the efflux of
:tion products, inorganic phosphate and glucose from
lumen of the ER (Tl, T2 and T3, respectively) [4-8].
jlucose-6-phosphatase catalyses a crucial step in the
ase of glucose from the liver - a function which is
il for maintaining blood glucose levels (see Refs. 9
1 10 for reviews). Kinetic analysis of the glucose-6-
isphatase activity in intact and disrupted microsomes
indicated that glucose 6-phosphate transport is
;-limiting in hepatic glucose 6-phosphate hydrolysis
Nothing is known about the regulation of Tl, but its
ition makes it a possible target for manipulation in
treatment of diabetes mellitus, where hepatic glu-
2 output and glucose-6-phosphatase activity are both
kedly increased. Also Tl transport capacity is more
straining in diabetic than in starved liver micro-
tes [4],
reviation; ER, endoplasmatic reticulum.
espondence: A. Burchell, Department of Obstetrics and
aecology, Ninewells Hospital and Medical School, Dundee, DDI
, U.K.
While investigating the effects of pharmacological
agents on Tl, we studied the diuretic drug, amiloride.
This compound produced a profound decrease in the
Km of glucose-6-phosphatase in intact hepatic micro¬
somes, which was shown to be due to increased trans¬
port capacity of Tl.
This is, to our knowledge, the first report of an
activator of any of the hepatic microsomal glucose-6-
phosphatase proteins and, we believe, alters the inter¬
pretation of the mechanisms involved in the regulation
of this multimeric enzyme complex.
Materials and Methods
Chemicals
Glucose 6-phosphate (monosodium salt) and Cocktail
T (scintillant) were obtained from BDH Chemicals,
Poole, U.K. BM-Test-Glycemie strips were from the
Boehringer (London, U.K.) Mannose 6-phosphate (dis-




civNvc-N=C^The structure of amiloride NH2
hydrochloride H2N^N^NH2
histone 2A and streptozotocin were from Sigma, Poole,
U.K. Cacodylic acid, also from Sigma, was recrystal-
lised from 95% ethanol. [U-14C]Glucose 6-phosphate
from Amersham International, Amersham, U.K. and
-4165/89/$03.50 © 1989 Elsevier Science Publishers B.V. (Biomedical Division)
nitrocellulose from Schleicher & Schuell, Dassel, F.R.G.
All other chemicals were analytical grade reagents.
Amiloride solution was made fresh in 10% dimethyl/
sulphoxide and to volume in buffered cacodylate (pH
6.5).
P values were calculated from Mests with pooled
analysis of variance using Microstat (Release 4.0) soft¬
ware, Ecosoft, IN, U.S.A.
Microsomal preparation
Microsomes were prepared from livers of male Wistar
rats in buffered sucrose/Hepes (pH 7.4) as previously
described [11]. Diabetes was induced by a single tail
vein injection of streptozotocin (75 mg/kg body weight)
in buffered citrate (pH 4.5). Only animals in which the
development of diabetes was confirmed 48 h later by
the measurement of blood sugar concentration were
used [12]. Starved rats were killed after a 16 h fast.
Assays
Glucose-6-phosphatase and mannose-6-phosphatase
activities were assayed and calculated as in Ref. 13 and
are expressed as /xmol Pj released/min per mg micro¬
somal protein. Amiloride was added to the substrate
prior to the addition of microsomes. Control assays
contained 1 % dimethyl sulphoxide. Microsomes isolated
from liver homogenates and not treated further prior to
assay are referred to as untreated, and are a mixture of
intact and disrupted microsomes. The proportion of
intact microsomes was determined by assays of low Km
mannose-6-phosphatase activity, which is only ex¬
pressed in disrupted microsomes [14]. All the micro¬
somal preparations used in this paper were more than
89% intact in both the presence or absence of amiloride.
All the undisrupted values reported in this paper are
intact values, which eliminates the large errors in activ¬
ity measurements which can occur if even a small
proportion of microsomes are disrupted.
Glucose 6-phosphate transport (Tl) activity was
measured at 20 °C, using a modification of the assay
described by Waddell and Burchell [15,16], Starved rat
liver microsomes were diluted 1:100 in cacodylate buffer
(pH 6.5) and then added to the glucose 6-phosphate
incubation mix (buffered to pH 6.5 with 40 mM
cacodylate) containing the indicated amount of
amiloride or 1% dimethylsulphoxide (as control). 0.25
ml aliquots were drawn at each time point and the
reaction was stopped by rapid filtration through a nitro¬
cellulose filter using a Bio-Rad dot blot apparatus. In
each 0.25 ml aliquot there was 1 mM glucose 6-phos-
phate including tracer [U-14C]glucose 6-phosphate (0.5
pCi/ml) and 0.02 mg microsomal protein. After drying
the nitrocellulose, the individual wells were cut out as
lxl cm squares and suspended in scintillant, and the
amount of retained radioactivity was counted using a
liquid scintillation counter. The background radioactiv¬
ity due to the wetting of the membrane by incuba
mix and by nonspecific binding to microsomes
estimated by control incubations containing fully
rupted microsomes as blanks, as previously descri
[16]. The values obtained using fully disrupted mi
somes were subtracted from the counts obtained \
intact microsomes to give the radioactivity taken
into the microsomal vesicle. The uptake via Tl
calculated as described [15] and expressed in nm
glucose 6-phosphate per mg microsomal protein. 1
tein concentrations were estimated by the methoc
Lowry as modified by Peterson [17],
Results
The glucose-6-phosphatase activity in intact mi-
somes is a measure of the combined rates of glucos
phosphatase enzyme and the three transport protein:
wide range of amiloride concentrations were addec
glucose-6-phosphatase assays, and 5 mM amiloride
found to give the maximal effect (data not shown),
addition of 5 mM amiloride to control intact fed
liver microsomes reduced the the Km for glucos
phosphatase activity approx. 2.3-fold without appre
bly altering the Fmax. The addition of 5 mM amilo
to intact starved rat liver microsomes reduced the
for glucose-6-phosphatase activity approx. 2.5-f
again without appreciably altering the Fmax (see T;
I). The addition of amiloride to intact diabetic rat 1
microsomes resulted in a greater decrease in the Km
glucose-6-phosphatase activity (approx. 4.5-fold).
Km of intact microsomes is contributed to by the
zyme and transport proteins Tl, T2 and T3. Disrup
TABLE I
Glucose-6-phosphatase activity in fed, starved and diabetic rat
microsomes
Data are the mean + S.E. from at least four separate preparat
Each preparation comprised six rat livers. Differences calculated I
control values. * P = 0.01; * * P < 0.01.
Intact microsomes Disrupted microsom
Km Vmax Km Vmax
(mM) (fiM/min (mM) (/iM/m
per mg) per mg)
Fed
Control 3.3 + 0.4 0.09 + 0.02 0.5 + 0.1 0.12 + 0.
1 mM Amiloride 1.8 + 0.1 ** 0.09 + 0.02 0.5 + 0.2 0.11+0.
5 mM Amiloride 1.4 + 0.2 ** 0.11 + 0.02 0.5 + 0.1 0.12 + 0.
Starved
Control 3.8±0.5 0.18 + 0.02 1.2 + 0.5 0.32 + 0.
1 mM Amiloride 2.3 + 0.4 0.14+ 0.01 0.9 + 0.4 0.28 + 0.
5 mM Amiloride 1.6 + 0.3 ** 0.17 + 0.01 0.7 + 0.2 0.25 + 0.
Diabetic
Control 5.2 + 0.7 0.28 + 0.05 1.6 + 0.3 0.66 + 0.
1 mM Amiloride 2.4 + 0.3 ** 0.22 + 0.01 1.2 + 0.2 0.50 + 0.





[. The effect of amiloride on glucose 6-phosphate uptake into
isomal vesicles. Nanomoles of glucose 6-phosphate/mg micro-
1 protein taken up into microsomes in the presence (□) and
ce (■) of 5 mM amiloride. Each point is the mean (+ S.E.) of
eight (amiloride) or seven (control) assays.
licrosomes removes the controlling influence of the
; transport proteins and therefore is a direct mea-
of the activity of the glucose-6-phosphatase en-
;. Amiloride had a much smaller effect on the
ity of the glucose-6-phosphatase enzyme in fully
starved or diabetic disrupted microsomes, than it
n the respective intact microsomes (Table I),
irect measurement of glucose 6-phosphate trans-
into microsomal vesicles with and without 5 mM
aride is shown in Fig. 1. The overall amount of
abel (a mixture of [14C]glucose 6-phosphate sub-
2 and [14C]glucose product) inside the lumen of the
Dsomal vesicles is increased in the presence of
Dride.
jssion
tere have been many reports of inhibitors of the
■.in components of rat hepatic microsomal glucose-
rsphatase but very few reports of activators (see
18 for a recent review). The only compounds
ted to activate glucose-6-phosphatase in intact mi-
imal vesicles in vitro were polyamines [19-21] and
ne [22], These compounds have recently been shown
;rease glucose-6-phosphatase activity by disrupting
xsomal vesicles and removing the rate limitations
sed on glucose-6-phosphatase activity by the trans-
proteins rather than by directly interacting with
}f the protein components of the glucose-6-phos-
ise system [23]. The intactness of the microsomal
es in the assay reported in Table I was not signifi-
y altered by the presence of amiloride, and the
ntage of intact microsomes in all the untreated
ysomal preparations used was more than 89%. In
ion, all the data shown have been corrected (as
ibed in Materials and Methods) for the percent
intactness. Therefore, the effects of amiloride on glu-
cose-6-phosphatase activity in intact microsomes must
be due to a direct effect on one or more of the proteins
of the glucose-6-phosphatase system. Amiloride has a
small effect on the Km of the glucose-6-phosphatase
enzyme in fully disrupted hepatic microsomes (Table I)
and amiloride has been reported not to cross cell mem¬
branes [24], The decrease in the Km of glucose-6-phos-
phatase activity in intact microsomes could not, there¬
fore, be caused by a direct effect of amiloride on the
glucose-6-phosphatase enzyme itself. The most likely
site of amiloride action therefore seems to be Tl, the
glucose 6-phosphate transport protein.
Glucose-6-phosphatase enzyme activity is higher in
diabetic rat liver microsomes than in starved or fed rat
liver microsomes (see Table I) as previously reported
[4,9,12 and 14]. This is caused by the presence of high
levels of the catalytic subunit of glucose-6-phosphatase
in diabetic rat liver microsomes [12], The transport
capacity of Tl is thought not to alter significantly in
fed, starved or diabetic rat liver microsomes [4]. Hence,
as the Fmax of the enzyme increases from fed to diabetic
liver microsomes, Tl becomes more rate limiting and
cannot transport enough glucose-6-phosphate into the
lumen for the more active glucose-6-phosphatase en¬
zyme. This results in a fall in the concentration of
glucose 6-phosphate in the lumen of the ER and hence
a higher Km in intact vesicles. Amiloride reduces the
Km of glucose-6-phosphatase activity in intact micro¬
somes prepared from livers of fed, starved and diabetic
rats to approx. the same value, a value very close to the
Km of the glucose-6-phosphatase enzyme. This is the
predicted result of increasing Tl capacity beyond the
potential of the enzyme to hydrolyse glucose 6-phos-
phate [4],
If amiloride's only effect was to increase Tl trans¬
port capacity, the F"max of glucose-6-phosphatase activity
in intact microsomes would have risen to a value similar
to the Fmax of the glucose-6-phosphatase enzyme in
disrupted microsomes in the presence of 5 mM
amiloride. However, this did not occur. The Fmax of
intact microsomes from diabetic liver microsomes was
51% of the value in disrupted microsomes (see Table I).
The simplest explanation is that amiloride is inhibiting
T3, the glucose transport protein. Inhibition of T3
would lead to a build-up of glucose inside the lumen of
the microsomes. This would explain the increase in the
levels of [14C]glucose + [14C]glucose 6-phosphate in the
lumen of microsomes in the presence of amiloride (see
Fig. 1). Glucose inhibition of glucose-6-phosphatase
enzyme activity was discussed in some detail in Ref. 4,
where high glucose levels were found to decrease the
Fmax °f the enzyme by 52% and increase the Km by 53%
(see Ref. 4, Table I). This is extremely similar to results
obtained here with diabetic microsomes in the presence
of 5 mM amiloride where the intact F"max is 49% lower
than the enzyme's and the intact Km is 50% higher (see
Table I).
Amiloride is known to inhibit several different Na+
transport proteins, e.g., Na+ channels, Na+/H + and
Na+/Ca+ antiporters and Na+/glucose cotransporters
(for reviews see Refs. 24-28). However, it has also been
reported [4] that the transport of glucose 6-phosphate,
glucose and phosphate into the lumen of hepatic micro¬
somes do not involve co-transport with Na+ [4],
Amiloride is also known to affect the phosphorylation
states of a number of proteins because it is a non¬
specific inhibitor of protein kinases [29], To date, there
is to our knowledge no evidence that glucose-6-phos-
phatase activity in intact microsomes is altered by phos¬
phorylation or dephosphorylation [30]. No ATP or GTP
was added to our assays or microsomal preparations,
and so amiloride cannot be activating T1 via inhibition
of a microsomal protein kinase. Therefore, the simplest
explanation is that amiloride is interacting directly with
both T1 and T3.
The pharmacological concentrations of amiloride
have been estimated to be 3-20 jttM [24], but the
maximal effect of amiloride on glucose-6-phosphatase
activity is at a concentration of 5 mM. This, coupled to
the fact that amiloride does not enter hepatocytes,
explains why amiloride does not affect glucose tolerance
in man. However, the fact that T1 can be activated by
amiloride raises the possibility of designing similar
pharmacological agents which could be used to regulate
blood glucose at this site.
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APPENDIX B
POST MORTEM REPORT ON CASE 1
Date of death 01 10 86 Date of Post Mortem 02 10 86
External Appearances
The body is that of a middle aged male Caucasian 63kg in weight and 172cm in
height. An area of subcutaneous haematoma is present in the right hypochondrium.
There is no evidence of pedal oedema and no enlarged peripheral lymph nodes are
seen or palpated. There is also no evidence of muscle or fat wasting.
Internal Appearances
Cardiovascular System
The pericardial sac and cavity appear normal. The heart (380g) shows no significant
abnormality of note. The left ventricle is 14cm thick and the right 2cm thick, 2cm
from the apex. The valves (mitral 10cm, aortic 7cm, pulmonary 8cm and tricuspid
11cm) appear unremarkable. The coronary arteries show mild atheroma and are
patent throughout their dissected courses. The aorta and major arteries to the head
and neck, upper limbs and lower limbs show only mild atheroma. The Circle of
Willis appears unremarkable as do the pulmonary vasculature and the systemic
venous system.
Respiratory System
Both pleural cavities appear normal. The trachea and main bronchi show no
abnormalities of note. The lungs (left 650g, right 670g) are markedly congested and
oedematous. There is no evidence of a chest infection.
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Gastrointestinal System
The tongue is healthy. The oesophagus stomach, small and large intestines show no
obvious abnormalities. The gall bladder appears normal. Free bile flow can be
elicited and the bile duct is probe patent. The pancreas (420g) appears
unremarkable. The liver (6,000g) is massively enlarged and fills most of the
abdominal cavity. A large tumour measuring 140mm in maximum dimension is
present in the right lobe. The rest of the liver shows a variegated appearance with
numerous yellowish nodules present within the whole of the parenchyma.
Genitourinary System
The kidneys (right 210g, left 220g) are heavy and enlarged for the size of the
patient and are pale. The ureters and bladder appear unremarkable. The prostate and
testes are of normal sizes.
Central Nervous System
The meninges appear normal. The brain (l,440g) shows no obvious abnormality in
serial slices.
Endocrine System
The pituitary, parathyroids, thyroid (20g) and adrenals (lOg together) show no
obvious abnormalities.
Reticulo-Endothelial System
The spleen (440g) is enlarged and markedly congested. A single enlarged lymph
node is identified. The thymus is atrophic.
Musculo-Skeletal System
No obvious abnormality is seen in this system.
Comment
Autopsy shows marked bilateral pulmonary congestion and oedema. There is a large
neoplasm involving the right lobe of the liver with numerous nodules in the rest of
the parenchyma. The liver is massively enlarged. The spleen is also greatly enlarged
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and markedly congested. Both kidneys are also enlarged and heavy. The
appearances of the liver and kidneys are in keeping with glycogen storage disease.
Sections were taken for histology and the histological report followed later.
HISTOLOGY REPORT
Lungs
Sections show pulmonary oedema and numerous tumour emboli in pulmonary
arteries and arterioles.
Liver
Sections show diffuse infiltration by primary liver cell carcinoma with a very
variable pattern comprising areas of clear cells, pseudoacinar structures and reticular
pattern. The uninvolved areas show moderate steatosis and rarefaction of the
cytoplasm of "non-fat containing" hepatocytes. The nuclei are large with a central
nonstaining area in places. There are large areas of necrosis. Sections of liver fixed
in Rossman's fluid and stained with PAS and PAS and diastase show massive
accumulation of glycogen in hepatocytes not involved in the neoplastic process, with
some nuclei also containing glycogen. The neoplastic hepatocytes contain glycogen
to a lesser degree. (A photograph of the liver histology is shown in Figure 3.1 &
3.2)
Kidneys
Sections show ischaemic damage with some sclerotic glomeruli. There is an
increase in the interstitial fibrous connective tissue especially in the medulla. The
kidneys are largely autolytic but recognisable proximal tubules show cytoplasmic
vacuolation with pale empty nuclei. PAS with and without diastase of sections from
kidney blocks fixed in Rossman's fluid show increased glycogen in the cytoplasm
and also in the nuclei of the tubules.
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Figure B.l
Photographs of sections of kidney taken at post mortem, (a) x75 (b) x250. For
details of histology see text above.
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Spleen
This is markedly congested and shows an increased number of macrophages in the
red pulp.
Skeletal Muscle
Sections show no remarkable features and no excess of glycogen can be seen with
special stains on blocks fixed in Rossman's fluid.
Brain
No excess glycogen can be demonstrated.
Lymph node
This shows reactive changes only.
Comment
Histological examination of autopsy material shows pulmonary oedema and
extensive tumour emboli in the pulmonary arterial tree. There are large amounts of
glycogen in hepatocytes and proximal tubular cells of the kidneys in excess of
normal as evidenced by glycogen in the nuclei. No excess of glycogen can be shown
in cardiac muscle, skeletal muscle and brain tissue suggesting a type I glycogen
storage disease (von Gierke's disease). There is extensive infiltration of the liver by
primary liver cell carcinoma which gave rise to the tumour emboli in the lungs.
Congestive splenomegaly is present.
Final Necropsy Report
1. Disease or condition leading to death:
Severe bilateral pulmonary oedema due to (or as a consequence of) Extensive
tumour emboli due to (or as a consequence of) Primary liver cell carcinoma.
2. Other significant conditions contributing to the death but not related to the
disease or condition causing it:
Type 1 glycogen storage disease.
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APPENDIX C
MOTHER AND DAUGHTER WITH TYPE IX GSD
B.l Introduction
These two cases are included here for completeness sake as they were diagnosed at
the same time as the eight cases in Chapter 3, eventhough they do not have
primarily an abnormality of glucose-6-phosphatase, although the activity of the
hepatic system in both is a little depressed, possibly reflecting the high glycogen
stores. The assays on liver and muscle samples from both these women were
performed by Mrs. Lesley Gibb.
B.2 Methods
All methods were as described in Chapter 2 above. Skeletal muscle biopsies were
taken under local anaesthetic from tibialis anterior using Tilley-Henkel biopsy
forceps (designed for removal of nasal polyps). The 1cm incision was closed with
steristrips after 15 minutes direct pressure to secure haemostasis. Samples were
transferred dry and fresh to both pathology and biochemistry laboratories.
Total phosphorylase activity (a + b) was measured in the direction of glycogen
synthesis in the presence of 5'-AMP as described by Hedrick and Fisher (1963).
Phosphorylase kinase activity was measured by the method of Krebs as modified by
Cohen (1973). "Physiological" phosphorylase kinase activity is measured at pH6.8,
and maximal activity is measured at pH 8.8. unfortunately the sensitivity of the
assay does not allow discrimination between normal and half-normal activity in
extracts of human biopsy samples.
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B.3 Mother
Born in Malawi 270851 of mixed race parentage (father Pakistani, mother V2
Caucasian and V2 negro). Four live siblings, her mother had had nine other
pregnancies which had not produced live children (the exact circumstances are
unclear as they were separated at a young age). The patient had had 3 pregnancies
all producing live infants.
At the age of 34 she presented to a neurologist with a 1xh year history of right-sided
headache and recurrent funny turns. At night these attacks (according to her
husband) consisted of a cry followed by clenching of teeth and generalised shaking.
During the day she described episodes of loss of memory, blankness during, for
example, conversations, dropping objects and occasional acute loss of posture.
There was no clear temporal relationship to food (or lack of) and the attacks at that
time had been going on for 9 months. Examination was normal. An EEG showed
some spike discharges from the right parietal lobe and left posterior temporal
regions, but this was not felt consistent with an active interictal record. She was
given carbamazepine as a therapeutic trial with little obvious benefit. Later the
attacks were thought to be anxiety-related, but she gained little help from a clinical
psychologist.
By 1988 (age 37 years) her attacks were persisting but by now were more clearly
preceded by a craving for sweet food and had worsened since she had gone out to
work and ate less regularly. She also complained of persistent dysuria and right iliac
fossa/peri-umbilical pain - urine culture was negative and an IVU was normal (a
right duplex ureter was noted). On examination she was thin and introverted and
had palpable hard stool in her colon, however she had no abdominal organomegaly.
All routine blood testing was normal (including serum liver enzymes, bilirubin and
clotting studies). During a 48 hour fast she twice felt slightly unwell: examination
was unremarkable and on both occasions blood glucose was 3.5 mmol/1 and serum
insulin levels were 10 and < 10 mU/1. At the end of the fast and after exercise
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blood glucose was 4.1, insulin 13mU/l and lactate 7.3 mmol/1. Results of oral
glucose tolerance test and glucagon test are shown in Table B. 1.
In view of the blunt glucose response to glucagon a liver biopsy was performed.
The histology and electron microscopy of the liver (including estimated glycogen
stores) were normal. The results of the initial biochemical analyses (Table B.2)
suggested a form of GSD but the glucose-6-phosphatase activity did not suggest that
the abnormality was a type 1 GSD. A skeletal muscle (anterior tibial) biopsy was
performed to further classify the abnormality. Again the histology and electron
microscopy were normal. Electromyography was performed and showed some
excess of high frequency components which can be seen in but are not specific for,
myopathic processes. One minute of ischaemic exercise did not produce cramping,
but repetitive stimulation of the right ulnar nerve did result in reduced amplitude of
the evoked potentials measured in abductor digiti minimi.
Measurement of total phosphorylase (a & b) was normal in both liver (0.5 U) and
skeletal muscle (1.6 U). However phosphorylase kinase activity in both tissues was
reduced to approximately 10% normal (pH 6.8: liver 0.008 U; muscle 0.005 U;
pH 8.6 liver 0.015 U; muscle 0.01 U).
Thus the diagnosis was type IX GSD and she responded very well to diet containing
corn starch (and to the reassurance that she was not mad!).
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Table B. 1
Results of a) oral glucose tolerance tests and b) fasting glucagon tests in a mother
and daughter with type IXc GSD.
Times given in minutes relative to the dosing time.


















Time: 0 30 60 90 120
Glucose: 4.7 6.9 4.0 2.9 3.0
Daughter
Time: 0 30 60 90 120
Glucose: 4.5 6.1 4.7 2.9 2.8









Born 110771. Normal birth after normal pregnancy; birth weight unknown.
Separated from her mother at a relatively early age as her mother and father
divorced. She had no knowledge of her mother's symptoms when she presented at
age 17 with episodic dizziness and light-headedness. These symptoms were worse
just before lunch when she was at work, especially if she had missed breakfast. The
symptoms improved within 1 hour of taking a meal and their onset was not related
to alcohol intake. Clinical examination and routine blood tests were all normal.
During a 48 hour fast she had one "funny turn" when her blood glucose was
estimated at 2.8 mmol/1 (unfortunately on a glucose oxidase strip only). At the end
of the fast and after exercise her blood glucose was 3.5 mmol/1. The blood glucose
response to glucagon when fasting was blunt and an oral glucose tolerance test was
unusual in showing two peaks of glucose at 30 and 120 minutes (Table B.l).
Liver biopsy was normal to light and electron microscopy, and the glucose-6-
phosphatase and glycogen assays are shown in Table B.2. The glycogen stores are
elevated in the liver and the glucose-6-phosphatase activity is at the low end of
"normal". Muscle biopsy showed high-normal glycogen stores (19.9 mg/g muscle)
on assay but was histologically normal. Total phosphorylase (a + b) activity was
normal in liver (1.1 U) and muscle (5.3 U). Phosphorylase kinase activity at pH 6.8
(0.09 U liver and 0.12 U muscle) and at pH 8.6 (0.11 U liver and 0.23 U muscle)
were both within the range of normal, however the assay at this level cannot
distinguish normal from half-normal. In view of the glycogen accumulation and her
mother's diagnosis this data was interpreted as showing this girl to have partial type
IX GSD.
Her symptoms have disappeared with regular meals containing uncooked corn
starch. She has one son (delivered normally after a normal pregnancy) who is
hyperactive but otherwise well. She has two brothers by the same parents, both of
whom are asymptomatic, but one of whom had a blunt glucose response (+2.4
220
mmol/1) to glucagon. The other brother's test was normal. Neither brother has had
any further investigations performed and the father was untraceable.
B.5 Discussion
Type IX glycogen storage disease is well recognised as being mild and survival to
adulthood is the norm (Abarbanel et al 1986). These two cases have several unusual
features. The vagueness of the mother's symptoms may be related to her inability to
describe them clearly (or of the doctors to elicit them!) but one wonders how many
other people have been described as having anxiety-related symptoms and been
referred to clinical psychologists. Both women developed biochemical
hypoglycaemia after their glucagon test which was only seen in one of the other
eight cases (Case 8) described in Chapter 3. This is not specific for any
abnormality, but in time it may become clear that some types of GSD patients do
develop hypoglycaemia after glucagon administration. The double peak in blood
glucose levels during a standard 75g oral glucose tolerance test in the daughter is
likewise noted but the aetiology and significance remain obscure. Unfortunately
serum insulin levels were not measured.
Four human variants of type IX GSD are currently recognised: type IXa (autosomal
recessive - abnormal liver but normal muscle PK activity); type IXb (sex-linked -
abnormal liver but normal muscle PK activity [Huijing & Fernandes 1969]); type
IXc (autosomal recessive - abnormal activity in liver and muscle [Lederer et al
1980]) and type IXd muscle PK deficiency with normal liver activity (Abarbanel et
al 1986).
Type IXc GSD (phosphorylase kinase deficiency affecting muscle and liver) is
thought to be inherited in an autosomal recessive fashion (Bashan et al 1981 and
Lerner et al 1982). These two cases show that that is incorrect (at least for these
two cases).
While the phosphorylase kinase activity measured in the liver sample from the
daughter is low-normal rather than being clearly low, she undoubtedly has a
disorder of glycogen metabolism and in view of her mother's diagnosis the chances
of it being caused by a different (and unmeasured by us) liver enzyme defect are
very small. The development of the daughter's siblings and child are being watched
with interest.
Although the disease is usually mild, the diagnosis is an important one to recognise
as understanding the illness and knowledge of dietary manipulation can save the
patient a lot of distress.
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